',6&/2685(
5('$&7('35272&2/$0(1'0(17
$%,16&/
$3+$6(23(1/$%(/08/7,&(17( 5678'<72$66(666$)(7<$1'
()),&$&<2)6(&21'7+,5'/,1(75($70(17:,7+1$%ÂŠ3$&/,7$;(/
$%,,1&20%,1$7,21:,7+(3,*(1(7,&02',)<,1*7+(5$3<2)& &
25,008127+(5$3<2)'859$/80$%0(',25$6
02127+(5$3<,168%-(&76:,7+ $'9$1&('12160$//&(///81*
&$1&(516&/&$%281'/
7KHLQIRUPDWLRQFRQWDLQHGLQWKHDWWDFKHGUHSRUWLVWKHSURSHUW \RI&HOJHQHDQGVKRXOGQRWEHVKDUHGRU
XVHGIRUDQ\SXUSRVHRWKHUWKDQWKDWIRUZKLFKLWZDVSURYLGHG 
&HOJHQHLVFRPPLWWHGWRSURYLGLQJLQIRUPDWLRQDERXWLWVFOLQLFD OWULDOVWRUHVHDUFKHUVDQGSDWLHQWVZLWKWKH
JRDORIIXUWKHULQJVFLHQFHDQGHQKDQFLQJKHDOWKFDUHZRUOGZLGH /DZVDQGUHJXODWLRQVUHTXLUHKRZHYHU
WKDW&HOJHQHSURWHFWVSDWLHQWSULYDF\7KHFRPSDQ\PD\IXUWKHU KDYHOHJDORUFRQWUDFWXDOREOLJDWLRQVQRW
WRGLVFORVHFRPPHUFLDORUWHFKQLFDOLQIRUPDWLRQSURYLGHGE\RU UHODWHGWRFHUWDLQSDUWQHUFRPSDQLHVRU
YHQGRUV7KHDWWDFKHGUHSRUWLVSUHVHQWHGLQLWVRULJLQDOIRUPDWEXWFH UWDLQLQIRUPDWLRQKDVEHHQUHGDFWHGLQRUGHU
WRFRPSO\ZLWKWKHDIRUHPHQWLRQHGREOLJDWLRQVRUWRSURWHFW&HO JHQHÂ¶VFRQILGHQWLDOFRPPHUFLDO
LQIRUPDWLRQ7KHUHGDFWLRQVDUHEDVHGRQWKHIROORZLQJSULQFLS OHV

x5HGDFWHGLQIRUPDWLRQKDVEHHQUHSODFHGE\JUH\VSDFHPDLQWDLQL QJRULJLQDOVSDFLQJDQGSDJLQDWLRQ
x$Q\LQIRUPDWLRQWKDWPLJKWDOORZWKHLGHQWLILFDWLRQRILQGLYLGX DOVKDVEHHQUHGDFWHGIRU
DQRQ\PL]DWLRQ
x$WWDFKPHQWVWRWKLVUHSRUWWKDWFRQWDLQFRQILGHQWLDOLQIRUPDWLR QDUHQRWPDGHDYDLODEOH6XFK
DWWDFKPHQWVLQFOXGHWKRVHWKDWFRQWDLQLGHQWLILDEOHSDWLHQWLQI RUPDWLRQVXFKDVVXEMHFWOLVWLQJV
QDUUDWLYHVDQGSURILOHV7KH\DOVRPD\FRQWDLQFRQILGHQWLDOF RPPHUFLDOLQIRUPDWLRQVXFKDV
PHWKRGRORJLHVDQGK\SRWKHVLVJHQHUDWLQJDQGH[SORUDWRU\DQDO\V HV
x&URVVUHIHUHQFHVWRWKHVHDWWDFKPHQWVVXFKDVOLQNVWRVXEMHFW OLVWLQJVLQ6HFWLRQDUHQRW
UHGDFWHGIURPWKHERG\RIWKHUHSRUW+RZHYHUWKHK\SHUOLQNV LQWKHHOHFWURQLFGRFXPHQWDUHQR
ORQJHUIXQFWLRQDO
x,QIRUPDWLRQDERXW&HOJHQHYHQGRUVDQGWKHLUVHUYLFHVDUHUHGDFW HGEHFDXVHPDQ\FRQWUDFWVSURKLELW
GLVFORVXUHRIWKDWLQIRUPDWLRQ)XUWKHUODZVDQGUHJXODWLRQV SUHYHQWXVIURPGLVFORVLQJFHUWDLQ
LQIRUPDWLRQDERXWRXUYHQGRUVRUWKHLUVHUYLFHVEHFDXVHLWLVS URWHFWHGE\FRS\ULJKW

,QIRUPDWLRQDERXW&HOJHQHÂ¶VUHGDFWLRQSROLFLHVDQGWKHDYDLODEL OLW\RIDGGLWLRQDOGDWDIURPWKLVUHSRUWPD\
EHIRXQGDWKWWSZZZFHOJHQHFRPUHVHDUFKGHYHORSPHQWFOLQLFD OWULDOVFOLQLFDOWULDOVGDWDVKDULQJ

&(/*(1(35235,(7$5<,1)250$7,21//
)&&)&&
66
///81*///81*
RXOGQRWEHRXOGQRWEH
UHVHDUFKHUVUHVHDUFKHU
DQGUHJXOGUHJXODWD
YHOHJDORUFYHOHJDOR
HODWHGWRFHUODWHGWRFHU
XWFHUWDLQLQIXWFHUWDLQLQ
SURWHFW&HOJURWHFW&HOJ
ZLQJSULQFLZLQJSULQFL
E\JUH\E\JUH\VSD
LGHQWLILLGHQWLILFDWLL
FRQWDLQFRQIFRQWDLQFRQ
DWFRQWDLQLGWFRQWDLQL
7KH\DOVRPKH\DOVRP
SRWKHVLVJHQSRWKHVLVJ
WKHVHDWWDFKWKHVHDWWD
HERG\RIWKHERG\RIWK
QDOQDO
QDERXW&HOJDERXW&HO
UHRIWKDWLQHRIWKDWLQ
PDWLRQDERXLRQDER
RUPDWLRQDERUPDWLRQDE
EHIRXQGDWKHIRXQGDWK
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 1 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016TITLE PAGE
A PHASE 2, OPEN-LABEL, MULTICENTER STUDY TO 
ASSESS SAFETY AND EFFICACY OF SECOND/THIRD-
LINE TREATMENT WITH NABÂ®-PACLITAXEL (ABI-
007) IN COMBINATION WITH EPIGENETIC 
MODIFYING THERAP Y OF CC-486, OR 
IMMUNOTHERAPY OF DURVALUMAB (MEDI4736), 
OR AS MONOTHERAPY IN SUBJECTS WITH 
ADVANCED NON-SMALL CELL LUNG CANCER 
(NSCLC): ABOUND.2L+
INVESTIGATIONAL PRODUCTS: CC-486, nab-Paclitaxel (ABI-007), 
durvalumab (MEDI4736)
PROTOCOL NUMBER: ABI-007-NSCL-006
DATE FINAL: 29 May 2014
AMENDMENT 1.0 FINAL: 24 Jun 2014
AMENDMENT 2.0 FINAL: 18 Jul 2014
AMENDMENT 3. 0 FINAL: 14 Apr 2016
AMENDMENT 4.0 FINAL: 31 May 2016
AMENDMENT 5.0 FINAL: 09 Dec 2016
EudraCT NUMBER 2014-001105-41
IND NUMBER 123160
SPONSOR NAME / ADDRESS: Celgene Corporation
86 Morris Avenue
Summit, NJ 07901
United States
CONFIDENTIAL
This protocol is provided to you as an Investigator, potential Investigator, or consultant for review by 
you, your staff, and ethics committee/institutional review board. The information contained in this 
document is regarded as confidential and, except to the extent necessary to obtain informed consent, 
may not be disclosed to another party unless such disclosure is required by law or regulations.
Persons to whom the information is disclosed must be informed that the information is confidential 
and may not be further disclosed by them.&(/*(1(35235,(7$5<,1)250$7,2136)36), , 
H H 
NCNCER ER 
-P-Paclitaxeaclitaxe
abab(MEDIMED
07-07-NSCLNSC
9May May 201201
24 Jun 224 Jun 2
18 J18
DDRESS:DDRES
ThisThis*/*(/&(
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 2 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016MEDICAL MONITOR / EMERGENCY CONTACT INFORMATION 
Contact Information:
Name:
Title:
Address: 86 Morris Avenue
Summit, NJ 07901
United States
Phone:
E-mail:
Contact Information:
Name:
Title:
Address: 86 Morris Avenue
Summit, NJ 07901
United States
Phone:
E-mail:
Note: The back-up 24 hour global emergency contact call center should only be used if you 
are not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls.
Back-up 24 Hour Global Emergency Contact Call Center: 
&(/*(1(35252lobal emerobal emer
linical Reslinical R
Global EmGlobal Em(1(235,(7$5<,1)250$7,210$5000
25)2,1<5<$
5,
23323
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 3 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016CELGENE THERAPEUTIC AREA HEAD SIGNATURE PAGE
{See appended electronic signature page}.
Signature of Celgene Therapeutic Area Head dd mmm yyyy
Printed Name of Celgene Therapeutic Area Head and Title
By my signature, I indicate I have reviewed this protocol and find its content to be 
acceptable.
<,1,1)250$7,210$0$5000
ts content toconten
<,1
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 4 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016SITE PRINCIPAL INVESTIGATOR SIGNATURE PAGE
Signature of Site Principal Investigator dd mmm yyyy
Printed Name of Site Principal Investigator
Institution Name:_______________________________________
By my signature, I agree to personally supervise the conduct of this study at my study 
site and to ensure its conduct is in compliance with the protocol, informed consent, Institutional Review Board (IRB)/Ethics Committee (EC) procedures, instructions from 
Celgene representatives, the Declaratio n of Helsinki, ICH Good Clinical Practices 
Guidelines, and local regulations governing the conduct of clinical studies.
&(/*(1(35235,(7$5<,1)250$7,210$0$5000
s studys study  at m atyy
, informed nformed
ocedures, inedures, i
Good ClinGood C
ct of clinicaof clinic
$5$5
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 5 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016COORDINATING PRINCIPAL INVESTIGATOR SIGNATURE PAGE
Signature of Coordinating Principal Investigator dd mmm yyyy
Printed Name of Coordinating Principal Investigator
Institution Name:_______________________________________
By my signature, I agree the protocol has been written to comply with ICH Good 
Clinical Practices guidelines and agree to offer guidance throughout the study as needed.
&(/*(1(35235,(7$5<,1)250$7,210$0$50000
wiwiththiiICH GICH h
ghout the stout the st
5<5<
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 6 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016PROTOCOL SUMMARY
Study Title
A Phase 2, Open-label, Multicenter Study to Assess Safety and Efficacy of Second/Third-line 
Treatment with nabÂ®-Paclitaxel1(ABI-007) in Combination with Epigenetic Modifying Therapy 
of CC-486, or Immunotherapy of Durvalumab (MED I4736), or as Monotherapy in Subjects with 
Advanced Non-small Cell Lung Cancer (NSCLC): ABOUND.2L+
Indication
Second/third-line treatment of advanced NSCLC.
ObjectivesPrimary
!To estimate the efficacy of nab-paclitaxel administered intravenously (IV) on Days 8 
and 15 with epigenetic modifying therapy of CC-486 once daily (QD) on Days 1 to 14 every 21 days or nab-paclitaxel administered intravenously (IV) on Days 1 and 8
with immunotherapy of durvalumab administered IV on Day 15 every 21 days, and 
nab-paclitaxel monotherapy administered IV on Days 1 and 8 every 21 days as 
second/third-line treatment for advanced NSCLC.
Secondary 
!To estimate the relative efficacy of each of the combination therapy arms to the 
monotherapy arm.
!To evaluate the safety and tolerability of nab-paclitaxel administered intravenously 
(IV) on Days 8 and 15 with epigenetic modifying therapy of CC-486 once daily (QD) on Days 1 to 14 every 21 days, or nab-paclitaxel administered intrave nously 
(IV) on Days 1 and 8 with immunotherapy of durvalumab administered IV on Day 
15 every 21 days, and nab-paclitaxel monotherapy administered IV on Days 1 and 8 
every 21 days as second/third-line treatment for advanced NSCLC.
Exploratory 
!To assess healthcare res ource utilization for the tr eatment arms.
!To assess the qualit y of life (QoL) for the treatment arms.
!To determine baseline tumor characteristics which predict response to nab-paclitaxel 
as a single agent and in combination with epigenetic modifying therapy of CC-486 or in combination with immunotherapy of durvalumab. 
!To evaluate genomic correlates of response to nab-paclitaxel as a single agent and in 
combination with epigenetic modifying therapy of CC-486 or in combination with immunotherapy of durvalumab. 
                                               
1nabÂ®is a registered trademark of Celgene Corporation.&(/*(1(35235,(7$5<,1)250$7,21uslyly(IV) IV) y ono
y (QD) on y (QD) on
sly (IVy (IV ))on 
DayDay 15 15evev
11and 8 d 8 evev
the combinthe combi
tytyofofnabnab-
enetenetic ic momodd
1 days1 days ,or or
immunothemmunoth
abb-paclipacli taxtaiii
ndnd/thi/thidddrddi--lil
ltlthcare hcare resr
the the qualitqualit
etermineetermine bab
s a single ag a single ag
in n combinombin
!!To evo ev
coco
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 7 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016!To evaluate anti-tumor activity of nab-paclitaxel/durvalumab combination therapy 
using Investigator assessment according to immune related response criteria updated with RECIST 1.1 (irRECIST), and its association with PD-L1 expression.
Study Design
This is a Phase 2, open-label, multicenter study to assess efficacy and safety of:
onab-paclitaxel in combination with epigenetic modifying therapy of CC-486,
onab-paclitaxel in combination with immunotherapy of durvalumab, 
oandnab-paclitaxel monotherapy 
as second/third-line treatment in subjects with  advanced NSCLC who have received no more 
than one prior chemotherapy regimen. Approximately 240 subjects with advanced NSCLC will 
be assigned 1:1:1 into one of the following treatment arms: nab-paclitaxel /CC-486 combination 
therapy, nab-paclitaxel /durvalumab combination therapy or nab-paclitaxel monotherapy prior to 
receiving the first dose of investigational product (IP). Rando mization/tr eatment assignment 
strategy of subjects to the three treatment arms  is described in the Overview of Statist ical 
Methods below and in Section 10.1. 
The study will consist of up to a 28-day Screening Period, a Treatment Period and a Follow-up 
Period.
The Screening Period for eligibility determination begins upon subject written informed consent.  
All screening assessments must be completed within 28 days prior to first dose of IP.
The Treatment Period begins with the first dose of IP as described in Section 8.  Subjects will 
receive one of the following treatments based on the randomization/tr eatment assignment:
!nab-Paclitaxel 100 mg/m
2IV infusion over 30 minutes on Days 8 and 15 and CC-486 
200 mg orally QD on Days 1 to 14 of each 21-day treatment cycle, or  
!nab-Paclitaxel 100 mg/m2IV infusion over 30 minutes on Days 1 and 8 and 
durvalumab 1125 mg IV infusion ove r approximately 1 hour on Day 15 of each 21-
day treatment cycle, or  
!nab-Paclitaxel 100 mg/m2IV infusion over 30 minutes on Days 1 and 8 of each 21-
day treatment cycle
No additional anticancer agents are allowed during study treatment.  All supportive care
(including but not limited to growth factors, antiemetics, analgesics, zoledronic acid, 
denosumab) is permitted as per the Investigato râ€™s discretion and should be administered 
according to local institutional pract ice. Sub jects will continue treatment un til disease 
progression, development of an unacceptable tox icity, death, lost to follow-up, withdrawal of 
consent, or termination of the study by the Sponsor. Subjects in the nab-paclitaxel/durvalumab 
arm may continue treatment beyond disease progression per Response Evaluation Criteria in 
Solid Tumors (RECIST) guidelines, Version 1.1 as described in Section 4.1.2.1 .
Tumor evaluations will be assessed by the investigative sites and response will be determined 
according to RECIST guidelines, Version 1.1 ( Eisenhauer, 2009 ), and immune-related RECIST 
criteria (irRECIST) when applicable.&(/*(1(35235,(7$5<,1)250$7,21o more  more 
NSCLC wNSCLC w
48486 combin6 combin
momonotherapnotherap
atmatment assient assi
view of Staview of S
atment Peratment Per
s upon subjupon su
28 days pri28 days pri
ffIPIPas descas de
n the randn the rand
nfuusisionon oveovenn
 toto14 14ofofeff
m22IV infuIV infu
gIV infusioIV infusio
le, or  e, or  
100 100 mg/mm
entntcyclecycle
cancerancer ageage
not limited not limite
is permitteis permitt
g to o localcalini
ession, devession, deve
sentsent, or ter, or ter
rmrmmmmmay coay co
Solid TuSolid T
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 8 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016All scheduled laboratory samples will be sent to a central laboratory for analysis. Local 
hematology and chemistry tests may be perfor med as required for s ubject management/treatment 
decisions. Local laboratory values that are considered abnormal and clinically significant will be 
recorded as an adverse event (AE)/serious adverse event (SAE) and also recorded on the laboratory electronic Case Report  Form (eCRF) (see Section 11.3).
All subjects who discontinue from treatment for an y reason other than withdrawal of consent, 
lost to follow-up, death, or termination of th e study by the sponsor will enter the Follow-up 
Period. It will consist of a visit 28 days after the last dose of IP or End of Treatment Visit, 
whichever is later. Thereafter, subjects in the nab-paclitaxel/CC-486 combination and nab-
paclitaxel monotherapy arms will be follow ed for survival by phone call contact approximately 
every 90 days (+/- 14 days) for at least 12 mont hs after the last sub ject is ra ndomized/assigned in 
either arm or 120 progression-free survival (PFS) events have been observed between these two 
arms, whichever comes later. Subjects  in the nab-paclitaxel/durvalumab arm will be followed for 
survival in a similar manner for at least 12 months after the last subject is assigned to this arm.
During the study, subjects will have computed tomography (CT) scans every 42 days (-3/+7 
days) until documented progression of disease
, withdrawal of consent, lost to follow-up, death, 
or termination of the study by the Sponsor. Subjects in the nab-paclitaxel/durvalumab arm who 
continue beyond disease progression per RECIST 1.1 will continue to have CT scans every 42 
days (-3/+7) until progression per immune-related RECIST criteria (irRECIST 1.1) ( Nishino, 
2013 ). Those subjects entering the Follow-up Period without documented progression will 
continue to have CT scans in accordance with local standard of care (or approximately every 90 
days) until documented progression of disease , withdrawal of consent, lost to follow-up, death, 
or termination of the study by the Sponsor. All post-treatment anticancer therapies will be 
recorded during the Follow-up Peri od.  
Study Population
Male and female subjects with advanced NSCLC who have received no more than one prior
chemotherapy regimen for their advanced diseas e will be eligible for this study (immunotherapy 
in prior line of treatment is allowed, including platinum doublet combination). Subjects will receive study therapy as second or third line of treatment for advanced disease.
Length of Study
The enrollment of 240 subjects on this study w ill take approximately 28 months. The total length 
of this Phase 2 study with follow-up for survival is estimated to be approximately 40 months.
The End of Trial is defined as either the date of the last visit of the last subject to complete the 
post-treatment follow-up, or the date of receipt of the last data point from the last subject that is required for primary, secondary and/or exploratory analysis, as prespecified in the protocol, 
whichever is the later date.
Study Treatments
Subjects will receive nab-paclitaxel in combination with CC-486 or durvalumab, or nab-
paclitaxel monotherapy during the study. The CC-486, nab-paclitaxel, and durvalumab are
designated as IP and w ill be pack aged and supplied by the Study S ponsor. &(/*(1(35235,(7$5<,1)250$7,21matelymately
assignedssigned inin
en theen the sesetwtw
ll be fol be fo llollww
gnedgne to thio thi
veryery 42 day42 yy
llost to follost to fol
litaxel/durvlitaxel/du
nue to havenue to have
riiteria (teria (ii irirRE
ut documt docum e
dard of ard of caca
rawal ofrawal of co
stst--treatmentreatme
eddNSCLCNSCLC
anced dianced di ses
wed, includiwed, includ
d or thid or thi rd lrdiii
00subjectsubject s o
dydywiwiththiiiffhhololfff
ial is defineal is defin
ent fent fololfflolow-w-
for fprimarprima
ever iever s thethe
tudy Treatudy Trea
SubjectsSubjec
clit
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 9 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Overview of Statistical Methods
The primary objective of this study is to  estimate the efficacy of the CC-486 and nab-paclitaxel 
combination therapy, that of the durvalumab and nab-paclitaxel combination therapy, and that of 
the nab-paclitaxel monothe rapy. The secondary efficacy ob jective is to estimate the relative 
efficacy of each of the combination regimens to the monotherapy regimen and the tolerability of 
each of the 3 treatment regimens.  
Approximately 240 subjects will be assigned to one of the three treatment arms (approximately 
80 subjects per group).  A permuted-block randomization method will be employed to assign the 
subjects among the treatment arms that are enrolling simultaneously, stratified by the following 
baseline factors: ECOG performance status (0 versus 1), gender (males versus females), and smoker (yes versus no). Randomization/treatment assignment of subjects will be carried out 
centrally using an Interactive Response Technolo gy (IRT) system. Prior to Protocol Amendment 
4.0, all subjects were randomized 1:1 to the nab-paclitaxel/CC-486 combination therapy and 
nab-paclitaxel monotherapy arms . As Protocol Amendment 4.0 implementation was in effect 
after enrollment in the nab-paclitaxel/CC-486 combination therapy and nab-paclitaxel 
monotherapy arms completed with each reaching approximately 80 subjects, all subjects enrolled while Protocol Amendment 4.0 is in effect and at the time of Protocol Amendment 5.0 
implementation will be assigned to the nab-paclitaxel/durvalumab combination therapy arm until 
approximately 80 subjects have been enrolled in that arm. Hence, treatment assignment of 
subjects to the nab-paclitaxel/CC-486 combination therapy and nab-paclitaxel monotherapy 
arms was in effect conducted completely in  a randomized fashion and randomization between
thenab-paclitaxel/durvalumab combination and nab-paclitaxel monotherapy arms will not apply.  
Evaluations of the study endpoints will be based primarily on the point estimates and the 
associated 95% confidence intervals of the w ithin- and between -treatment differences (each 
combination therapy vs. monotherapy).
An independent Data Monitoring Committee (DMC) will be established to review the interim 
safety and efficacy data.  
Efficacy Analyses
The intent-to-treat population, which includes all rando mized (or assigne d) subjects regardless of 
whether the subject receives any IP or has any e fficacy assessments performed, will be used for 
all eff icacy analyses. The primary efficacy endpoint is PFS, which is defined as the time from the 
date of rando mization/tr eatment assignment to the date of disease progression or death ( from any 
cause) on or prior to the data cutoff date for analyses, whichever occurs first, based on the 
Investigatorâ€™s assessment of the data from CT scans using RECIST 1.1 guidelines. Baseline tumor measurements will be determined from the radiologic evaluation performed within 28 
days before the start of study therapy. 
Progression-free survival will be summarized us ing Kaplan-Meier methods with median PFS 
time (including two-sided 95% confidence interval [CI]) for each treatment arm.  The relative 
treatment effect between each of the combination the rapy and monotherapy arms with respect to 
PFS will be estimated by the hazard ratio (HR) a nd the associated two-sided 95% CIs using the 
stratified Cox proportional hazard model with ECOG performance status (0 versus 1), gender
(males versus females), and smoker (yes versus no) as the stratification factors. No statistical 
inferential tests will be performed. To expl ore the effect of treatment post initial progression, the he
wingwing
 and and 
ried out ried out 
oll AmendmAmendmll
n therapyn therapy ay
tion was intion was i
abab-paclitaxpac
bjects, allbjects, all sll
ol AmendmAmenl
ab combinaab combina
nce, treatmnce, treat
yand and nabnab--p
d fashiofashio nn
paclitaxel paclitax
primarily oprimarily o
ththinin--and band b
mmittee (DMmittee (DM
on, n, which which i
ives anyives any IP
The Theprimarprim
ioionn//ntreatmtreatm
or to the daor to the da
s assessmes assessme
asurementsurements
efore the stefore the st
ogressiongression -f-f
time (incluime (inclu
reatmreatm ene
S
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 10 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016PFS defined by irRECIST criteria may be estimated for those subjects in the nab-
paclitaxel/durvalumab combination arm.
The secondary endpoints include disease control rate (DCR), overall response rate (ORR), and 
overall survival (OS). Disease control rate and ORR will be summarized within each treatment arm by the observed rates and the associated 95% CIs. The relative treatment effect of each of 
the combination therapy arms to the monotherapy arm will be summarized by the ratio of the 
observed rates. Overall survival w ill be analyzed us ing similar statist ical methods as that for the 
PFS endpoint.
Safety Analyses
The treated population, which incl udes all subjects who receive at least one dose of IP, will be 
the analysis population for all safety analyses. 
Adverse events will be analyzed in terms of treatment-emergent adverse events (TEAEs), 
defined as any AE or SAE occurring or worsening on or after the day of the first dose of the IPthrough 28 days after the last dose of the last IP administration.  
In addition, any SAE with an onset date more than 28 days after the last dose of IP that is 
assessed by the Investigator as related to IP w ill be considered a TEAE. For the nab-
paclitaxel/durvalumab arm, AEs with an onset from 29 days up to 90 days after the last dose of 
any IP will be summarized separately.
Treatment-emergent adverse events, Grade 3 or higher TEAEs, SAEs, TEAEs leading to dose 
reduction, and dose interruption, TEAEs leading to treatment discontinuation, and TEAEs with 
an outcome of death will be summarized by treatment arms using MedDRA system organ class 
and preferred terms.
Sample Size
This study is designed primarily to estimate the treatment effect within each of the combination 
and monotherapy arms and secondarily the relat ive effect between each of the combination 
therapy and the monotherapy arms with respect to the primary and secondary efficacy endpoints. 
The sample size was chosen to support the estimation of the within - and between-treatment 
effects with reasonable precision. Table 1 below summarizes the precisions that can be achieved 
given different scenarios of hypothetical observed hazard ratios between the two treatment arms 
for PFS events, assuming a total of approximately 120 events are observed between two
treatment arms, and the time to PFS has an exponential distribution. 
Table 1: Progression-Free Survival â€“ Two-sided 95% Confidence Interval of 
Hypothetical Observed Hazard Ratio between Treatment Arms
Hypothetical Number of 
Events ObservedHypothetical Observed Hazard 
Ratio of PFS Events95% Confidence Interval of 
Hazard Ratioa
1200.60 (0.42, 0.86)
0.65 (0.45, 0.93)
0.70 (0.49, 1.00)
aAssuming a standard error of 0.18 for the log hazard ratio.&(/*(1(35235,(7$5<,1)250$7,21 will be will be 
((TEAEsTEAEs )
first dose ofirst dose
ast dose of st dose of 
EAEEAE .ForFort
to 90 dayto 90 s
TEAEs, EAEs, SSA
eatmenteatment didi
ent arms ent arms uu
mate the tremate the t
rilyilyththe relae re
s s wiwiththiii resp resh
support thsupport th
isioision.n.TablTa
of hypotheof hypo
ming a total ming a tot
d thhe timee time tt
ProgressiProgress
HypothHypoth
pothetical Nothetical N
Events OEvents O*
(/
EDMS Doc. Number:nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 11 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Assuming the median times of PFS are 4.17, 4.25 and 2.5 months, respectively, for the nab-
paclitaxel/CC-486 combination therapy, the nab-paclitaxel/durvalumab combination therapy and 
nab-paclitaxel monotherapy arms, and an approximate 28 months accrual period for a total of 
approximately 240 subjects, it is estimated that an approximate total of 170 PFS events among the 
three arms will be observed by approximately 3 months after the last subject is assigned to the 
nab-paclitaxel/durvalumab arm, assuming an exponential distribution for PFS. 
One nonbinding interim analysis for PFS with early stopping rule for fut ility will be c onducted 
when approximately 60 events have been observed between the nab-paclitaxel/CC-486 
combination and nab-paclitaxel monotherapy arms. An additional non-binding interim analysis 
for futility with early st opping rule with the PFS endpoint between the nab-
paclitaxel/durvalumab combination and nab-paclitaxel monotherapy ar ms will be conducted 
when approximately 30 PFS events have been observed in the nab-paclitaxel/durvalumab arm 
(60 or more events are expected to have o ccurred in the monotherapy arm at that point).
At the interim analysis data review on , based on the recommendation of the DMC, 
treatment with CC-486 will be discontinued in the nab-paclitaxel/CC-486 combination arm; 
subjects in this arm may be allowed to continue on nab-paclitaxel single agent, at the 
Investigatorâ€™s discretion.  
Similarly, following the outcome of the interim analysis between nab-paclitaxel/durvalumab 
combination and nab-paclitaxel monotherapy arms, and taking into account the DMC 
recommendations, subjects may be allowed to remain on either nab-paclitaxel or durvalumab as 
a single agent or both agents, at the Investigatorâ€™s discretion.
Data Monitoring Committee
An independent Data Monitoring Committee (DMC) will be established with the responsibilities 
for safeguarding the interests of study participants and monitoring the overall conduct of the 
study. Final recommendations of the DMC will reflect the judgment of the DMC members and will be considered advisory in nature to the Sponsor. The decision to implement the 
recommendations of the DMC will be made by the Sponsor, following consultation with the trial 
Coordinating Investigator and Steering Co mmit tee. A DMC charter w ill be established.ysis sis 
ducted ucted 
alumab armlumab arm
t poit pointntiii).).
dation of thdation of t
combinatcombi
gle agent, atle agent, a
en nnabnab-pac
ng into accng into acc
either either nabnab
retion.retion.
(DMC) wil(DMC) wil
cipants andipants an
MC will refMC will r
to the to the SponS
l be made bl be made b
Steering Coteering Co
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 12 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016TABLE OF CONTENTS
TITLE PAGE .................................................................................................................1
PROTOCOL SUMMARY .............................................................................................6
1. INTRODUC TION ..................................................................................... 19
1.1. Non-small Cell Lung Cancer ..................................................................... 19
1.2. nab-Paclitaxel in NSCLC .......................................................................... 20
1.3. Rationale for nab-Paclitaxel as Second/Third-line Treatment in Subjects 
with Advanced NSCLC ............................................................................. 22
1.4. Rationale for nab-Paclitaxel in Combination With Epigenetic Modifying 
Therapy of CC-486 as Second/Third-line Treatment in Subjects with 
Advanced NSCLC ..................................................................................... 23
1.5. Rationale for nab-Paclitaxel in Combination With Immunotherapy of 
Durvalumab as Second/Third-line Treatment in Subjects with Advanced 
NSCLC...................................................................................................... 26
2. STUDY OBJE CTIVES .............................................................................. 31
2.1. Primary Objective ...................................................................................... 31
2.2. Secondary Objectiv e.................................................................................. 31
2.3. Exploratory  Objectiv es .............................................................................. 31
3. STUDY ENDPOI NTS............................................................................... 32
3.1. Primary Endpoint ....................................................................................... 32
3.2. Secondary Endpoints ................................................................................. 32
3.2.1. Efficacy ..................................................................................................... 32
3.2.2. Safe ty ........................................................................................................ 32
3.3. Exploratory Endpoints ............................................................................... 32
4. OVERALL STUDY DESIGN ................................................................... 33
4.1. Study De sign............................................................................................. 33
4.1.1. Screening Period........................................................................................ 33
4.1.2. Treatment Pe riod....................................................................................... 33
4.1.2.1. Treatment Beyond Progression for Subjects in the nab-
Paclitaxel/Durvalumab Arm ....................................................................... 34
4.1.3. End-of-Treatme nt Visi t.............................................................................. 34
4.1.4. Follow-up Period ....................................................................................... 34
4.2. Study Design Rationale ............................................................................. 35
4.3. Study D uration .......................................................................................... 38&(/*(1(35235,(7$5<,1)250$7,212
gg
.................... 232
rapyapyofofyy
th Advanceth Advan
.....................
...............
....................
.........................
..........................
..........................
...........................
...........................
.........................
.....................
dpodpointnts....
STUDY DSTUDY 
DesignDesign ........
eening Pereening P
TreatmenTreatmen
TreatmTreatm
PaPa
4.1.3.4.1.3
1.4.14
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 13 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 20164.4. End of Trial ............................................................................................... 38
5. TABLE OF EVENTS................................................................................ 39
6. PROCEDURES......................................................................................... 43
6.1. Medical Hi story ......................................................................................... 43
6.2. Prior and Concomitant Medications and Procedures .................................. 43
6.3. Pregnancy Testing ..................................................................................... 44
6.4. Complete Chest Computed Tomography (CT ) Scan ................................... 44
6.5. Weight and Height ..................................................................................... 44
6.6. ECOG Performan ce Score ......................................................................... 44
6.7. Peripheral Neuropath y Assessment............................................................ 45
6.8. Adverse Event Reporting ........................................................................... 45
6.9. Qu ality of Life Questionnaires ................................................................... 45
6.10. Healthcare Resource U tilization Questi onnaire .......................................... 45
6.11. Laboratory A ssessmen ts ............................................................................ 45
6.12. Tumor Tissue Sample Collection and Peripheral Blood Collection 
(Exploratory A ssessments) ........................................................................ 46
6.13. Electroca rdiogram ..................................................................................... 47
6.14. CT Scan of the Head or Brain Magnetic Resonance Imaging (MRI) .......... 47
6.15. Bone Scans and X-rays.............................................................................. 47
6.16. Physical Examinations ............................................................................... 48
6.17. Vital Si gns................................................................................................. 48
6.18. Surviv al..................................................................................................... 48
7. STUDY POPULATION ............................................................................ 49
7.1. Number of Sub jects and Sites .................................................................... 49
7.2. Inclusion Criteri a ....................................................................................... 49
7.3. Exclusion Criteri a...................................................................................... 50
8. DESCRIPTION OF ST UDY TREATM ENTS........................................... 54
8.1. Description of Investigational Products ...................................................... 54
8.1.1. nab-Paclitaxel ............................................................................................ 54
8.1.2. CC-486 (Azacitidine for Oral Administration) ........................................... 54
8.1.3. Durvalumab (MEDI4736) .......................................................................... 54
8.1.4. Monitoring During/After Durvalumab In fusion ......................................... 55
8.2. Treatment Administration and Schedule .................................................... 56&(/*(1(35235,(7$5<,1)250$7,214
......4444
.................... 454
..........................
..........................
..........................
..................
alBlBllood Coood C
.......................
...........................
netetic Resonic Reso
..........................
...........................
.............................
........................
LATIONLATION
f Subjects aSubjects a
oon Crin Cri teriteriiiaa
clusioclusio n Crin C
DESCRIPDESCRIP
DescrDescr
.1.1. nn
&8.1.2..1
3
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 14 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 20168.3. Dose Omissions and Modifications ............................................................ 56
8.3.1. Rules for Dose Omissions and Modified Schedules ................................... 56
8.3.2. Rules for Dose  Modif ications .................................................................... 58
8.4. Method of Treatment Assignment .............................................................. 62
8.5. Packaging and Labeling ............................................................................. 62
8.6. Investigational Product Accountability and Disposal ................................. 62
8.7. Investigational Product Compliance ........................................................... 63
8.8. Overdose ................................................................................................... 63
9. CONCOMITANT MEDICATIONS AND PROCEDURES ....................... 64
9.1. Permitted Concomitant Med ications and P rocedure s.................................. 64
9.2. Prohibited Concomitant Medications and Procedures ................................. 65
9.3. Required Concomitant Medications and Procedures for Subjects Receiving 
CC-486...................................................................................................... 66
9.3.1. Description o f G-CS F................................................................................ 66
9.3.2. Administration of G-CS F........................................................................... 66
10. STATISTICAL ANALYSES ..................................................................... 67
10.1. Overvi ew................................................................................................... 67
10.2. Study Population Definitions ..................................................................... 68
10.2.1. Intent-to-treat Population ........................................................................... 68
10.2.2. Per-protocol (PP) Population ..................................................................... 68
10.2.3. Treated Population ..................................................................................... 68
10.3. Sample Size and Po wer Consider ations ...................................................... 68
10.4. Background and Demographic Characteristics ........................................... 71
10.5. Subject Disposition .................................................................................... 72
10.6. Efficacy Analysis ....................................................................................... 72
10.6.1. Primary Efficacy  Endpoint s....................................................................... 72
10.6.2. Secondary Eff icacy Endpoi nts................................................................... 73
10.6.2.1. Disease Cont rol R ate ................................................................................. 73
10.6.2.2. Overall S urvival ........................................................................................ 73
10.6.2.3. Overall Res ponse R ate............................................................................... 73
10.6.3. Exploratory Endpoints ............................................................................... 73
10.6.3.1. HealthCare Utilizatio n ............................................................................... 73
10.6.3.2. Qu ality of Lif e Questionnaires ................................................................... 73&(/*(1(35235,(7$5<,1)250$7,213
......6464
.................... 646
..........................
bjects Recebjects Rec
....................
...............
......................
.......................
...........................
...........................
..........................
onn......................
.......................
ower Consiwer Consi
nd Demograd Demogr
spositsposit ion.
cy Analysisy Analysis
imary Efficmary Eff
SecondarSecondar
1.1. DiDiseasea
.6.2.2..2.2. OO
10.6.2.3.0.6.2.3.
6
EDMS Doc. Number:nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 15 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 201610.6.3.3. Biomarker, Tumor Characteristics, and Geno mic Analyses ........................ 73
10.6.3.4. Anti-tumor Activity and PD-L1 Expression ( nab-Paclitaxel/Durvalumab 
Arm).......................................................................................................... 74
10.7. Safety An alysis.......................................................................................... 74
10.7.1. Adverse Events .......................................................................................... 74
10.7.2. Laboratory Assessmen ts ............................................................................ 74
10.7.3. IP E xposure ............................................................................................... 75
10.8. Study Therapy Termination ....................................................................... 75
10.9. Deaths ....................................................................................................... 75
10.10. Interim An alysis ........................................................................................ 75
10.11. Data Monit oring Co mmittee ...................................................................... 76
10.12. Scientific Steering Committee ................................................................... 76
11. ADVERSE EV ENTS ................................................................................. 77
11.1. Monitoring, Recording and Re porting of Advers e Even ts .......................... 77
11.2. Evaluation of A dverse Events.................................................................... 77
11.2.1. Se riousness................................................................................................ 78
11.2.2. Severity / Intensi ty..................................................................................... 79
11.2.3. Caus ality ................................................................................................... 79
11.2.4. Durati on .................................................................................................... 80
11.2.5. Action Taken ............................................................................................. 80
11.2.6. Outco me.................................................................................................... 80
11.3. Abnormal Laborat ory Valu es..................................................................... 80
11.4. Pregna ncy.................................................................................................. 80
11.4.1. Females of Childb earing Po tential ............................................................. 81
11.4.2. Male Subjects ............................................................................................ 81
11.5. Reporting of Serious Adverse Ev ents......................................................... 81
11.5.1. Safety  Querie s ........................................................................................... 82
11.6. Expedited  Reporting of Adverse Events ..................................................... 82
11.7. Definition of Adverse Events of Special Interest ........................................ 83
12. DISCONTINUATIONS ............................................................................ 84
12.1. Study Treatment Di scontinu ation ............................................................... 84
12.2. Study Discont inuation ............................................................................... 84
12.3. Subject Replacement ................................................................................. 85&(/*(1(35235,(7$5<,1)250$7,21...7575
............... 7575
.......................... 7
.....................
....................
ventsvents ......
......................
.......................
...........................
...........................
..........................
...........................
.......................
oryryValuesValuesyy
.....................
f Childbearf Childbear
Subjectsubjects ....
porting of porting o
SafSafetetfffy yQuQu
ExpeExpe
.7.
&DD
12.2
1
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 16 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 201613. EMERGENCY PROCEDURES ................................................................ 86
13.1. Emergency Contact .................................................................................... 86
13.2. Emergency Identification of Investigational Products ................................ 86
14. REGULATORY CONSIDERATIONS ...................................................... 87
14.1. Good Clinical Practice ............................................................................... 87
14.2. Inve stigator Responsibilities ...................................................................... 87
14.3. Subject Information and Informed Consent ................................................ 88
14.4. Confidentiality ........................................................................................... 88
14.5. Protocol A mendments................................................................................ 88
14.6. Institutional Review Board/Independent Ethics Committee Review and 
Approval ................................................................................................... 88
14.7. Ongoing Information for Ins titutional Review Board / Ethics Committee... 89
14.8. Closure of the St udy.................................................................................. 89
15. DATA HANDLING AND RECORDKEEPING ........................................ 90
15.1. Data/Docu ments ........................................................................................ 90
15.2. Data Management ...................................................................................... 90
15.3. Record Retention ....................................................................................... 90
16. QUALITY CONTROL AND QUALITY ASSURANCE ........................... 92
16.1. Study Monitoring and S ource Data Veri ficatio n......................................... 92
16.2. Audits and Inspections............................................................................... 92
17. PUBLICATIONS ...................................................................................... 93
18. REFERENCES.......................................................................................... 94
19. APPENDICES ........................................................................................... 99
Appendix A: ECOG Perfor mance Status Score .......................................................... 99
Appendix B: Recommendations for Management of Treatment-Induced Diarrhea ... 100
Appendix C: Treatment Modification and Toxicity Management for nab-Paclitaxel 
/Durvalumab arm..................................................................................... 1018
......8888
and and 
.......................... 8
CoCommittemm
....................
...............
......................
.......................
...........................
LITY ASSLITY AS
Data Verificata Verific
...........................
.......................
........................
.....................
PerformancPerforman
oommendatmmendat
TreatmentTreatmen
/Durvalum/Durvalum
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 17 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016LIST OF TABLES
Table 1: Progression-Free Survival â€“ Two-sided 95% Confidence Interval of 
Hypothetical Observed Hazard Rati o between Treatment Arms ................. 10
Table 2: Blinded Radiology Assessment of Overall Response Rate (Intent-to-treat 
Population) ................................................................................................ 21
Table 3: Data for Control Arms using Taxanes from Phase II and III Studies 
Blinded...................................................................................................... 36
Table 4: Table of Events.......................................................................................... 39Table 5: Requirements for Collection Based on Archival Tumor Sample Type ........ 46
Table 6: Permanent Dose Reductions for Hematologic and Nonhematologic 
Toxicities and Dosing on the Study............................................................ 61
Table 7: Disease Control Rate â€“Two-Sided  95% Confidence Interval of Hypothetical 
Disease Control Rate with a Sample Size of 80 Subjects in a Treatment 
Arm........................................................................................................... 69
Table 8: Progression-Free Survival â€“ Two-Sided 95% Confidence Interval of 
Hypothetical Observed Hazard Rati o between Treatment Arms ................. 69
&(/*(1(35235,(7$5<,1)250$7,214646
.................... 616
HypotheticHypothetic
TreatmentTreatm
..........................
nce Intervace Interv
atment Armtment A
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 18 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016LIST OF FIGURES
Figure 1: Anti-PD-L1 in Combination with Platinum-Based Doublets ...................... 29
Figure 2: Overall Study Design ................................................................................. 37
&(/*(1(35235,(7$5<,1)250$7,21
EDMS Doc. Number:nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 19 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 20161. INTRODUCTION
1.1. Non-small Cell Lung Cancer
Lung cancer is the leading cause of cancer-related deaths among men and women worldwide, 
with 1.2 million new cases diagnosed each year. Non-small cell l ung cancer (NSCLC) is the 
most common type of lung cancer, accounting for 80% of all new cases. There are an estimated 
1.1 million lives lost per year (approx imately 500,000 in the United States [US] a nd European 
Union [EU] alone) due to NSCLC. Smoking is the causative factor for up to 85% of cases 
(http://www.lungcancercoalition.org/en/pages/about/awareness).
The majority of patients are not diagnosed  until the tumor has progressed beyond the primary 
site. Despite step-wise advances in patient selection, targeted agents, and optimizing
chemotherapy regimens, patients with advanced NSCLC continue to have an unmet medical 
need ( Schiller, 2013 ).
Platinum-containing chemotherapy regimens remain (eg, platinum-based agents with taxanes) 
the standard first-line treatment in the US and Japan. In the EU, a third-generation 
chemotherapeutic agent (docetaxel, gemcitabine, paclitaxel, or vinorelbine), most commonly gemcitabine or vinorelbine, plus a platinum drug is used for advanced NSCLC ( NICE, 2011 ). 
For first-line therapy in patients with Stage IV NSCLC and good performance status, the 
American Society of Clinical Oncology (ASCO) clinical practice guideline recommends treatment with a platinum-based two-drug combination of cytotoxic drugs ( Azzoli, 2009 ). For 
patients without disease progression, the option of maintenance monotherapy with pemetrexed or 
erlotinib could also be considered ( Gerber, 2013; Schiller, 2013 ). A trend that is becoming more 
prevalent is personalized NSCLC treatment base d on tumor histology (squamous versus
nonsquamous), on molecular characteristics of the tumor, and on the patientâ€™s clinical status 
using agents targeting specific receptors, kinases and pathways (ie, epidermal growth factor receptor [EGFR], echinoderm microtubule-associated protein-like 4 [EML4] and anaplastic 
lymphoma kinase [ALK] fusion protein).
Single agent chemotherapy (pemetrexed, EGFR-inhibitors and taxanes) are standards of care for 
second-line treatment of patients with locally advanced or m etastatic NSCLC after f ailure of 
prior platinum-based chemotherapy. Docetaxel has be en widely evaluated in this setting, and is 
currently approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as a single agent for the treatment of patients with locally advanced or 
metastatic NSCLC after failure of prior chemotherapy  (the US label specifies prior platinum-
based chemotherapy). For patients with  a good performance status at the time of disease 
progression following first-line chemotherapy, docetaxel, despite a low response rate, was
associated with a 10% to  20% prolongation of 1-year survival and an improved quality of life 
when compared with ifosfamide, vinorelb ine, or best supportive care (BSC) alone ( Hanna, 
2004 ). Erlotinib is indicated in the US and EU for the treatment of patients with locally advanced 
or metastatic NSCLC after failure of at least one prior chemotherapy regimen, although no 
survival benefit has been demonstrated in patients with EGFR-IHC negative tumors.  Pemetrexed is indicated in the US and EU as a single agent for the treatment of patients with 
locally advanced or metastatic nonsquamous NSCLC after prior chemotherapy. However, the 
approval and subsequent increased use of pemetrexed  and erlotinib in the first-line setting poses 
an unmet need in the second-line setting, wh ereby new therapeutic options are needed.rimaryrimary
et medicalt medical
agents withgents with
generatgenerat ioion
elbine), molbine), m
nced NSCLced NSCL
od performod perfo
actice guidectice guid
of cytotoxicf cytotox
intenance mintenance m
chiller, 201chiller, 20
d on tumd on tum o
of the tumoof the tumo
kinases andkinases and
uleule-associassoc
tein).ein).
metrexed, Emetrexed, E
nts wints wi ththiilolo
motherapytherapy
he US Foodhe US Foo
EMA) MA) as a as a
Cafafter failuter failufff
herapyerapy ))y. F. For
fofollollowing wing 
d wiwiththii a 10a 1hh
cocompared wmpared w
44).).ErlErotiotinniii
or mr metastattastat
survivalurviva
m
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 20 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Recently, nintedanib, a triple angiokinase inhibitor, was approved in the European Union (EU) in
combination with docetaxel as second-lin e therapy for NSCLC. The results showed that 
compared to docetaxel alone, nintedanib plus docetaxel significantly extended the median OS 
from 10.3 to 12.6 months for patients with a dvanced adenocarcinoma, after first-line 
chemotherapy (p = 0.0359; hazard ratio [HR]: 0.83) ( Reck, 2014a ). In addition, ramucirumab 
was approved in the US in combin ation with docetaxel as second-line therapy. The Phase 3 
REVEL trial compared ramucirumab, a vascular endothelial growth factor (VEGFR)-2 antagonist, plus docetaxel with placebo plus docetaxel in NSCLC patients who experienced 
disease progression after treatment with platinum-based chemotherapy for locally advanced or 
metastatic disease. Median OS was better in  the ramucirumab group than in the placebo group 
(10.5 vs 9.1 months; HR, 0.857; p = .0235), as wa s median progression-fr ee survival (PFS) (4.5 
vs 3.0 months; HR, 0.762; p < .0001) ( Garon, 2014 ).
More recently, advances in immunotherapy have seen approvals of nivolumab (US and EU) and 
pembrolizumab (US) in the advanced NSCLC setting after prior chemotherapy. In this setting,
nivolumab has shown benefit in overall su rvival with 9.2 months (95% CI, 7.3 to 13.3) versus 
6.0 months (95% CI, 5.1 to 7.3) with docetaxel in advanced squamous NSCLC (Checkmate 017 study) ( Brahmer, 2015 ), and 12.2 months (95% CI, 9.7 to 15.0) versus 9.4 months (95% CI, 8.1 
to 10.7) with docetaxel (HR 0.73; 95% CI, 0.59 to 0.89; p = 0.002) in nonsquamous disease
(Checkmate 057 study) ( Borghaei, 2015 ). However, PFS benefit was modest (3.5 months with 
nivolumab versus 2.8 months with docetaxel (HR 0.62; 95% CI, 0.47 to 0.81; p <0.001) or did 
not favor nivolumab in these populations. Regar ding its safety profile, nivolumab is most 
commonly associated with immune-related adverse reactions. Most of these including severe 
reactions resolved following initiation of appropriate medical therapy, or withdrawal of 
nivolumab. In the pooled dataset of two studies in squamous NSCLC, the most frequent adverse 
reactions were fatigue (33%), decreased appetite (15%), and nausea (12%). The majority of adverse reactions were mild to moderate (Grades 1 or 2) ( Opdivo
Â®Prescribing Information ). In
comparison, the efficacy of pembrolizumab was investigated in a sub-group of a cohort of 280 
patients enrolled in a multicenter, open-label multi-cohort, activity-estimating study which showed an overall response rate (ORR) of 41% (95% CI, 29 to 54) in both squamous and 
nonsquamous subjects. Serious adverse reactions occurred in 38% of patients receiving 
pembrolizumab and the most frequent reported in at least 2% of patients were pleural effusion, pneumonia, dyspnea, pulmonary embolism, and pneumonitis ( Keytruda
Â®Prescribing 
Information ).
Similarly and as will be described below, the PD-L1 inhibitor durvalumab has demonstrated 
encouraging clinical activity both as a monotherapy and in combination with other agents 
including standard chemotherapies in metastatic melanoma, NSCLC and other advanced solid 
tumors, with acceptable and manageable reported toxicities.
1.2. nab-Paclitaxel in NSCLC
nab-Paclitaxel is approved in the first-line setting in  combination with carboplatin for patients 
with NSCLC in the US, EU, Japan, Argentina, Australia, New Zealand and other countries.  The 
approval was based on the evaluation of Phase I and II data ( Belani, 2008 ; Rizvi, 2008 ; Socinski, 
2010 ), as well as the pivotal Phase 3 study (CA031), ( Socinski, 2012 ). The pivotal Phase 3 study 
was a multicenter, randomized, open-label study conducted in 1052 chemo-naÃ¯ve subjects with &(/*(1(35235,(7$5<,1)250$7,21r 
roup roup 
FS))(4.5 (4.5 
US and EUUS and EU
pypy. In this sIn this s
, 7.3 to7.3 to 13.313 3
NSCLCNSCLC (C(
us 9.4 monts 9.4 mon
2) in nonsquin nonsq
it twas mwas od
% CI, 0.47 tCI, 0.47 t
afetafety yprofipro
acactitons. Moons. M
te medical te medical
in squamouin squamou
etite (15%),tite (15%),
GradeGrade ss1 or1 or
mab was inmab was 
penen-lalabel bel m
ORR) of 4ORR) of 4
s adverse readverse r
st frequent t frequen
momnaryary emy
will be descwill be desc
inical activnical act
anandard chedard che
withhi accept accepthh
. nana
nabna-PacliPacli
wiwiththiii NNhh
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 21 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Stage IIIB/IV NSCLC to compare nab-paclitaxel in combination with carboplatin to paclitaxel 
injection in combination with carboplatin as first-line treatment in patients with advanced 
NSCLC. nab-Paclitaxel was administered as an IV infusion ove r 30 minutes at a dose of 
100 mg/m2 on Days 1, 8, and 15 of each 21-day cycle. Paclitaxel injection was administered as 
an IV infusion over 3 hours at a dose of 200 mg/m2, following premedication. In both treatment 
arms carboplatin at a dose of area under the cu rve (AUC) = 6 mg*min/mL was administered IV
on Day 1 of each 21-day cycle after completion of nab-paclitaxel/paclitaxel infusion. Treatment 
was administered until disease progression, development of an unacceptable tox icity or patient 
withdrawal. The primary efficacy outcome  measure was overall response rate (ORR) as
determined by a central independent review  committee using RECIST guidelines (Version 1.0).
In the intent-to-treat (all-ra ndomized) population, the median age was 60 years, 75% were men, 
81% were white, 49% had carcinoma/adenocarcinoma, 43% had squamous cell lung cancer, 76% 
were ECOG performance status (PS) 1, 15% were â‰¥70 years of age and 73% were current or 
former smokers. Patients received a median of 6 cycles of treatment in both study arms. Patients 
in the nab-paclitaxel/carboplatin arm ha d a statistically significantly higher overall response rate 
compared to patients in the paclitaxel inject ion/carboplatin arm [(33% versus 25%; response rate 
ratio, 1.313; 95% CI, 1.082 to 1.593; p = 0.005), see Table 2 ].
Non-inferiority analysis of overall survival (OS) demonstrated that nab-paclitaxel /carboplatin
(nab-p/C) treatment is not inferior to paclitaxe l/carboplatin (P/C) treatmen t. Overall survival in 
the nab-paclitaxel arm was 12.1 months versus 11.2 months in the control arm (p = 0.271; HR = 
0.922). There was an approximately 10% increase in PFS in the nab-p/C versus P/C arm and PFS 
in the nab-p/C arm was noninferior to PFS in the P/C arm (HR nab-p/C/P/C 95% CI upper bound, 
1.086).
Table 2: Blinded Radiology Assessment of Overall Response Rate (Intent-to-treat
Population)
Variable
Category/Statisticnab-Paclitaxel/
carboplatin
(N=521)Paclitaxel/
carboplatin
(N=531)Response Rate 
Ratio
(pA/pT) p-value
Patients with Confirmed Complete or Partial Overall Response
n (%) 170 (33%) 132 (25%) 1.313 0.005*
Confidence Interval (CI) a28.6, 36.7 21.2, 28.5 1.082, 1.593
Complete Response, n (%) 0 1 (< 1%)
Partial Response, n (%) 170 (33%) 131 (25%)
PA/PT: response rate of nab-paclitaxel/response rate of paclitaxel.
a95% CI of response rate and 95.1% CI of response rate ratio.
* Indicates p-value < 0.049.Note: p-value is based on a chi-square test.Source: Data on File.
Adverse events (AEs) were assessed in 514 nab-paclitaxel/carboplatin-treated patients and 524 
paclitaxel injection/carboplatin-tr eated patients. The following common ( â‰¥ 10% incidence) AEs&(/*(1(35235,(7$5<,1)250$7,21n 1.0). 1.0).
ere mmen, en, 
cancer, 76cancer, 76
e current orcurrent o
udydyarmarmy s.s.P
overall respoverall res
ersus 25%sus 25 ;
t nabn-ppaclacl
C)C)treatmtrea en
in the conin the con
in the in the nabn
arm arm(HR(HR naR
t of Overaof Overa
aclitaxelaclitaxel //ll
arboplatinarboplat
(N=521(N=5235555
lete or Partilete or Part5235353535CI) CI) aa(3333
1( sponseonse, n (%, n (%(1 esponseponse , n (, n (*(/*responseespon raterate
% CI of % CI of respresp
Indicates pIndicates p -
Note: No p-p-valval
ourceource ::
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 22 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016were observed at a similar incidence in nab-paclitaxel/carboplatin and paclitaxel/carboplatin
arms: alopecia 56%, nausea 27%, fatigue 25%, decreased appetite 17%, asth enia 16%, 
constipation 16%, diarrhea 15%, vomiting 12%, dyspnea 12%, and rash 10% (incidence rates are 
for the nab-paclitaxel plus carboplatin treatment group). Toxiciti es, particularly neuropathy and 
Grade 3/4 neutropenia were less pronounced using nab-paclitaxel in the dose and schedule 
employed. Laboratory-detected abnormalities which occurred with a difference â‰¥5% for nab-
paclitaxel plus carboplatin versus paclitaxel injection plus carboplatin (Grades 1 to 4 [and Grade 3/4]) were: anemia (98% vs 91% [28% vs 7%]), neutropenia (85% vs 83% [47% vs 58%]) and 
thrombocytopenia (68% vs 55% [18% vs 9%]).  
1.3. Rationale for nab-Paclitaxel as Second/Third-line Treatment in
Subjects with Advanced NSCLC
Patients who fail first-line chemotherapy are elig ible for second-line treatment with single agent 
docetaxel, pemetrexed or erlotinib. In patients with good performance (eg, ECOG PS 0 or 1) and 
general health status, further treatment with chemo therapy is an important consideration that has 
been shown to extend overall survival. Despite the availability of second-line therapy, the trend of increased use of pemetrexed, as well as erlotinib (in selected patients) in the first-line and 
maintenance settings, potenti ally limits  the number of available second-line treatment options for 
many patients. Furthermore, the tolerability i ssues associated with the administration of 
docetaxel once every 3 weeks (q3w) h as prompted active research in the past decade to evaluate 
whether weekly regimens of taxanes could be  optimized to improve the toxicity profile. The 
availability of an effective second-line cytotoxic chemotherapy with an improved efficacy/safetyprofile over current available options would be a valu able addition for both the patient and the 
treating physician. Paclitaxel has also demonstrated potential activity in second-line NSCLC in a 
few studies ( Socinski, 1999 ; Juan, 2002 ; Socinski, 2002 ; Sculier, 2002 ; Buccheri, 2004 ; Ceresoli, 
2004 ; Yasuda, 2004 ). More recently, advances in immunotherapy have seen increased use of 
immune checkpoint inhibitors (eg, nivolumab, pembrolizumab) in the first and/or second-line 
setting for advanced NSCLC disease. 
nab-Paclitaxel exhibits 10-fold higher mean C
maxof free paclitaxel, delivers 33% higher drug 
concentration to tumors in preclinical xenograft models, and demonstrates enhanced transport 
across endothelial cell monolayers, wh en compared with paclitaxel ( Desai, 2006; Gardner, 
2008 ). Distribution of nab-paclitaxel to peripheral tissues as demonstrated in a recent study was 
4-fold faster and 10-fold more extensive than of Cremophor EL-paclitaxel micelles, which 
results in a unique and distinct profile of paclitaxel in tissues ( Li, 2015 ). The Cremophor EL-free 
medium enables nab-paclitaxel to be given over a shorter duration without the need for 
premedication to prevent solvent-related hypersensi tivity reactions, thus also avoiding negative 
impact of steroids on paclitaxel induced apoptosis and decreased antitumoral activity of chemotherapeutic agents as reported in pre-clinical models glucocorticoids ( Abraxane
Â®
Prescribing Information ;Zavodovskaya, 2015; Herr, 2003; Sui, 2006; Khan, 2013; Pang, 2006).
When administered with carboplatin in the first-line setting, weekly nab-paclitaxel has 
demonstrated a more favorable efficacy:safety profile compared to the every 3 weeks schedule.  
This weekly schedule of nab-paclitaxel allows the opportunity for closer (ie, shorter interval)
monitoring of side effects and optimizing dos e-intensity through timely adjustments.  &(/*(1(35235,(7$5<,1)250$7,21in
wiwiththiisingle single hh
COGCOG PSS00
consideratconsiderat
dd-lineineththere
ents) in the ts) in the
econdo-lineline
with the admwith the
esearch in tearch in t
to o improveimpro
mmothotherapyrap wy
alaluable adduable addll
rated potenated pote
inski, 2002inski, 2002
nces in immnces in im
luumab, pemmab, pe
e. . 
higher meahigher mea
reclinical xeeclinical x
nolayersolayer , w
ab-ab-paclipacli taxtaiii
foold ld momore re
e and distine and distin
es s nabnab-pacpa
oon to preven to prev
f steroieroif dsds
otherapeutotherapeut i
escribing Incribing In
When admWhen adm
ememonon
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 23 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Finally, recently published data has demonstrated efficacy of nab-paclitaxel as monotherapy in 
the second line setting in advanced NSCLC with ORR ranging from 16.1% to 33% and a median 
PFS of up to 5 months ( Chen, 2012; Saxena, 2012; Yuan, 2012 ).  
Rationale for dose and schedule
As previously noted, nab-paclitaxel 100 mg/m2weekly (Days 1, 8 and 15) in combination with 
carboplatin (21 day cycle) is a pproved in the US, EU, Japan, Argentina, Australia, New Zealand 
and other countries for the treatment of locally advanced or metastatic NSCLC in the first-line setting.  However, there is limited data of monotherapy nab-paclitaxel in the second or third-line 
setting; hence, this study will assess the efficacy and tolerability of weekly nab-paclitaxel, when 
administered on Days 1 and 8 of each 21-day cycle.  The allowance of a one week rest period in this study (ie, no treatment on Day 15), takes into  account research findings from other taxanes, 
whereby patients in the second-line setting are unlikely to tolerate the same dose-intensity 
compared to chemo-naÃ¯ve patients (eg, sharpe r dose reduction in the second-line setting). 
Therefore, the proposed nab-paclitaxel schedule (2 weeks treatment, 1 week rest) could offer the 
option of maintaining consistent dose-intensity for NSCLC patients in this setting.
1.4. Rationale for nab-Paclitaxel in Combination With Epigenetic 
Modifying Therapy of CC-486 as Second/Third-line Treatment in Subjects with Advanced NSCLC
CC-486 is an orally bioa vailable formulation of the nucleoside analog 5- azacitidine (AZA).  
After its incorporation into a cellâ€™s DNA during the S-phase of the cell cycle, CC- 486 forms 
covalent adducts with DNA Methyltransferase 1 (DNMT1) and depletes this enzyme required for the maintenance of DNA methylation patterns, thereby altering the epigenetic status of the cell. 
Epigenetic changes are covalent modifications of chromatin (DNA and histone proteins) that 
mediate the stable transmission of a geneâ€™s transcriptional status through cell division.  One of the first recognized epigenetic alterations in cancer was DNA methylation. The addition of a 
methyl group to cytosine in the dinucleotide CpG is catalyzed by DNA methyltransferases 
(DNMTs) and is associated with transcriptional repression of genes with high density of CpGs (CpG islands) in the vicinity of their promoters ( Jones, 2007 ).  Genomic methylation patterns are 
precisely regulated during normal embryonic devel opment and differentiation and have been 
found to be altered in specific ways in cancer. Specifically, cancer cell genomes are typified by 
reduced methylation globally with focal areas of aberrant hypermethylation in the CpG islands of 
genes encoding known tumor suppressors such as PTEN and BRCA1 as well as genes encoding 
proteins required for apoptosis, including caspase 8, DAPK and Apaf-1.  DNA methylation-based silencing can thus contribute to the establishment and maintenance of the transformed state 
and limit the effectiveness of anti-cancer therapies .  The recognition of the role of aberrant 
methylation in carcinogenesis and its reversibility has led to the development of DNMT inhibitors for cancer. Subcutaneous (SC) AZA wa s the first DNMT inhibitor to be approved in 
myelodysplastic syndromes (MDS) in 2004 ( Kaminskas, 2005 ).
The notion that sequential treatment with an epigenetic modifying agent followed by a cytotoxic
agent can result in improved response to the latter is supported by numerous preclinical 
experiments and now by early clinical results.  In breast cancer cell lines, restoring expression of 
the aberrantly methylated pro-apoptotic gene TMS1 with azacitidine can restore taxane &(/*(1(35235,(7$5<,1)250$7,21ine ne
when when 
period period in in
er taxanes,er taxanes
ntntensiensitytyii
ne setting)e setting
k rest) couldk rest) cou
is setting.s settin
With EpiWith Epi
Thirdhir-linene
eoside analoside an
phase of thphase of t
DNMT1) anDNMT1) an
therebyhereby alalytel
ons of chrons of chro
eâ€™s transcripeâ€™s transc
ons in cancons in c
nucleotide Ccleotide C
h transcripth transcript
of their proof their pro
 normal emormal em
pecific waypecific wa
n glgloballyobally wwyy
known tumonown tumo
red for apoped for apo
cing can thuing can th
the effecte effec i
ylatylatioion nin cin c
ibitors for bitors for 
myelodyspmyelodysp
he nohe no
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 24 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016sensitivity ( Gordian, 2009 ).  In a model of platinum resistant ovarian cancer, azacitidine reversed 
resistance to carboplatin ( Li, 2009 ).  This effect required pretreatment of the cells with 
noncytotoxic levels of azacitidine for 24 hours before the addition of carboplatin and was not 
observed with concurrent exposure to both agents.  More recently, Juergens and colleagues observed an unusually high ORR of approximately 20% in multiple-relapsed NSCLC patients 
treated with a variety of regimens after being treated with a combination of SC AZA and another 
epigenetic agent, entinostat, a histone deacetylase inhibitor ( Juergens, 2011 ).  In one case, a 
patient who had previously progressed on a regimen of paclitaxel, carboplatin and bevacizumab 
responded to the same triplet after treatment with SC AZA and entinostat, suggesting that the 
epigenetic modifying agents had reversed acquired resistance to the cytotoxic/anti-angiogenic regimen.  In a Phase 1/2 study of SC AZA with nab-paclitaxel in subjects with advanced 
metastatic solid tumors and breast cancer ( Dumlao, 2011 ), escalating doses of SC AZA (75 to
100 mg/m
2) were administered on Days 1 through 5, followed by nab-paclitaxel (100 mg/m2) 
intravenous (IV) on Days 8, 15, and 22 of a 28-day cycle.  Of 16 subjects treated at the time of 
publication, clinical activity has included 3 co mplete responses (CR, 1 Diffuse Large  B-cell 
Lymphoma [DLBCL], 2 ovarian), 4 partial responses (PR) in ovarian and endometrial cancer and 4 stable diseases (SD, 2 lung, 1 pancreatic, and 1 sarcoma).  
CC-486 entered clinical testing in 2006 in subjects with MDS, chronic myelomonocytic 
leukemia [CMML], and acute myeloid leukemia [AML], with daily extended dosing schedules of 14 and 21 out of 28 days in a non-crossover fashion.  Daily doses of 300 mg CC-486 have 
proven to be tolerated on both the 14 and 21 out of 28-day schedules with myelosuppression, 
gastrointestinal symptoms, and fatigue being the most common toxicities ( Garcia-Manero, 
2011 ).  Subjects treated with CC-486 for 14 or 21 days had DNA hypomethylation that persisted 
through the end of cycle.  This contrasts with the lack of persistent hypomethylation at the end of 
cycle when subjects were treated with SC AZA for 7 out of 28 days. 
 
 
 
  
 
 
 
 
 
 
 &(/*(1(35235,(7$5<,1)250$7,21enic enic 
d 
ZA (75 ZA (75 toto
10000mg/mg/mm2
ed at the timd at the t
use Large Buse Large 
d endometrendom
onic on mmyeloyel
daily extendaily ex
ly doses ofy doses of
ay scheduley schedu
commocommo n tnt
days had days had DND
e lack of pee lack of pe
ZA for 7 ouZA for 7 ou
3523552352
(35(31((1(*(1*(/*(/*&(/&(&
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 25 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
This Phase 2 study will test the hypothesis that epigenetic modifying therapy with CC-486 can 
improve the anti-tumor activity of nab-paclitaxel in second/third-line NSCLC patients (see 
Section 4.2for study rationale). Although docetaxel has been assessed in other randomized 
studies as a chemotherapy backbone, the considerable neutropenia-related toxicity could 
potentially pose safety concerns if combined with CC-486, and the steroid premedication could 
confound the epigenetic impact of CC-486.  In addition, the q3w dosing schedule of docetaxel 
restricts dose adjustment options, thus potentially yielding lower chemotherapy dose-intensity.
Please refer to the Investigatorâ€™s Brochures (IBs) of CC-486 and nab-paclitaxel (ABI-007) for 
detailed information concerning the available pharmacology, toxicology, drug metabolism, 
clinical studies, and adverse event profile of the IPs.
 
 
&(/*(1(35235,(7$5ettic icmomodifydify
secondecon /thir/thd
xel has beexel has bee
iderable neuderable ne
d with CCd with CC
86.  In addi6.  In a
s potentiallys potent
Brochures (Brochures
ng the availg the avai
e event profevent pr50$7,210$
25025)251)21),1<,15<$5<
(31((1(*(1*
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 26 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 20161.5. Rationale for nab-Paclitaxel in Combination With Immunotherapy 
of Durvalumab as Second/Third-line Treatment in Subjects with Advanced NSCLC
Durvalumab 
Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa 
subclass that inhibits binding of PD-L1 to PD-1 and CD80 and is being developed by AstraZeneca/MedImmune for use in the treatment of cancer.  (MedImmune is a wholly owned 
subsidiary of AstraZeneca; AstraZeneca/MedImmune will be referred to as AstraZeneca 
throughout this document.)  As durvalumab is an engineered mAb, it does not induce antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity.  The proposed 
mechanism of action for durvalumab is interferen ce of the interaction of PD-L1 with PD-1 and 
CD80.
To date durvalumab has been given to more than  1900 patients as part of ongoing studies either 
as monotherapy or in combination with other anti-cancer agents.  Refer to the current 
durvalumab Investigatorâ€™s Brochure for a complete summary of non-clinical and clinical information including safety, efficacy and pharmacokinetics.  
A Phase 2 trial of durvalumab is currently ongoing to assess efficacy and safety of the immune 
checkpoint inhibitor (dose of 10 mg/kg once every two weeks [q2w]) in patients with locally advanced or metastatic NSCLC in the third-line setting ( Rizvi, 2014 ) (ATLANTIC trial, 
[STUDY_ID_REMOVED]).  
Preliminary data of an open-label Phase 1b study of durvalumab 20 mg/kg every 4 weeks plus 
tremelimumab 1 mg/kg in immunonaive patients wi th advanced or metastatic squamous or non-
squamous NSCLC showed a manageable tolerability profile, with antitumor activity i rrespective 
of PD-L1 status (ORR 22%, 95% CI 9-44) ( Antonia, 2016 ).  
 
 
 
 
 
 
 
 
 ibodybody --
hhPDPDhh -1 and1 an
going studigoing stud
o the currenthe curren
inical and inical and
ficacy and scacy 
ks ks [q2w][q2 ) )ini
iizvi, 2014zvi, 2014 )
e 1b stud1b stud yy
naive pataive pat ieien
nageable tonageable to
5% CI 95% CI 9 --4447$5(7$(75,(35,(
(351(31((1*(1/*(/*(/*&(/&(&
EDMS Doc. Number:nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 27 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
nab- Paclitaxel in combination with immune checkpoint inhibitors
Tumor lysis as a consequence of chemotherap y treatment leads to release of tumor antigens, 
which in turn are recognized by the immune system, thus priming the immune system for 
checkpoint inhibitor activity ( Bracci, 2014; Chen, 2013; Mellman, 2011 ). Accumulating 
evidence suggests that immune activation plays an important role in chemotherapy efficacy
(Zitvogel, 2013 ). In addition to increasing tumor antigenicity, chemotherapy also reduces tumor 
burden and acts directly on immune cell populations, activating dendritic cells, depleting immunosuppressive regulatory T cells at low doses , depleting myeloid-derived suppressor cells, 
and increasing tumor-infiltrating lymphocytes ( Tanaka, 2009; Banissi, 2009; Kodumudi, 2010; 
Dieci, 2014 ). Taxanes have been shown to facilitate dendritic cell maturation and cytokine 
secretion ( Chen, 2013a ). In patients with lung cancer, paclitaxel was associated with generation
of pro -inflammatory markers, including interleukin 2 and interferon gamma, and the expression 
of T cell activation markers ( Zhang, 2008 ). Taxanes have been demonstrated to modulate the 
immune system by impairing regulatory T cells, which are drivers of peripheral tolerance, but 
not effector T cells, which are drivers of tumor -cell killing ( Tanaka, 2009 ). Taxanes are also 
known to act on myeloid cells such as myeloid -derived suppressor cells and alternatively &(/*(1(352with with iimmmm5 nce of chemce of chem
ized by theized by t
activitactivit y(y(BrB
thhat immunat immun
)). In addit. In addit ioi
cts directcts direct lyly
uppressive pressive 
creasing tumcreasing tum
ci, 2ci, 2014014))..TT
ecretion (ecretion ( CC
ofof pro proff --in
TTc5,(7$5<,1)250$7,210$50$25025)25,1)<,15<,5<$5<7$5(7$,(75,(35,235523
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 28 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016differentiated (M2) macrophages to decrease their immunosuppressive functions ( Kodumudi, 
2010 ).
The data above suggest a potential f or synergistic activity of cytotox ic therapy, such as taxanes, 
with checkpoint inhibitors, including those that target PD -1 or PD -L1.  nab -Paclitaxel has 
demonstrated cytotoxic activity in non -small cell lung cancer (overall response rate = 33% vs 
25% with paclitaxel in a Phase III trial) (Socinsk i, 2012) and, as stated above, does not require 
steroid pretreatment, which may make it a logical choice for combination with immune 
checkpoint inhibitor.
Therefore, this Phase 2 study will furthe r assess the potential synergistic activity of nab-
paclitaxel, a cytotoxic agent, in combination with the anti-PD-L1 checkpoint inhibitor 
durvalumab in second/third-line treatment for advanced  NSCLC, from an efficacy and safety 
standpoint.  The current study will allow patients who progress on prior checkpoint inhibitor 
therapy (eg, as their first-line or second-line therapy) as it is hypothesized that the companion 
chemotherapy of nab-paclitaxel may re-sensitize the disease to allow patient to respond to checkpoint inhibitors.
!nab- Paclitaxel in combination with anti-PD-L1
More recently, preliminary results of an ongoing Ph ase 1b trial in first line metastatic NSCLC of
another immune checkpoint anti-PD-L1 inhibitor, atezolizumab, showed high response rates in combination with the following platinum-based doublets: 60 % (95% CI: 15-95) in the 
carboplatin/paclitaxel cohort (Arm C; n = 5), 75% (95% CI: 43-95) in the 
carboplatin/pemetrexed arm (Arm D; n=14), a nd 62 % (95% CI: 32-86) with four patients 
experiencing complete response when atezolizumab was combined with carboplatin/ nab-
paclitaxel regimen (Arm E; n=13) ( Liu, 2015 ). The most frequent AEs included nausea (Arms C 
and D, 50%; Arm E, 73%), fatigue (Arm C, 38%; Arm D, 36%; Arm E, 73%) and constipation (Arm C, 25%; Arm D, 71%; Arm E, 27%). The most common MPDL3280A-related Grades 3 to 
4 AEs included anemia (Arms D and E, 7%), neutropenia (Arm C, 13%; Arm D, 7%) and 
thrombocytopenia (Arms D and E, 7%). No pneumonitis was seen. One MPDL3280A-related Grade 5 AE due to candidemia after prolonged neutropenia was seen in Arm D. Thirty patients
were efficacy evaluable (Arm C, 5; Arm D, 12; Arm E, 13). Over all, tr eatment with 
atezolizumab plus chemotherapy (including mainten ance therapy) was well tolerated, without
apparent exacerbation of chemotherapy-associated adverse events.
 
 
&(/*(1(35235,(7$5<,1)250$7,21nd safetnd safet y y 
nt inhibitor  inhibitor
the companhe comp
t to respondt to respon
n fiirst line mrst line iii
abb,,showedshow
0% % (95% (95%
% CI: 43 CI: 43 -959
% (95% CI% (95% 
abbwas cowas co m
The mThe m ost fost
38%; Arm 38%; Arm
%). T). The moshe mos
E, 7%), neuE, 7%), neu
7%). No pn%). No p
fter prolonfter prolon
C, 5; ArmC, 5; Arm
herapy (incrapy (inc
f chemothf chemoth
1((1(*(1*(
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 29 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Figure 1: Anti-PD-L1 in Combination with Platinum-Based Doublets
Liu et al. ASCO- J une 2015. Abstract 8030
!nab- Paclitaxel in combination with anti-PD-1
An ongoing Celgene-sponsored Phase 1 trial ([STUDY_ID_REMOVED]) in solid tumo rs is assessing the 
safety and efficacy of the anti-PD-1 agent nivolumab in combination with nab-paclitaxel and
carboplatin in a cohort of subjects  with advanced NSCLC patients in the first-line setting ( nab-
paclitaxel 100 mg/m2on Days 1, 8 and 15 and carboplatin AUC 6 on Day 1 of each 21-day cycle 
(Cycles 1 to 4 only); nivolumab 5 mg/kg on Day 15 of each 21-day cycle starting in Cycle 1). 
Preliminary results show that amongst the 9 sub jects having received study treatment including 
nivolumab, 6 had partial responses and 3 stab le disease. No dose limiting toxicities were 
observed. Most common AEs were low grade vomiting, diarrhea, alopecia, peripheral 
neuropathy and neutropenia (data on file). These results are consistent with another Phase 1 trial 
comparing anti-PD-1 antibody nivolumab (10 mg/ kg IV q3w) combined with three different 
platinum-doublet regimens in 52 patients with chemotherapy-naÃ¯ve advanced NSCLC, with a
reported ORR of 33% with gemcitabine/cisplatin, 47% with pemetrexed/cisplatin, as well as with 
paclitaxel/carboplatin, while stable disease was reported in 58%, 47%, and 27% of subjects, respectively (Checkmate 012; [STUDY_ID_REMOVED]); ( Antonia, 2014 ). Grades 3 to 4 treatment-related 
adverse events were reported in 45% of patients (25% to 73% across arms), including 
pneumonitis (4 patients, 7%; managed by protocol al gorithm), and fatigue and acute renal f ailure 
(3 patients, 5% each).
Rationale for fixed dose and schedule 
 
 
 
 
 
 
 
 
 
 
  Similarly, a population PK model 
(35235,(7$5<,1)250$isiassessasses ini
nabnab-paclipacli tataiii
e firstirst-line lin
n DayDay 1 of1 ofyy ff
ay cycle stacycle stayy
ceived ceived stud
dose limitdose limit ii
diiarrheaarrhea , al,
ts are consts are cons
kgkgIV IVq3wq3w)
hemotheraphemotherap
atin, 47% watin, 47% w
e was repore was repor
5410241027,21
); ((AA
% ofofpatientpatien
aged by praged by p
and schedund schedu
(31((1(*(1*(/*(/*&(/&(&&
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 30 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016was developed for tremelimumab using data from Phase 1 through Phase 3 (N=654; doses= 0.01 
to 15 mg/kg q4w or once every 90 days (Q90D); metastatic melanoma) ( Wang, 2014 ). A 
population PK mod el indicated minor impact of body WT on the PK of tremelimumab 
(coefficient of â‰¤ 0.5). The WT-based (1 mg/kg q4w) and fixed dosing (75 mg/kg q4w; based on 
median body WT of ~75 kg) regimens were compared using predicted PK concentrations (5th, 
median and 95th percentiles) using a popul ation PK model in a simulated population of 1000 
patients with body WT distribution of 40 to 120 kg. Similar to durvalumab, simulations indicated 
that both body WT-based and fixed dosing regimens of tremelimumab yield similar median 
steady state PK concentrati ons with slightly less between-subject variability with fixed dosing 
regimen.
Similar findings have been reported by others ( Ng, 2006; Wang, 2009; Zhang, 2012; Narwal,
2013 ). Wang and colleagues investigated 12 monoclonal antibodies and found that fixed and 
body size-based dosing perform similarly, with fixed dosing being better for 7 of 12 antibodies 
(Wang, 2009 ). In addition, they investigated 18 therapeutic proteins and peptides and showed 
that fixed dosing performed better for 12 of 18 in terms of reducing the between-subject 
variability in PK/PD parameters ( Zhang, 2012 ). 
A fixed dosing approach is preferred by the prescribing community due to ease of use and 
reduced dosing errors. Given the expectation of  similar PK exposure and variability, it is 
considered feasible to switch to fixed dosing regimens.
Sequential administration of chemotherapy and checkpoint inhibitor will allow for limitation of 
potential interactions and better management of toxicities.
Please refer to the Investigatorâ€™s Brochures (IBs) of durvalumab and nab-paclitaxel (ABI-007) 
for detailed information concerning the availabl e pharmacology, toxico logy, drug metabolism, 
clinical studies, and adverse event profile of the investigational products (IPs).
&(/*(1(35235,(7$of of (7$5<,1)250$7,21g g
Narwalarwal ,,
fixed and fixed and 
f 12 antibof 12 antibo
des andes d shd sh
tweenween -subjsubj
due to easdue to e
sure and vasure and v
nt inhibitornt inhibitor
ies.ies
durvalumdurvalum
le pharmace pharma
the the investiinvesti
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 31 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 20162. STUDY OBJECTIVES
2.1. Primary Objective 
The primary objective of the study is:
!To estimate the efficacy of nab-paclitaxel administered intravenously (IV) on Days 8 
and 15 with epigenetic modifying therapy of CC-486 once daily (QD) on Days 1 to 
14 every 21 days, or nab-paclitaxel administered intravenously (IV) on Days 1 and 8
with immunotherapy of durvalumab administered IV on Day 15 every 21 days, and 
nab-paclitaxel monotherapy administered IV on Days 1 and 8 every 21 days as 
second/third-line treatment for advanced NSCLC.
2.2. Secondary Objective
The secondary objective of the study is:
!To estimate the relative efficacy of each of the combination therapy arms to the 
monotherapy arm.
!To evaluate the safety and tolerability of nab-paclitaxel administered IV on Days 8 
and 15 with epigenetic modifying therapy of CC-486 QD on Days 1 to 14 every 21 days, or nab-paclitaxel administered intravenously (IV) on Days 1 and 8 with 
immunotherapy of durvalumab administered IV on Day 15 every 21 days, and nab-
paclitaxel monotherapy administered IV on Days 1 and 8 every 21 days as second/third-line treatment for advanced NSCLC.
2.3. Exploratory Objectives
The exploratory objectives of the study are:
!To assess healthcare resource utilization for the treatment arms.
!To assess the qualit y of life (QoL) for the treatment arms .
!To determine baseline tumor characteristics which predict response to nab-paclitaxel 
as a single agent and with epigenetic modifying therapy of CC-486 or immunotherapy 
of durvalumab. 
!To evaluate genomic correlates of response to nab-paclitaxel as a single agent and 
with epigenetic modifying therapy of CC-486 or immunotherapy of durvalumab.
!To evaluate anti-tumor activity of nab-paclitaxel/durvalumab combination therapy 
using investigator assessment according to immune related response criteria updated with RECIST 1.1 (irRECIST), and its a ssociation with PD-L1 expression.
&(/*(1(35235,(7$5<,1)250$7,21d 
herapyerapy armyy
eladministeadminist
66QD on DQD o
ly y (IV) on (IV) on 
IV on DayV on Da
n Dayn Day s 1 ans 1 an
d NSCLCd NSCLC
re:re:
urce utilizaurce util
of life (of life ( QoQo
eline tumoeline tum
ent and ent and withi
mabmab.  
aluate genoluate geno
 epi epih genetigene
To evaluatTo evaluat
using inusing i
wiwiththii
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 32 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 20163. STUDY ENDPOINTS
Study efficacy endpoints will be assessed by the Investigator using RECIST 1.1 guidelines.
3.1. Primary Endpoint
The primary endpoint is:
!Progression free survival.
3.2. Secondary Endpoints
The secondary endpoints are: 
3.2.1. Efficacy
!Disease control rate.
!Overall response rate.
!Overall survival.
3.2.2. Safety
!The type, frequency, and severity of AE s and SAEs graded using National Cancer 
Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0). 
!Discontinuation rate.
!The median dose intensity.
!The incidence of dose reduction.
3.3. Exploratory Endpoints
!Healthcare resource utilization during the study via patient feedback.
!Changes in the Lung Cancer Symptom Scale (LCSS), European Organisation for 
Research and Treatment of Cancer (EORTC) QLQ C30, and EuroQoL 5D-5L (EQ-5D-5L).
!The correlation between pretreatment tum or characteristics and response to the study 
treatment determined using next-generation sequencing methods, 
immunohistochemistry, or other analysis methods.
!Analysis of PFS and DCR and their association with PD-L1 expression using 
Investigatorâ€™s assessments according to irRECIST. 
&(/*(1(35235,(7$5<,1)250$7,21AEsAE gradedgrade
ia fa for Advor Adfff
ionion..
ointsnt
eututilizatioilizatio
e Lung CanLung Can
nd Treatmend Treatm
correlatcorrelat ioio
eatmatmententdede
immunohimmunoh
!!AnalAnal
InIn
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 33 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 20164. OVERALL STUDY DESIGN
4.1. Study Design
This is a Phase 2, open-label, multicenter study to assess safety and efficacy of:
!nab-paclitaxel in combination with epigenetic modifying therapy of CC-486,
!nab-paclitaxel in combination with immunotherapy of durvalumab, 
!andnab-paclitaxel monotherapy 
as second/third-line treatment in subjects with  advanced NSCLC who have received no more 
than one prior chemotherapy regimen. Approximately 240 subjects with advanced NSCLC will be assigned 1:1:1 into one of the following treatment arms: nab-paclitaxel/CC-486, nab-
paclitaxel/durvalumab combination therapy or nab-paclitaxel monotherapy prior to receiving the 
first dose of investigational product (IP). Randomization (details in Section 10.1), when 
conducted, will be centralized and stratified by ECOG performance status (0 versus 1, see 
Appendix A ), gender (males versus females), and smoker (yes versus no).
The study will consist of up to a 28-day Sc reening Period, a Treatment Period and a Follow-up 
Period.  
4.1.1. Screening Period 
The Screening Period for eligibility determination begins upon subject written informed consent.  
All screening assessments must be completed within 28 days prior to first dose of IP.
4.1.2. Treatment Period 
The Treatment Period begins with the firs t dose of IP as described in Section 8.  Subjects will 
receive one of the following treatments based on the randomization/tr eatment assignment:
!nab-Paclitaxel 100 mg/m
2IV infusion over 30 minutes on Days 8 and 15 and CC-486 
200 mg orally QD on Days 1 to 14 of each 21-day treatment cycle, or  
!nab-Paclitaxel 100 mg/m2IV infusion over 30 minutes on Days 1 and 8 and 
durvalumab 1125 mg IV infusion over approximately 1 hour on Day 15 of each 21-
day treatment cycle, or  
!nab-Paclitaxel 100 mg/m2IV infusion over 30 minutes on Days 1 and 8 of each 21-
day treatment cycle.
No additional anticancer agents are allowed during study treatment.  All supportive care
(including but not limited to growth factors, antiemetics, analgesics, zoledronic acid, denosumab) is permitted as per the Investigato râ€™s discretion and should be administered 
according to local institutional pract ice. Sub jects will continue treatment until disease 
progression, development of an unacceptable toxicity, death, lost to follow-up, withdrawal of consent, or termination of the study by the Sponsor.
During the study, subjects will have computed tomography (CT) scans every 42 days (-3/+7 
days) until documented progression of disease
, withdrawal of consent, lost to follow-up, death, 
or termination of the study by the Sponsor. Tumor evaluations will be assessed by the &(/*(1(35235,(7$5<,1)250$7,21more ore
CLC will CLC will 
nabnab--
to to receivinreceivin
0.10.1), when ), when 
(0 versus 10 versus 1
o)).
ent Periodt Perio
ns upon suns upon su
n 28 days pn 28 days 
dose of IPdose of IP
based on thbased on 
m22IV infuIV infu
n Days 1n Days 1 toto
0000mg/mmg/m2mI
125 m125 m ggmmIV
ent cynt cy cle, ocle, o
clitaxel 10clitaxel 10
treatment treatmen
nalalantanticanican
ng but not ng but not
sumab)sumab) is pis
ccording to ccording to 
progressioprogressio
onsenonsen
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 34 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016investigative sites and response will be determined according to RECIST 1.1 guidelines, and 
immune-related RECIST criteria (irRECIST) when applicable. All scheduled laboratory samples 
will be sent to a central laboratory for analysis. Local hematology and chemistry tests may be 
performed as required for sub ject management/treatment decisions. Local laboratory values that 
are considered abnormal and c linically significant will be recorded as an AE/SAE and also 
recorded on the laboratory eCRF (see Section 11.3).
4.1.2.1. Treatment Beyond Progression for Subjects in the nab-Paclitaxel/Durvalumab 
Arm
Subjects in the nab-paclitaxel/durvalumab arm may be permitted to continue treatment beyond 
initial RECIST 1.1 defined progressive disease as long as they meet the following criteria:
!Continue to meet all other study protocol eligibility criteria
!Investigator assessed clinical benefit and absence of rapid disease progression or 
clinical deterioration
!Stable performance status
!Tolerance to IP
!Treatment beyond progression will not delay an imminent intervention to prevent
serious complications of disease progression (eg, brain metastases)
Subjects will be re-consented with an informed  consent document describing any reasonably 
foreseeable risks or discomforts and other alternative treatment options.
Response assessment should continue every 42 days (-3/+7 days) as per Table of Events
(Table 4 ). The assessment of clinical benefit should be balanced by clinical judgment as to 
whether the subject is clinically deteriorating and unlikely to receive any benefit from continued treatment with nab-paclitaxel/ durvalumab. If the Investigator feels that the subject continues to 
achieve clinical benefit by continuing treatment and the subject consents, the subject may remain 
on the trial and will continue to receive moni toring according to the schedule in the Table of 
Events. The decision to continue treatment should be discussed with the Sponsorâ€™s Medical 
Monitor and documented in the study source documents.
Study therapy should be disc ontinued if further progression is documented by irRECIST. 
4.1.3. End-of-Treatment Visit
The End-of-Treatment Visit is defined as the vi sit when decision for treatment discontinuation is 
made. 
4.1.4. Follow-up Period
All subjects who discontinue from treatment for reas ons other than withdrawal of consent, lost to 
follow-up, death, or termination of the study by the Sponsor w ill enter the Follow-up Period. It 
will consist of a visit 28 days after last dose of IP or  End-of-Treatment Visit, whichever is later,
followed by phone follow-up for survival approximately  every 90 days (+/- 14 days) for at least
12 months after the last subject is randomized or 120 PFS events have been observed, whichever 
comes later, between the nab-paclitaxel/CC-486 co mbination and nab-paclitaxel monotherapy &(/*(1(35235,(7$5<,1)250$7,21eyyonoyyyd d 
riria:a
progressionprogressio
mminent inteminent i
g, brain metbrain m
docdocumentumen
etreatmenttreatme
days (days ( -3/+73/+
should be bshould be b
ing and unling and unl
ab. If the ab. If the I
g treatmeng treatme
ceive moceive mo n
ue treatmee treatm
n the studythe study y
e die discontinuscontin
f--TreatmeTreatme
&reatmeatm ent Vent V
Follool
ll ll subjects subjects
foollolw-w-uu
ill coill co
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 35 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016arms. Subjects in the nab-paclitaxel/durvalumab arm will also attend a follow-up visit 90 days 
after the last dose of IP, and will be followed for survival in a similar manner for at least 12 
months after the last subject is assigned to this arm. Those subjects entering the Follow-up 
Period without documented progression will continue to have CT scans in accordance with local standard of care (or approximately every 90 days) until documented progression of disease
, 
withdrawal of consent, lost to follow-up, d eath, or termination of the study by the Sponsor. All 
post-treatment anticancer therapies will be recorded during th e Follow-up Period.  
4.2. Study Design Rationale
This is an open-label study designed to es timate the effects of addi ng CC-486 or durvalumab to 
nab-paclitaxel and nab-paclitaxel monotherapy in second/third-line NSCLC. A placebo-
controlled study would not be feasible for this population as blinding would be difficult and would need a double dummy design.  
A key objective in this study is to determine the chemo-pr iming effect of CC-486  and to estimate 
the effect of the combination of nab-paclitaxel with PD-L1 checkpoint inhibitor. Second/third-
line NSCLC enables a unique setting to evaluate epigenetics: 
a) It is currently unknown whether patients in second or later lines of treatment have 
optimal immune function/reserve which is cr itical for sa fety and activation of immune 
cells that target cancer cells,
b) Due to the overlapping (and dose-limiti ng) toxicities of doublet/tr iplet chemotherapy 
regimens in the first-line setting, it would be very challenging to combine epigenetic therapy at a dose level to elicit clinically meaningful benefit.
Although docetaxel has been assessed in other randomized studies as a chemotherapy backbone
as shown in Table 3 , the considerable neutropenia-related toxicity could potentially pose safety 
concerns if combined with CC-486, and the steroid premedication could confound the epigenetic 
impact of CC-486.  In addition, the q3w dosing schedu le of docetaxel restricts dose adjustment 
options, thus potentially yielding lower chem otherapy dose-intensity. As mentioned above, nab-
paclitaxel has shown benefit for both squamous and nonsquamous histologies. Furthermore, 
recent data with immune checkpoint inhibitors (eg, nivolumab) have shown greater efficacy in 
subjects with squamous histology versus nonsqua mous histology with manageable toxicities. 
Hence it will be important in the current study to assess the efficacy and safety of nab-paclitaxel 
either as monotherapy or in combination tr eatment in subjects with squamous and nonsquamous 
NSCLC histologies.
For patients with NSCLC whose disease progressed after initial chemotherapy, the goal of 
therapy is to delay further progression for as long as possible; hence, the use of PFS as the 
primary endpoint for efficacy evaluation.  
&(/*(1(35235,(7$5<,1)250$7,21mabmab to to 
oo--
ficult and icult and 
C-48-486 and t6 and
hibitorhibitor .Sec
lines of treines of tr
fetfety y and aca
ties ofes of  dou doff
very challenvery challen
meaningfulmeaningfu bbl
r randomizer randomize
ropeniaopenia -rerela
the steroidthe stero
3w dosing 3w dosi
ower chemwer chem
r both squaboth squa
eckpoeckpo intintinhh
istolologyog vey
tant in the cant in the 
pyyor in coor in coyy
iesies.
wiwiththii
* NSCLNSCLhh
to delo del ayay ffyff
yyendpoendpo intint
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 36 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Table 3: Data for Control Arms using Taxanes from Phase II and III Studies Blinded
Study compound
(year)Doce
(Shepherd, 
2000)Doce
(Hanna, 
2004)nab-Pac
(Chen  
2012, 
Saxena, 
2012, 
Yuan 
2012)Doce
(Reck, 
2014a)
LUME-1Doce
(Garon, 
2014)Doce
(Brahmer, 
2015)
Checkmate 
017 Doce
(Borghaei, 
2015)
Checkmate 
057Doce 
(Vansteenkiste, 
2015)
POPLAR
Phase III III II III III III III II
N 55 + 48 28816 (x2) -  
33272 625 137 290 143
Efficacy
ORR (%) 7.1 8.8 18 - 33 3.3 14 9 12 15
SD rate (or DCR)
(%)42.7 46.4 31  -  42 37.9 53 34 33 n/a
PFS (TTP)
(median, in months)na 2.9 2.1 â€“ 5.0 2.7 3.0 2.8 4.2 3.0
OS (median, in 
months)7.0 7.9 n/a 9.1 9.1 6.0 9.4 9.7
Toxicity
Neutropenia (%)
Neutrophils 
decreased (%)67.3 40.2 n/a12.1
29.939 33 31 n/a
Febrile 
neutropenia1.8 12.7 n/a 4.7 10 11 10 n/a
Thrombocytopenia 
(%)0 0.4 3 NR 1 n/a n/a n/a
Anemia (%) 5.5 4.3 3 3.5 6 22 20 n/a
Peripheral 
Neuropathy (%)1.8 1.1 3 NR 2 12 n/a n/a
Fatigue / Asthenia 
(%)18.2 5.4 3 5.1 10* 46.5 46.6 n/a
DCR = disease control rate; Doce = docetaxel; nab-Pac = nab-paclitaxel; N = number of subjects randomized; n/a = not 
available; ORR = overall response rate; OS = overall survival; PFS = progression free survival; SD = standard deviation; TTP =time to progression; *Grade â‰¥ 3.
Furthermore, maintaining quality of life during this period, especially in reducing/managing 
toxicity is also an important consideration.  Therefore, the proposed study is designed to 
optimize the evaluation of efficacy with a tolerable dose/schedule of chemotherapy, and its combination with an epigenetic modifying therapy or with an immune checkpoint inhibitor.
&(/*(1(35235,(7$5<,1)250$7,217,2II7,27,27,2143143$70$
12125555
3333)21)2.82.81)1)1)1)
6.06<5<$555
9.99.939777$(74.7475,(((
35(
3 NN3535353532333
53
1.1.15552355.4333
1(1(1(1(3
e;DoceDoce ==docdoc
erall response rall response 
n;n;*Grade *Grade â‰¥ 3â‰¥
ore, me, maintaainta
tytyiiyys also ans also an
imizemize thheee
combinatombinat ioio
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 37 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Figure 2: Overall Study Design
IP = investigational product; IV = intravenous; OS = overall survival; PFS = progression-free survival; QD = once daily.nab-paclitaxel 100 mg/m2IV 
infusion over 30 minutes on 
Days 1 and 8 of each 21-day 
cycle until disease progression
(n = 80)onab-paclitaxel 100 mg/m2IV 
infusion over 30 minutes on Days 1 and 8 of each 21-day cycle 
odurvalumab 1125 mg IV over 
approximately 1 hour on Day 15 
of each 21-day cycle
until disease progression
(n = 80)
Follow-up Period: 28-day Follow-up Visit (after last dose of IP or End-o f-Treatment Visit, whichever is later)
Monotherapy or CC-486 combination arms: fo llowed for OS by phone approximately every 90 days for at least 12 months after last subject is randomized 
in either the monotherapy arm or the CC-486 combination arm or 120 PFS events have been observed, whichever is later
nab-paclitaxel/durvalumab arm: 90-Day Follow-up Visit and consequent follow-up for OS by phone approximately every 90 days for at lea st 12 months 
after last subject is allocated to this armonab-paclitaxel 100 mg/m2IV 
infusion over 30 minutes on Days 
8 and 15 of each 21-day cycle
o CC-486 200 mg orally QD
     Days 1 to 14 of each 21-day
cycle
until disease progression
(n = 80)Screening for Eligibility (up to 28 days)
(n=240)
priprietetct; t; IV = intraIV = intra/*/*(352352323
35355,(7$5<,15<5<,1)25
mm22IV IV
utes on Dayutes on Day
-day cycle day cycle 
25 mg25 mg IV oV
ely 1 hour oly 1 hour o
1-day cycleday cycle
til disease pil disease p
(n =
y Followollow -up
followefollow d forfo
y arm or the y arm or the
ayayFollowollow --upup,1,1250$7,21e Corporae Corpora
21
250$7250$7
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 38 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 20164.3. Study Duration 
Recruitment is expected to take approximately 28 months, and the final analysis of PFS between 
the nab-paclitaxel/CC-486 combination and nab-paclitaxel monotherapy arms  will be performed 
when approximately 120 PFS events have occurred, estimated as approximately 25 months from 
first subject randomized. The final analysis for the nab-paclitaxel/durvalumab arm will be 
conducted when approximately 50 events have occurred in this arm. The total length of this 
Phase 2 study with follow-up is estimated to last approximately 40 months.
4.4. End of Trial
The End of Trial is defined as either the:
!date of the last visit of the last subject to complete the post-treatment follow-up, or 
!date of receipt of the last data point from the last subject that is required for primary, 
secondary and/or exploratory analysis, as prespecified in the protocol, whichever is 
the later date.
&(/*(1(35235,(7$5<,1)250$7,21fofollollow-upw-up
equired for equired fo
protocolrotocol , wh
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 39 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 20165. TABLE OF EVENTS
Table 4: Table of Events
Screening/ 
BaselineTreatment Period
Every 21-day Cycle Follow-Up Period
AssessmentDay -28 to
Day -1Day 1
( Â±2 days)Day 8
(Â±2 
days)Day 15
(Â±2 
days)Every 42 days 
(-3/+7 days)
(starting Day 1
Cycle 1)End-of-
Treatment/
Discontinu
-ation Visit28-day Follow-up 
Visit (after last 
dose of IP)90-day Follow-up 
Visit for subjects in 
the nab-paclitaxel/ 
durvalumab arm
(after last dose of IP)Survival Follow-upa
Every 90 days (+/- 14 
days) (after 28-day 
follow-up visit)
Informed Consent X - - - - - - - -
Medical History (including Tobacco 
Exposure History), Prior Medication 
and ProceduresX- - - - - - - -
Serum Î²-hCGbX- - - - - - - -
Urine Pregnancy Testb-X - - - XX
(nab-paclitaxel/ 
durvalumab arm)X
(nab-paclitaxel/ 
durvalumab arm)-
Reminder to Avoid PregnancybX- - - X X X -
Complete Chest CT Scan and Any 
Other Studies Required for Tumor 
ImagingcX- - -X Xc-- X
Weight and Height d XX X X - - - - -
ECOG Status X X - - - X X X -
Concomitant Medication/Procedures - X X X - X X X X
Peripheral Neuropathy Assessment e XX - - - X X - -
Healthcare Resource Utilization 
Questionnaire-X - - - X X - -
LCSS, EORTC QLQ C30 and EQ-
5D-5L-X - - - X X - -
Hematology f,gXX X X - X X Xk-
&(/*priprietet/*(1(35235,(7$5<,1)250$7,21e Corporae Corpora
21
FollowFollow -UU0$
ollowollow --up up 
(after last after la
dose of IP)dose of IP)90-90-da
VisiV
t22252
--,1<<<<,5<--$57$7$7$7$(7$-5,(-335
523XX X555222
352
--35355335XX333(33
XX((((
XX1(((
((
--*(*(*(*(X/*((((/
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 40 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Table 4: Table of Events (Continued)
Screening/ 
BaselineTreatment Period
Every 21-day Cycle Follow-Up Period
AssessmentDay -28 to
Day -1Day 1
( Â±2 days)Day 8
(Â±2 
days)Day 15
(Â±2 
days)Every 42 days 
(-3/+7 days)
(starting Day 1
Cycle 1)End-of-
Treatment/
Discontinu
-ation Visit28-day Follow-up 
Visit (after last 
dose of IP)90-day Follow-up 
Visit for subjects in 
the nab-paclitaxel/ 
durvalumab arm 
(after last dose of IP)Survival Follow-upa
Every 90 days (+/- 14 
days) (after 28-day 
follow-up visit)
Serum Chemistry f,h XX - - - X X Xk-
Archived Tumor Tissue Sample for 
Biomarker (biopsy, surgical 
specimen, or other diagnostic tumor 
sample)-X
(C1D1 
only)-- - - - - -
Plasma for Biomarker Analyses -X
(C1D1 only 
predose)-- - - --
-
Blood for Pharmacogenomic 
Analyses-X
(C1D1 only 
predose)-- - - - - -
Adverse Event Evaluation in the 
Monotherapy or nab-Paclitaxel/CC-
486 Combination ArmAfter signing ICF and until 28 days after the last dose of IP --
Adverse Event Evaluation in the nab-
Paclitaxel/Durvalumab combination
ArmAfter signing ICF and until 90 days after the last dose of IP X-
nab-Paclitaxel Monotherapy Arm and   
nab-Paclitaxel/Durvalumab
Combination Arm
nab-Paclitaxel Administration /
Accountabilityi-X X - - - - -
nab-Paclitaxel/CC-486 Combination 
Arm
nab-Paclitaxel Administration /
Accountabilityi-- X X - - - - -
&(/*priprietet/*(/**(1((35235,(7$5<,1)250$7,21e Corporae Corpora
21
w-Up PeriodUp Period7,2
)day Followday Follow -
isititfor subjefor subje
the nabthe nab --papa
durvaludurval
(after l(afte0$
22222
-1)2
< --<<<
7$5<
7$7$7$(7$
il 28 days aftel 28 days afte5,(
CF and until 9and until 923
XX555
(335
1(
*(
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 41 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Table 4: Table of Events (Continued)
Screening/ 
BaselineTreatment Period
Every 21-day Cycle Follow-Up Period
AssessmentDay -28 to
Day -1Day 1
( Â±2 days)Day 8
(Â±2 
days)Day 15
(Â±2 
days)Every 42 days 
(-3/+7 days)
(starting Day 1
Cycle 1)End-of-
Treatment/
Discontinu
-ation Visit28-day Follow-up 
Visit (after last 
dose of IP)90-day Follow-up 
Visit for subjects in 
the nab-paclitaxel/ 
durvalumab arm 
(after last dose of IP)Survival Follow-upa
Every 90 days (+/- 14 
days) (after 28-day 
follow-up visit)
nab-Paclitaxel/CC-486 Combination 
arm
CC-486 Administration /
Accountabilityi-X - - -- -
nab-Paclitaxel/Durvalumab
Combination Arm
Durvalumab Administration /
Accountabilityi-- - X - - - - -
Survival Phone Call - - - - - - - - Xa
Physical ExaminationjXX - - - X - - -
Vital SignsjXX X X - X - - -
Electrocardiogram (ECG) X
Will be done as per standard of care during the Treatment Period and as clinically indicated; however, results will not be routi nely 
collected in the eCRFs. If CT/bone scans show lesions pertinent for RECIST 1.1 or irRECIST criteria evaluation, data will be 
collected on the pertinent tumor evaluation eCRFs. If ECGs are abnormal and clinically significant, the data will be recorded on  the 
AE/SAE eCRF.Bone Scan (X-rays if needed)If clinically 
indicated
CT Scan of the Head or Brain 
Magnetic Resonance Imaging (MRI)If clinically 
indicated 
(mandatory if symptomatic)
AE = adverse event; Î²-HCG = beta human chorionic gonadotropin; C1D1 = Cycle 1 Day 1; CT = computed tomography; ECOG = Eastern Cooperative Oncology Group; eCR F=
electronic Case Report Form; EORTC QLQ C30 = European Organisati on for Research and Treatment of Cancer QLQ C30; EQ-5D-5L = EuroQo l 5D-5L; ICF = informed 
consent form; IP = investigational product; irRECIST = immune-related Response Evaluation Criteria in Solid Tumors; IV = intrav enous; LCSS = Lung Cancer Symptom Scale;
QD = once daily; RECIST = Response Evaluation Criteria in Solid Tumors; SAE = serious adverse event.
aEvery 90 (+/-14) days (from 28-day Follow-up Visit ) for at least 12 m onths after the last subject is randomized in either the mon otherapy or the CC-486 combination arms or 
120 PFS events have been observed whichever comes later. Subjects in the nab-paclitaxel/durvalumab arm will be followed for survi val in a similar manner for at least 12 
months after the last subject is assigned to this arm.
bAll males and all women of child-bearing potential must be reminded to avoid pregnancy prior to administration of IP before begi nning each new cycle, at the End-of-Treatment 
Visit and at the Follow-up Visits. A pregnancy test is required for women of child-bearing potential only. For women of child-bear ing potential a serum Î²-hCG pregnancy test 
must be performed to assess eligibility at Screening/Baseline. Note: the screening serum pregnancy test can be used as the Cycl e 1 Day 1 test prior to study therapy if it is 
&(/priprietet/*(1(35235,(7$5<,1)250$7,21e Corporae Corpora
21
w-Up Up PeriodPeriod7,2
)day Followday Follow -
isititfor sufor su bjebje
the nabthe nab --papa
durvaludurval
(after l(afte0$
2
--2222
,1
5<-$57$7$7$7$(7$-(7(77(7
dardrdof care duf care d
RFs. If CT/bonRFs. If CT/
tinententumor emor e5,(
3dotropindotropin ;;C1D
opean Organisopean Organis
T = immune= immune --r
n Criteria in SoCriteria in So
up Vup V isit ) for isit ) for 
ever comes laever comes 
to this arm.to this arm.
aring potentiaing potentia
A pregnancy egnancy
igibility at Scrigibility at S
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 42 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016performed within the 72-hour timeframe.  A urine pregnancy test must be performed prior to administration of IP before beginning  each new cycle and at the End-of-Treatment 
Visit for all subjects, and at the Follow-up Visits for subjects in the nab-paclitaxel/durvalumab arm.
cAll subjects must have a radiographically documented measurable tu mor(s) by RECIST 1.1 criteria: Complete chest CT scan (including base of neck and adrenal gland) will be 
performed at Screening, every 42 days (-3/+7 days) (starting from  Cycle 1 Day 1) until disease progression, withdrawal of consent,  lost to follow-up, d eath, or termination of the 
study by the Sponsor. The results  of a complete chest CT scan (including base of neck and adrenal gland) performed per standard of care may be accepted and not repeated 
during Screening provided it was performed within 28 days of the first dose of IP (Cycle 1 Day 1). The methods of assessment chose n at baseline to follow tumors are to remain 
consistent throughout study duration. Those subjects entering the Follow-up Period without documented progression will continue to have CT scans in accordance with local 
standard of care (or approximately every 90 days) until documented progression of disease, withdrawal of consent, lost to follow -up, d eath, or termination of the study by the 
Sponsor.  If the CT scan was performed within 2 weeks of the En d-of-Treatment Visit, this End-of-Treatment Visit CT scan will no t need to be repeated. Subjects in the nab-
paclitaxel/durvalumab arm who continue beyond disease progression per RECIST 1.1 will continue to have CT scans every 42 days ( -3/+7) until progression per immune-related 
RECIST criteria (irRECIST) version 1.1 (Nishino, 2013).
dHeight will only be obtained at Screening Visit. Weight will be obtained at Screening and every visit during the Treatment Peri od before administration of IP.
eThe occurrence of peripheral neuropathy will be reported by the Investigator per protocol as an AE or SAE.
fAll scheduled laboratory samples will be sent to a central laboratory for analysis. Local hematology and chemistry tests may be  performed as required for subject 
management/treatment decisions. Local laboratory values that are considered abnormal and clinically significant will be recorde d as an AE/SAE and also recorded on the 
laboratory eCRF (see Section 11.3).
gHematology panel: hemoglobin, hematocrit, red blood cell count and morphology, mean corpuscular volume, mean corpuscular hemoglo bin, mean corpuscular hemoglobin 
concentration, white blood cell count with absolute and differential and percent (neutrophils, lymphocytes, monocytes, eosinoph ils, basophils, bands), platelet count, 
reticulocytes, erythrocyte sedimentation rate, international normalized ratio, prothrombin time, partial thromboplastin time, a nd fibrinogen. Additional laboratory samples for 
safety may be collected as clinically indicated.
hSerum chemistry panel: sodium, potassi um, bicarbonate, calcium, magnesium, phosphorus, blood urea nitrogen, serum creatinine an d clearance, uric acid, glucose, lactic
dehydrogenase, total protein, albumin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, gamma glutamyl  transferase, total, direct and indirect 
bilirubin, ferritin, amylase, lipase, thyroid stimulating hormone (TSH), T4, free T3, and free T4. Additional laboratory samples  for safety may be collected as clinically indicated.
inab-Paclitaxel 100 mg/m2IV infusion over 30 minutes on Days 8 and 15 and CC-486 200 mg orally QD on Days 1 to 14 of each 21-day treatment cycle; nab-paclitaxel 
100 mg/m2IV infusion over 30 minutes on Days 1 and 8 of each 21-day treatment cycle; or nab-paclitaxel 100 mg/m2IV infusion over 30 minutes on Days 1 and 8 and
durvalumab 1125 mg IV infusion over approximately 1 hour on Day 15.
jPhysical examination and vital signs assessment should be performed prior to IP administration at these visits. Additional phys ical examination and vital signs assessments may 
be performed throughout the study as clinically indicated. Only abnormal and clinically significant physical examination data and /or vital signs will be recorded as an AE/SAE 
on the eCRF. Vital signs will be (at a minimum): blood pressure, heart rate, respiratory rate, body temperature.
kHematology panel, serum chemistry will be performed at the 90-day Follow-up Visit for subjects in the nab-paclitaxel/durvalumab arm if applicable following AEs or abnormal 
assessments findings during the 28-day Follow-up Visit.
&(/*(1(35235priprietet35,(7$5<,1)250$7,21e Corporae Corpora
21he heEndEn-off--fffTrT
k and adrenal gand adrenal
up,up,deathd , or , or
be accepted anbe accepted a
seline to follone to fol
ve CT scans ine CT scans in
eatheath, or termi, or termi
ot need to be rt need to be r
days (ays ( -3/+7) un3/+7) 
PeriodPeriod beforebefore
sts may ts may be pebe pe
will be recordell be recorde
e, mean corpue, mean
s, monocytes, s, monocyte
thromboplastihrombopla
d urea nitrogend urea nitroge
ne aminotransne aminotr
e T4e T4. AdditionAddition
00 mg orally Q0 mg orally Q
clee; or ; or nabnab-p-p
P administratiP administrati
ddclinically sigclinically 
e, respe, resp iratory ira
ollowllow-up up VisitVis
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 43 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 20166. PROCEDURES
Subjects will be provided with a written Informed Consent Form (ICF), given the opportunity to 
ask any questions concerning the study and will sign an ICF prior to participating in any study 
procedures. After giving written informed consent, subjects will undergo a Screening Period to 
be assessed for eligibility. All subjects who sign an ICF must be entered into the Integrated Response Technology (IRT) immediately upon signature on the document. Subjects who do not 
meet the eligibility criteria will be considered sc reening failures and will not be eligible for the 
study. Subjects who fail initial screening may undergo re-screening up to 2 times at any time 
and an ICF will need to be resigned, as well as all screening procedures repeated (some 
procedures may not need to be done if previously done within 28 days prior to screening again).
Subjects that have met all eligibility cr iteria after the Screening Period w ill be eligible for
randomization /tr eatment assignment. 
6.1. Medical History
A complete medical history including, but not limited to, evaluation for past (up to 5 years) or
present cardiovascular, respiratory, gastrointestinal, renal, hepatic, neurological, endocrine,lymphatic, hematological, immunologic, dermatol ogical, psychiatric, gen itourinary, obstetrical, 
surgical history or any other diseases or disorde rs will be performed at Screening. All NSCLC-
related medical history s hould be recorded regardless of time. Smoking status/tobacco exposure 
history will be captured on the eCRF.
6.2. Prior and Concomitant Medications and Procedures
Prior medications are defined as any me dications started before randomization/treatment
assignment. All NSCLC-related prior medications/procedures shoul d be recorded regardless of 
time.
Concomitant medications are defined as any medication that was either initiated before 
randomization/tr eatment assignment and continued during the study treatment, or initiated 
on/after the date of randomization/treatment assignment and within 28 days after the last dose of 
IP for the monotherapy arm and the nab-paclitaxel/CC-486 combination arms, or 90 days after 
last dose of IP in the nab-paclitaxel/durvalumab combination arm. 
All subjects will have concomitant medications and procedures (including radiation therapy) 
recorded at each visit from the time of signature on the ICF until the 28-day Follow-up Visit for 
the monotherapy arm and the nab-paclitaxel/CC-486 combination arms or 90 days after last dose 
of IP in the nab-paclitaxel/durvalumab combination arm, for conditions that are clinically 
significant or ongoing. During the Follow-up Period only NSCLC-associated concomitant 
medications/procedures (including radiation thera py) will be recorded, ie, subsequent-line(s) of 
anti-cancer therapy. Additionally, for laboratory procedures performed per standard of care 
during follow-up, laboratory values that are cons idered abnormal and clinically significant will 
be recorded as an AE/SAE and also recorded on the laboratory eCRF.&(/*(1(35235,(7$5<,1)250$7,21e 
me e
ning again)ning again)
gible ble foforr
foor past (upr past (u
 neuroneuro lologig
hiatric, geniatric, 
rformed at rformed at
imme. Sm. Smokk
ationsation anan
tiionsonsstartestarte
dicatidicati ons/pons/p
ned as d aanyan
mentment and cand c
atatioionn/treat/trnn
m and the and tm
ab-ab-paclitaxpaclitax
aave concomve concom
h visith visit frofrom
rapyrapy armarmyy  an anmm
e nabnab--paclpacl
cant or ongcant or ong
icaticatioions/prns/pr
ntnti-i-cancer cancer 
during foduring fo
rec
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 44 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 20166.3. Pregnancy Testing
All males and all women of child-bearing potential must be reminded to avoid pregnancy prior to 
administration of IP before beginning each new cy cle, at the End-of-Treatment Visit and at the 
Follow-up Visits. A pregnancy test is require d for women of child-bearing potential only. For 
women of child-bearing potential a serum Î²-hCG pregnancy test with sensitivity of at least 25
mIU/mL must be performed to assess eligibility at Screening/Baseline. Note: the screening 
serum pregnancy test can be used as the Cycle 1 Day 1 test prior to study therapy if it is 
performed within the 72-hour timeframe.  A urine pregnancy test must be performed prior to administration of IP before beginning each new cy cle and at the End-of-Treatment Visit for all 
subjects, and at the Follow-up Visits for subjects in the nab-paclitaxel/durvalumab arm. The 
subject may not receive treatment until the Investigator has verified that the result of the pregnancy test is negative. See inclusion cr iteria for pregnancy testing requirements. Any 
pregnancies that occur in women who have r eceived IP must be immediately reported to Celgene 
Drug Safety (See Section 11.4).
6.4. Complete Chest Computed Tomography (CT) Scan
A complete chest CT scan (including base of neck and adrenal gland) and any other studies 
required for tumor imaging will be done at Screening, every 42 days (-3/+7 days) (starting from 
Day 1 Cycle 1), and End-of-Treatment, until documented progression of disease , withdrawal of 
consent, lost to follow-up, death, or terminatio n of the study by the Sponsor. The results of a 
complete chest CT scan (including base of neck and adrenal gland) performed per standard of 
care may be accepted and not repeated during Screening provided it was performed within 28 days of the first dose of IP (Cycle 1 Day 1). Those subjects entering the Follow-up Period 
without documented progression will continue to have CT scans in accordance with local 
standard of care (or approximately every 90 days) until documented progression of disease
, 
withdrawal of consent, lost to follow-up, death,  or termination of the study by the Sponsor. If the 
CT scan was performed within 2 weeks of End-of-Treatment Visit, this End-of-Treatment CT 
scan will not need to be repeated. Additional CT scans may be done at any time during the study if clinically indicated. All CT scans and reports should be archived at the site according to site 
regulations and copies provided to the Sponsor if requested. All post-treatment anticancer 
therapies will be recorded during the Follow-up Period.  
6.5. Weight and Height
Weight will be obtained at Screening and at every visit during the Treatment Period before administration of IP. Additional measurements of we ight may be collected per local standards at 
any time during the study as needed. Height will only be collected at Screening. All weight and 
height data will be collected on eCRFs.
6.6. ECOG Performance Score
Eastern Cooperative Oncology Group perfor mance status score will be collected at Screening, 
Day 1 of every treatment cycle, at the End-of-Treatment Visit and at the Follow-up Visits. 
Additional ECOG assessments may be performed at any time during the study as clinically 
indicated.&(/*(1(35235,(7$5<,1)250$7,21allall
The he 
he e 
ss. Any. Any
ported ported to Cto C
cancan
nd)ndand anyand an
days (days -3/+7+7
ogression ofogression 
dyy by the by the y SS
renal glandrenal gland
ning providning prov
e subjects ee subjects
to have CTo have C
0 days)days) untunii
deathdeath , or t, or t
ks of Endks of En -
Additddional Cnal 
cans and repans and rep
ded to ded to ththe SS
during theuring the
and Heigand Hei
obtained btained atat
n of n of IPIP.AdAd
during the sring the s
data will bedata will be
.6..6. EE
Eastern Eastern
yy
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 45 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 20166.7. Peripheral Neuropathy Assessment
Peripheral neuropathy (sensory or motor) assessmen t will be done at Screening, Day 1 of every 
treatment cycle, at the End-of-Treatment Visit and at the 28-day Follow-up Visit. Changes in 
neuropathy grade from baseline will be reported as an AE as per Section 11. Additional 
peripheral neuropathy assessments may be done at any time during the study as clinically 
indicated.
6.8. Adverse Event Reporting
Adverse events will be recorded from time of signature on the ICF until 28 days after the last 
dose of IP for the monotherapy and the nab-paclitaxel/CC-486 combination arms and until 90 
days after the last dose of IP for the nab-paclitaxel/durvalumab combination arm during the 
Follow-up Visits, including any unscheduled visits. See Section 11for details. 
6.9. Quality of Life Questionnaires
The LCSS, EORTC QLQ C30 and EQ-5D-5L questionnaires will be used to measure quality of 
life (QoL) for subjects in the study. The LCSS is comprised of 9 questions to be completed by 
the subject using a visual analogue scale (VAS) to denote intensity of a symptom. The EQ-5D-5L comprises 5 questions on mobility, self -care, usual activities, pain/discomfort, 
anxiety/depression and a VAS for overall QoL. Th ese questionnaires will be completed by the 
subject prior to interaction with study personnel, at Day 1 of every Cycle, at the End-of-Treatment Visit and at the 28-day Follow-up Visit.
6.10. Healthcare Resource Utilization Questionnaire
A healthcare res ource utilization questionnaire will be used to capture the additional use of 
healthcare res ources, including hospitalizations, emergency room visits, doctor or nurse visits, 
procedures, and/or additional medication during the study period. The assessment will be 
completed on Day 1 of every treatment cycle, at th e End-of-Treatment Visit and at the 28-day
Follow-up Visit. 
6.11. Laboratory Assessments
Blood for hematology a nd chemistry evaluation w ill be collected as per Table 4 , Table of Events. 
Blood for hematology will be co llected at Screening, Days 1, 8, and 15 of every tr eatment cycle, 
at the End-of-Treatment Visit and at the 28-day Follow-up Visit. Blood for serum chemistry will 
be collected at Screening, Day 1 of every tr eatment cycle, at the End-of -Treatment Visit and at 
the 28-day Follow-up Visit. Hematology panel a nd serum chemistry will be performed at the 90-
day Follow-up Visit for subjects in the nab-paclitaxel/durvalumab arm if applicable following 
AEs or abnormal assessments findings during the 28-day Follow-up Visit. Hematology panel 
will consist of: hemoglobin, hematocrit, red blood cell count and morphology, mean corpuscular 
volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, white blood cell count with absolute and differential and percent (neutrophils, lymphocytes, 
monocytes, eosinophils, basophils, bands), platelet count, reticulocytes, erythrocyte 
sedimentation rate, international normalized ratio, prothrombin time, partial thromboplastin time
and fibrinogen. Serum chemistry panel include s: sodium, potassium, bicarbonate, calcium, ast a
ntil 90 l 90 
ring ring ththe e
ed to meased to me
sttioions to bens to b
y ofo a symsymf
s, pain/discs, pain/
ioonnaires wnnaires w
 ofof every everff C
on Queston Quest
aire will be ire will be 
zations, emzations, em
on during n during 
ment encyyclecle
AssesAsses smem
and chemiand chemi
ogyg will willy  b bllee
eatmeatm ent Vent V i
at Screeningt Screenin
FoFollollow-w-upup
oow-up Visup Vi
or abnormaor abnorm
ill consist ll consist
vovolume, mme, 
lood clood c
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 46 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016magnesium, phosphorus, blood urea nitrogen, serum creatinine and clearance, uric acid, glucose, 
lactic de hydrogenase, total protein, albumin, alkaline phosphatase, aspartate aminotransferase, 
alanine aminotransferase, gamma glutamyl transferase, total, direct and indirect bilirubin,
ferritin, amylase, lipase, thyroid stimulating hormone (TSH), T4, free T3, and free T4. Additional laboratory samples for safety may be collected as clinically indicated. 
All scheduled laboratory samples will be sent to a central laboratory for analysis. Local 
hematology and chemistry tests may be perfor med as required for su bject management/treatment 
decisions. Local laboratory values that are considered abnormal and clinically significant will be 
recorded as an AE/SAE and also recorded on the laboratory eCRF (see Section 11.3).
Abnormal and clinically significant laboratory a ssessments at Screening will be recorded as 
medical history, and after Screening, as AE  or SAE (clinically significant laboratory 
abnormalities at Screening may result in a s ubject being ineligible for the study and should not 
be captured as an AE). 
Any abnormal values that persist should be follo wed at the discretion of the Investigator. The 
Investigator should file all copies of the reports, including faxes with the subjectâ€™s medical chart.
6.12. Tumor Tissue Sample Collection and Peripheral Blood Collection
(Exploratory Assessments) 
Histologically or cytologically confirmed advan ced NSCLC is a required inclusion criteria for 
entry into this study.  If a subjectâ€™s previously collected tumor tissue (also known as archival 
tumor) is av ailable, these samples will be collected for biomarker testing as detailed below at 
Cycle 1 Day 1.  If such samples do not exist, have been depleted, or do not contain sufficient tumor material to be an alyzed, this will not preclude participation in the study and a new biopsy 
or other procedure to collect tumor tissue will not be required. Table 5 delineates the specific 
requirements for commonly encountered archival tumor types.
Table 5: Requirements for Collection Based on Archival Tumor Sample Type
Sample Type Amount to CollectCollection 
Requirement for 
Biomarkers Comments/ Exceptions
Core biopsy or surgical 
specimen10 slides â‰¥4 âˆ€M 
thickness. If a block is 
provided, a core of 
viable tumor will also 
be collected.Mandatory if the sample 
exists. If the quantity of material 
is not sufficient, the 
available amount will be 
collected.
Fine needle aspirates 
(FNA)10 slides â‰¥4 âˆ€M. If a 
block is provided, a 
core of viable tumor 
will also be collected. Mandatory if the sample 
exists, unless a core 
biopsy or surgical 
sample was provided. If the quantity of material 
is not sufficient, the 
available amount will be 
collected.
Transbronchial 
endoscopy samples10 slides â‰¥4 âˆ€M. If a 
block is provided, a core of viable tumor will also be collected.Mandatory if the sample 
exists, unless a core 
biopsy or surgical 
sample was provided. If the quantity of material 
is not sufficient, the 
available amount will be 
collected. &TransbTransb
d&(/*(edle aspirate aspirat
A)A)*(1(35235,(7$5<,1)250$7,21e e 
d as d as 
d should shoul d nd n
e e InvestInvest igaiga
e subjectâ€™s subject
heral Blooeral Blo
Cis a requis a requ
tumumor tior tissus
or bioor bi markma
e been d been d epleep
clude partilude part
ill not be reill not be re
archival tuarchival tu
ollection Bollection
AmAmount toount to52
10 slides10 slides
thicknthickn
propro3
1(
*(
&&
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 47 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Table 5: Requirements for Collection Based on Archival Tumor Sample Type 
(Continued)
Sample Type Amount to CollectCollection 
Requirement for 
Biomarkers Comments/ Exceptions
Bronchial lavage, 
sputum, or other 
sample typesSlides or blocks 
representing >100,000 
tumor cellsCollection is strongly 
encouraged when these 
samples contain 
sufficient material.Collection is strongly 
encouraged when these 
samples contain sufficient 
material.
In addition, test results for tumor mutational status of genes, including but not limited to EGFR,
ALK, KRAS and PD-L1 will be collected, if available from prior testing, and recorded on eCRF if these tests have been performed.
Plasma for cell-free nucleic acids analyses will be collected on Cycle 1 Day 1 prior to first dose 
of IP, as will a sample of whole blood or peripheral blood mononuclear cells for a germ-line reference comparison. Types of techniques planned to be used for tumor and plasma analyses 
include:
!Gene expression by RNA sequencing
!Immunohistochemistry 
!DNA sequencing
!DNA methylation profiling
Details regarding the collection, storage, and shipment of the samples are given in the Laboratory 
Manual.
6.13. Electrocardiogram
Electrocardiograms (ECGs) will be done at Screening and as per standard of care during the Treatment Period, and as clinically indicated. Results  will be collected in the eCRFs as AE or 
SAE only if results are abnormal, changed and clin ically significant, unless the finding is already 
documented in medical history.
6.14. CT Scan of the Head or Brain Magnetic Resonance Imaging (MRI)
A CT scan of the head, or preferably brain MRI, will be done as per standard of care at Screening (mandatory if symptomatic), during the Treatment Period, and as clinically indicated.If CT scans show lesions pertinent for RECIST 1.1 criteria evaluation, data will be collected on 
the pertinent tumor evaluation eCRFs.
6.15. Bone Scans and X-rays
Bone scans and x-rays will be done as per standard of care at Screening, during the Treatment 
Period, and as clinically indicated. Results will be collected in the eCRFs. If bone scans or X-
rays show lesions pertinent for RECIST 1.1 criteria evaluation, data will be collected on the 
pertinent tumor evaluation eCRFs.&(/*(1(35235,(7$5<,1)250$7,21cient ent 
$77,
d to EGFRd to EGFR
orded on eCded on eC
ayy1 pri1 priyy or toor to
cells for a cells for
mor and plamor and pl
d shipment d shipment 
l be done l be done 
nically indinically in
normrmalal, ch
historyhistol .
Scan ofcan of thth
f f ththeeheadhead
g(mmandatorndator
scans showcans show
pertinent tupertinent tu
&6.15.6.1
EDMS Doc. Number:nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 48 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 20166.16. Physical Examinations
Physical examinations will be done at Screening, on Day 1 of every tr eatment cycle, at the End-
of-Treatment Visit, and as clinically indicated. Re sults will be collected in the eCRFs as AE or 
SAE only if results are abnormal and clinically significant.
6.17. Vital Signs
Vital signs (at a minimum blood pressure, heart rate, respiratory rate and body temperature) w ill 
be done at Screening, prior to IP administrati on on Days 1, 8, and 15 of every treatment cycle, at 
the End-of-Treatment Visit, and a s clinically indicated. Re sults will be collected in the eCRFs as 
AE or SAE only if results are abnormal and clin ically significant.
6.18. Survival 
After the End-of-Treatment Visit, the subjects will have a 28-day Follow-up Visit followed by a 
phone call approximately every 90 days (+/- 14 days) for at least 12 months after the last subject 
is randomized in either the nab-paclitax el/CC-486 combination therapy and nab-p aclitaxel 
monotherapy arm or 120 PFS events have been observed between these two arms, whichever 
comes later. Subjects in the nab-paclitaxel/durvalumab arm will be followed for survival in a 
similar manner for at least 12 months after the last subject is assigned to this arm.
The subjects will also be asked questions about other medications they may be taking for their 
NSCLC. Those subjects entering the Follow-up Period without documented progression will continue to have CT scans in accordance with lo cal standard of care (or approximately every 90 
days) until documented progression of disease
, withdrawal of consent, lost to follow-up, death, 
or termination of the study by the Sponsor.
&(/*(1(35235,(7$5<,1)250$7,21e, a, at t
RFs RFs as as 
VisiVisitifollollow
s after the s after the 
and nabd nab -pa
ese two armse two arm
be fofllowedwed
ssignedsigned to t
catiations theons th
wiwththiout docout do
tandard of tandard 
ththdrawal odrawal 
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 49 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 20167. STUDY POPULATION
7.1. Number of Subjects and Sites
Male and female subjects with advanced NSCLC who have received no more than one prior
chemotherapy regimen for their advanced diseas e will be eligible for this study (immunotherapy 
in prior line of treatment is allowed, including platinum doublet combination). Subjects will 
receive study therapy as second or third line of treatment for advanced disease. The study will 
randomize/assign a maximum of a pproximately 240 subjects if all 3 arms proceed to the end of 
the study. The study will be conducted at approximately 40 sites in the US, Canada, and Europe.
7.2. Inclusion Criteria
Subjects must satisfy the following criteria to be rando mized/assigned in the study:
1. Age â‰¥ 18 years at the time of signing the ICF.
2. Understand and voluntarily pr ovide written informed consent prior to the conduct of any 
study related assessments/procedures.
3. Able to adhere to the study visit schedule and other protocol requirements.
4. Histologically or cytologically confirmed advanced NSCLC who will receive study 
therapy as second- or third-line of treatment for advanced disease.
5. No other current active malignancy requiring anticancer therapy.
6. Radiographically documented measurable disease (defined by the presence of 
â‰¥1 radiographically documented measurable lesion).
7. One prior platinum-containing chemothera py for metastatic or recurrent NSCLC, unless 
patients are ineligible to receive it or if disease progressed within 6 months of a platinum-containing neoadjuvant/adjuvant regimen. Patients may have received no more than one 
line of chemotherapy; immunotherapy in prior line of treatment (first or second line) is 
allowed.
8. Absolute neutrophil count (ANC) â‰¥ 1500 cells/mm3.
9. Platelets â‰¥ 100,000 cells/mm3.
10. Hemoglobin (Hgb) â‰¥ 9 g/dL.
11. Aspartate transaminase (AST/serum glutamic oxaloacetic transaminase [SGOT]) and 
alanine transaminase (ALT/serum glutamic pyruvic transaminase [SGPT]) â‰¤ 2.5 Ã— upper 
limit of normal range (ULN) or â‰¤ 5.0 Ã— ULN if liver metastases.
12. Total bilirubin â‰¤ 1.5 ULN (unless there is a known history of G ilberts S yndrome).
13. Serum creatinine â‰¤1.5 x ULN, or calculated creatinine clearance â‰¥60 mL/min (if renal 
impairment is suspected 24-hour urine co llection for measurement is required).
14. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
15. Females of childbearing potential [defined as a sexually mature woman who (1) have not 
undergone hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy &(/*(1(35235,(7$5<,1)250$7,21f f
ropeope..
y:
r to r to ththe con
ol requireml requirem
SCLCSCLC whowh
anced dinced di ses
ntnticiancer thancer th
disease (dedisease (de
rable lesiorable lesio
motherapyotherapy ffyy
ttor if diseaor if di
ant regimenant regim
unotherapynotherapy
count (ANcount (A
000 cells/m000 cells/m
n (Hgb) n (Hgb) â‰¥ 9â‰¥ 9
te transamite transa
nenetransamtransam
mit of normt of norm
2. T2. Totalota bilbl
13.13SeruSeru
im
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 50 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016(the surgical removal of both ovaries) or (2) have not been naturally postmenopausal for 
at least 24 consecutive months (ie, has had menses at any time during the preceding 24 
consecutive months)] must:
a. Have a negative pregnancy test (ÃŸ-hCG) as  verified by the study doctor within 72 
hours prior to starting study therapy. She must agree to ongoing pregnancy testing 
during the course of the study, and after end of study therapy. This applies even if the 
subject practices true abstinence*from heterosexual contact.
b. Either commit to true abstinence*from heterosexual contact or agree to use, and be 
able to comply with, effective contraception without interruption, 28 days prior to 
starting IP, during the study therapy (in cluding dose interruptions), and for 3 months 
after discontinuation of study therapy. 
Male subjects must:
a. Practice true abstinence*or agree to use a condom during sexual contact with a 
pregnant female or a female of childbearing potential while participating in the study, 
during dose interruptions and for at least 6 months following IP discontinuation, even 
if he has undergone a successful vasectomy. 
b. Refrain from semen or sperm donation while taking durvalumab and for at least 3 
months after the last dose of durvalumab.
16. Females must abstain from breastfeeding during study participation and 3 months after IP 
discontinuation. 
7.3. Exclusion Criteria
The presence of any of the following will exclude a subject from enrollment:
1. Refractory to prior taxane therapy for advanced disease. Prior taxane used in the adjuvant 
setting does not exclude eligib ility, provide d there is no disease recurrence within 12 
months upon completion of chemotherapy in that setting.
2. Evidence of active brain metastases, including leptomeningeal involvement (prior 
evidence of brain metastasis are permitted only if asymptomatic and clinically stable for 
at least 8 weeks following completion of therapy). MRI of the brain (or CT scan w/contrast) is preferred. Antiepileptic treatment is permitted in the context of prophylaxis 
for seizures.
3. Only evidence of disease is non-measurable at study entry.4. Patients with known activating mutations in EGFR (such as exon 19 deletions or L858R).
5. Patients with known activating mutations in EML4-ALK.
6. Preexisting peripheral neuropathy of Grade > 2 (per NCI CTCAE v4.0).
* True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. [Periodic 
abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception].&(/*(1(35235,(7$5<,1)250$7,21to o
moontnthshs
contact withcontact with
rticicipatipating ing
g gIPPdidisconsco
urvalumab valumab 
udyudypartipartiyy cipc
lude a subjlude a subj
yyfofor advancr advanc
ilitlity,y, provi provi dd
chemotherhemothe
n metastasemetastase
etastasis aretastasis a
llowing cowing
preferred.referr AA
idence of didence of d
ents wients wi ththiiikkhh
PatiPaents wnts w
6. P6. P reexireexi
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 51 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 20167. Any unresolved toxicity NCI CTCAE Grade â‰¥2 from previous anticancer therapy with 
the exception of alopecia, vitiligo, and the la boratory values defined in the inclusion 
criteria.
8. Venous thromboembolism within 1 month prior to Cycle 1 Day 1.9. Current congestive heart failure (New York Heart Association Class II-IV).
10. History of the following within 6 months prior to Cycle 1 Day 1: a myocardial infarction, 
severe/unstable angina pectoris, coronary/p eripheral artery bypass graft, New York Heart 
Association (NYHA) Class III-IV heart failure, uncontrolled hypertension, clinically 
significant cardiac dysrhythmia or clinically significant electrocardiogram (ECG)
abnormality, cerebrovascular accident, transient ischemic attack, or seizure disorder.
11. Known hepatitis B or C virus (HBV/HCV) infection, known history of human 
immunodeficiency virus (HIV) infection, or receiving immunosuppressive or 
myelosuppressive medications that would in the opinion of the Investigator, increase the risk of serious neutropenic complications, history of active primary immunodeficiency, 
active tuberculosis (clinical evaluation that includes clinical history, physical examination 
and radiographic findings, and TB testing in line with local pract ice).
12. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, 
defined as ongoing signs/symptoms related to the infection without improvement despite 
appropriate antibiotics, antiviral therapy, and/or other treatment.
13. Subject has a history of interstit ial lung disease, history of slowly progressive dyspnea
and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary 
hypersensitivity pneumonitis or multiple alle rgies. Any lung disease that may interfere 
with the detection or management of su spected drug-related pulmonary toxicity.
14. Subject has a clinically significant malabsorp tion syndrome, persistent diarrhea, or 
known sub-acute bowel obstruction > NCI CTCAE Grade 2, despite medical 
management.
15. Treatment with any chemotherapy, investig ational product, biologic or hormonal therapy
for cancer treatment within 28 days prior to signing the ICF. Concurrent use of hormonal therapy for non-cancer-related conditions (eg, hormone replacement therapy) is 
acceptable.
16. History of or suspected allergy to any IP or their excipients.
17. Major surgical procedure (as defined by the I nvestigator) within 28 days prior to the first 
dose of IP.  Note: Local surgery of isolated lesions for palliative intent is acceptable.
18. Currently enrolled in any other clinical protocol or investigational trial that involves
administration of experimental therapy and/or therapeutic devices.
19. Any other clinically significant medical condi tion, psychiatric illness, and/or organ 
dysfunction that will interfere with the administration of the therapy according to this 
protocol or which, in the views of Investigator, preclude combination chemotherapy.
20. Any other malignancy within 5 years prior to randomization/treatment assignment, or 
advanced malignant hepatic tumors, with the exception of adequately treated squamous &(/*(1(35235,(7$5<,1)250$7,21rt rt 
orderorder ..
man man 
ive or ve or 
igatorigato , incin
y immunody immunod
storytory,,physiphy
practactice)ice).
(s) requirins) requirin
ectectioion win withthiii
her treatmeher treatme
e, historye, history oy
sis, idiosis, idio patpat
e allergies. allergies
suspected dsuspected d
nt malabsornt malabsor
ctiction >on > NC
23 mmothotherapyerap
witwithin 28 hin 28
ancerancer --relreat
or suspector suspect
surgiurgicalcal pr pll
se of IP.  Ne of IP.  N
CurrentCurrent ly ly
adminiadmini
19.19.AnAn
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 52 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016cell carcinoma of the skin, in-situ carcinoma of the cervix, uteri, non-melanomatous skin 
cancer, carcinoma in situ of the breast, or incidental histological finding of prostate 
cancer (TNM Classification of Malignant Tumours (TNM) stage of T1a or T1b). (All 
treatment of which should have been co mpleted 6 months prior to signing ICF).
21. Radiotherapy â‰¤ 4 weeks or limited field radiation for palliation â‰¤ 2 weeks prior to starting 
IP, and/or from whom â‰¥ 30% of the bone marrow was irradiated. Prior radiation therapy
to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed.
22. Any condition including the presence of laboratory abnormalities, which places the 
subject at unacceptable risk if he/she were to participate in the study.
23. Any medical c ondition that confounds the ability to interpret data from the study.
24. Female patients who are pregnant or breastfeeding or female patients of reproductive 
potential who are not willing to employ effect ive birth control from screening to 90 days 
after the last dose of durvalumab.  
25. Male patients of reproductive potential who are not willing to employ effective birth 
control from screening to 90 days after the last dose of durvalumab and from screening to 6 months after the last dose of nab-paclitaxel.
26. History of allogenic organ transplantation.
27. Active or prior documented autoimmune or inflammatory disorders (including 
inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the 
exception of diverticulosis], celiac disease, irritable bowel disease, or other serious 
gastrointestinal chronic conditions associated with diarrhea, systemic lupus erythematosus, sarcoidosis syndrome, or Wegenerâ€™s syndrome [granulomatosis with 
polyangiitis, Graves' disease, rheumatoid ar thritis, hypophysitis, uveit is, etc]) within the 
past 3 years prior to the start of treatment.  The following are exceptions to this criterion:
-Patients with vitiligo or alopecia
-Patients with hypothyroidism (eg, following Hashimotoâ€™s syndrome) stable on 
hormone replacement 
-Any chronic skin condition that does not require systemic therapy
-Patients without active disease in the last 5 years may be included but only after 
consultation with the study physician
28. Current or prior use of immunosuppressive medication within 14 days before the first 
dose of durvalumab.  The following are exceptions to this criterion:
-Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra articular 
injection)
-Systemic corticosteroids at physiologi c doses not to exceed 10 mg/day of 
prednisone or its equivalent
-Steroids as premedication for hypersen sitivity reactions (eg, CT scan 
premedication)&(/*(1(35235,(7$5<,1)250$7,21studytudy.
f reproductireproduc
creening tocreening 
emploemplo y yeffeff
valumab analumab a
ammatory ammatory
rohn's disearohn's dis
e, irritable b, irritable 
ociated withciated with
e, or Wegee, or Wege
umatoid artumatoid art
f treatmentf treatm
o or alo or al opecope
ypothyypothy roiroiyyydid
lacement cement 
onic skin coonic skin co
nts wints wi ththiiouou
onsultation onsultation
rent or priorent or prio
ose of durv of dur
--InI
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 53 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 201629. Receipt of live attenuated vaccine within 30 days prior to the first dose of IP.  Note: 
Patients, if enrolled, should not receive live vaccine during the study and up to 30 days 
after the last dose of IP.
30. Prior enrollment and treatment in a previous durvalumab clinical study. 31. Patients who have received prior anti-PD-1 or anti PD-L1:
#Must not have experienced a toxicity that led to permanent discontinuation of prior 
immunotherapy. 
#All AEs while receiving prior immunotherapy must have completely resolved or 
resolved to baseline prior to screening for this study.
#Must not have experienced a â‰¥ Grade 3 immune related AE or an immune related 
neurologic or ocular AE of any grade while receiving prior immunotherapy. NOTE: 
Subjects with endocrine AE of â‰¤ Grade 2 are permitted to enroll if they are stably 
maintained on appropriate replacement therapy and are asymptomatic.
#Must not have required the use of additional immunosuppression other than
corticosteroids for the management of an AE, not have experienced recurrence of 
an AE if re-challenged, and not currently require maintenance doses of > 10 mg 
prednisone or equivalent per day.
&(/*(1(35235,(7$5<,1)250$7,21or or 
une relatedune relate
otherapyotherapy . NN
if they are f they are
ptomptom atatic.ic.
pressioressio n othn o
e experiencexperienc
aintenance ntenance 
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 54 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 20168. DESCRIPTION OF STUDY TREATMENTS
8.1. Description of Investigational Products
Subjects will receive open-label nab-paclitaxel / CC-486, nab-paclitaxel /durvalumab or nab-
paclitaxel monotherapy during the Treatment Period of the study. nab-paclitaxel, durvalumab
and CC-486 are designated as  IP and will be packaged and supplied by the study S ponsor.
The reconstitution and IV administration of nab-paclitaxel should follow the local Prescribing 
Information for AbraxaneÂ®.
8.1.1. nab-Paclitaxel
nab-Paclitaxel will be supplied by the Sponsor in single-use vials in single count cartons. Each 
single-use 50 mL vial will contain paclitaxel (100 mg) and human albumin as a stabilizer.
Please see local prescribing information for AbraxaneÂ®for detailed instructions on the 
reconstitution, storage conditions and IV administration of nab-paclitaxel. Reconstituted nab-
paclitaxel s hould be store d in an area accessible only to study  personnel.
Temperature records for nab-paclitaxel must be made available to the Sponsor or other Sponsor-
nominated monitoring teams for verification of proper IP storage.
8.1.2. CC-486 (Azacitidine for Oral Administration)
The Sponsor will supply azacitidine 100 mg tablets for oral administration. Each tablet is 
formulated using excipients that are generally regarded as safe and are used in marketed drug 
products.
All tablets will be packaged in blister cards. Only sufficient IP for one cycle of treatment will be 
provided to each subject at the start of each treatment cycle. All tablets should be swallowed 
whole, and should not be broken or chewed. CC-486 may be taken on an empty stomach or with 
food. Subjects should drink 8 ounces (240 mL) of room temperature water with each dose. It is strongly recommended that all subjects receive a dose of a prophylactic antiemetic, preferably a 
5-HT3 antagonist, approximately 30 minutes prior to each dose of CC-486.
The IP must be stored as directed on package label at controlled temperature and a temperature 
log must be maintained in the source documents. The storage area should be secure and have 
access limited to study personnel. 
8.1.3. Durvalumab (MEDI4736)
Durvalumab will be supplied by the Sponsor in single use vials in single count cartons. Each 10R 
(10 mL) vial will be supplied as a liquid solution containing 500 mg (nominal) of IP at a concentration of 50 mg/mL. Durvalumab should be stored in accordance with the product label. 
The study site is to supply the following:
!IV infusion bags of normal saline (0.9% [w /v] sodium chloride injection, 250 mL 
size). Saline bags must be latex-free and can be made of polypropylene, polyethylene, polyolefin copolymers, or polyvinyl chloride. Infusion lines should contain a 0.2- Î¼m 
in-line filter.  &(/*(1(35235,(7$5<,1)250$7,21rtons. Eachrtons. Eac
tabilizer.tabilizer.
ons on the ns on the
ReconstiReconsti tutii
el.l.
thhe SponsoSpons
gee..
n)
r oral admir oral adm
rdrdededas safeas saf
Only suffiOnly suffi
ch treatmench treatmen
ewed.wed. CCCC
es(240 mL(240 mL
ubjects receubjects rec
ately 30 mintely 30 mi
directed ondirected
d in the soud in the sou
udyudypersonnpersonyy
rvalurvalu mabmab
mab will be b will be 
L) ) vial will vial will 
centration ocentration o
The studyThe study
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 55 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016!Since the compatib ility of durv alumab with other IV medications and solutions, other 
than normal saline, is not known, the durvalumab solution should not be infused through an IV line in which other solutions or medications are being administered.
Durvalumab will be administered using an IV bag containing 0.9% (w/v) saline or 5% (w/v) 
dextrose, with a final durvalumab concentration ranging from 1 to 20 mg/mL, and delivered through an IV administration set with a 0.2- or 0.22- Î¼m in-line filter.
The dose of durvalumab for administration must be prepared by the Investigatorâ€™s or siteâ€™s 
designated IP manager using aseptic technique. Total time from needle puncture of the MEDI4736 vial to the start of administration should not exceed:
!24 hours at 2Â°C to 8Â°C (36Â°F to 46Â°F)
!4 hours at room temperature
Standard infusion time is 1 hour. However, if there are interruptions during infusion, the total 
allowed time should not exceed 8 hours at room temperature. In the event that either preparation 
time or infusion time exceeds the time limits outlin ed above, a new dose must be prepared from 
new vials. Durvalumab does not contain preservatives, and any unused portion must be discarded.
For additional information on preparation and st orage please refer to the pharmacy manual.
8.1.4. Monitoring During/After Durvalumab Infusion 
First durvalumab  infusion
On the first infusion day, subjects in the nab-paclitaxel/ durvalumab combination arm will be 
monitored, and assessments collected/recorded in the eCRF prior to, during and after infusion of IP as presented in the bulleted list below.
Blood pressure (BP) and pulse will be collected from subjects before, during, and after each 
infusion at the following times (b ased on a 60-minute infusion):
!Prior to the beginning of the infusion (measured once from approximately 30 minutes 
before up to 0 minutes [ie, the beginning of the infusion])
!Approximately 30 minutes during the i nfusion (halfway through infusion) 
!At the end of the infusion (approximately 60 minutes Â±5 minutes)
!If the infusion takes longer than 60 minutes, then BP and pulse measurements should 
follow the principles as described above or be taken more frequently if clinically indicated.  A 1-hour observation period is recommended after the first infusion of 
durvalumab.
Subsequent durvalumab infusions
BP, pulse and other vital signs should be meas ured, collected/recorded in eCRF prior to the start 
of the infusion. Subjects should be carefully monitored and BP and other vital signs should be 
measured during and post infusion as per institution standard and as clinically indicated. Any clinically significant changes in vital signs should be entered onto an unscheduled vital signs 
CRF page.&(/*(1(35235,(7$5<,1)250$7,21fusiofusi n, the n, the
that either phat either p
e must be pmust be
ed portion md portion
refer to the efer to th
usion sion
clitclitaxel/duraxel/dur
d in d in the the eCeC
collectedcollect ff
sed on a 60d on a 60
ng of the ing of the in
inutes [nutes [ ieie,t
elyely 30 minu30 minyy
nd of the inof the in
e infusioe infusio n
oollollow the pw the p
indicatedndicated
durvaurva
ubsequent dubsequent d
&(BP, pulseBP, pulse
theth
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 56 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016For all infusions
In the event of a â‰¤ Grade 2 infusion-related reaction, the infusion rate of IP may be decreased by 
50% or interrupted until resolution of the event (up to 4 hours) and re-initiated at 50% of the 
initial rate until completion of the infusion. For subjects with a â‰¤ Grade 2 i nfusion-related 
reaction, subsequent infusions may be administered at 50% of the initial rate. 
Acetaminophen/paracetamol and/or an antihistamine (eg, diphenhydramine) or equivalent 
medications per institutional standard may be admin istered at the discretion of the investigator. If 
the infusion-related reaction is â‰¥ Grade 3 or higher in severity, IP will be discontinued. 
As with any antibody, allergic reactions to dos e administration are possible. Appropriate drugs 
and medical equipment to treat acute anaphylactic reactions must be immediately available, andstudy personnel must be trained to recognize and treat anaphylaxis. The study site must have 
immediate access to emergency resuscitation teams and equipment in addition to the ability to 
admit subjects to an intensive care unit if necessary.
8.2. Treatment Administration and Schedule
Following administration of nab-paclitaxel, the intravenous line should be flushed with sodium
chloride 9 mg/mL (0.9%) solution for injection to ensure administration of the complete dose, 
according to local practice.
Once randomized (or assigned), subjects will be treated with nab-paclitaxel / CC-486, nab-
paclitaxel / durvalumab or nab-paclitaxel monotherapy until disease progression, development of 
an unacceptable toxicity, death, lo st to follow-up, withdrawal of consent, or termination of the 
study by the Sponsor:
!nab-Paclitaxel 100 mg/m2IV infusion over 30 minutes on Days 8 and 15 and CC-486 
200 mg orally QD on Days 1 to 14 of each 21-day treatment cycle, or
!nab-Paclitaxel 100 mg/m2IV infusion over 30 minutes on Days 1 and 8 and 
durvalumab 1125 mg IV infusion over approximately 1 hour on Day 15 of each 21-
day treatment cycle, or  
!nab-Paclitaxel 100 mg/m2IV infusion over 30 minutes on Days 1 and 8 of each 21-
day treatment cycle
8.3. Dose Omissions and Modifications
8.3.1. Rules for Dose Omissions and Modified Schedules
nab-Paclitaxel Monotherapy Arm
If, for administrative reasons, treatment cannot be administered on the planned visit date, IP may 
be administered plus or minus 2 days from the scheduled date.
!Day 1 Dose Missed
If nab-paclitaxel cannot be administered on Day 1 within the 2 days allowable window,
nab-paclitaxel may not be skipped but only delayed 
Delay of Day 1 will automatically shift the following visit for this cycle &(/*(1(35235,(7$5<,1)250$7,21f f 
drugs drugs 
lable, andable, and
mmust have ust have mm
the abilitthe abilit yy
ould be flusd be flus
stration of tation of
ith itnabnab-pacpa
yyuntuntil il diseadisea
iththidrawaldrawal ol
sisionon over 3over n
o o 1414ofof eaceacff
IV infuIV infu sio
5V infusioinfusio n
or  or  
00 00 mg/mmg/m2m
cyclecycle
OmissionOmission
ules for Does for Do
litaxel Monxel Mo/*r administrr administ
e administee administe
!D
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 57 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016!Day 8 Dose Missed
If the nab-paclitaxel dose for Day 8 is given >9 days from Day 1, the Day 8 dose, when 
administered, can be either considered as delayed or skipped, depending on the intention of the 
Investigator.
nab-paclitaxel may be delayed up to Day 15: this  dose will be considered as delayed 
Day 8; the next visit will be the planned Day 1 of the next cycle which will not be 
automatically pushed back
nab-paclitaxel may be skipped: if the second nab-paclitaxel dose cannot be given in a 
cycle it may be skipped; the next dose would be administered as the Day 1 dose 
nab-Paclitaxel/CC-486 Combination Arm
If, for administrative reasons, treatment cannot be administered on the planned visit date, IP may 
be administered plus or minus 2 days from the scheduled date.
If any doses of CC-486 are missed, skip that day and resume as appropriate, do not double up on
subsequent days.
!Day 1 Dose Missed
If CC-486 cannot be administered on Day 1 within the 2 days allowable window,
The nab-paclitaxel Day 8 dose would not necessa rily be pushed back / delayed
Doses of CC-486 would be skipped (exposure to CC-486 would be reduced on that 
cycle). 
For hematologic toxicity, dosing should be reassessed at the next visit on Day 8.
!Day 8 Dose Missed
If nab-paclitaxel cannot be administered on Day 8 within the 2 days allowable window,
nab-paclitaxel may be delayed (eg, for neuropathy): this dose will be considered as 
delayed Day 8; the next dose (Day 15) may also be delayed up to the original Day 1 of the next cycle (approximately 20 days from Day 1 of this cycle) to maintain the protocol 
specified visit gap
nab-paclitaxel may be skipped (eg, hematotoxicity); the next dose would be administered 
as the Day 15 dose 
If the dose for Day 8 is given > 9 days from Day 1, the Day 8 dose, when administered, can be 
either considered as delayed or skipped, depending on the intention of the Investigator.
Upon resuming treatment after stopping both IPs on adjusted Day 8, consideration for nab-
paclitaxel resumption should take priority.
!Day 15 Dose Missed
If nab-paclitaxel cannot be administered on Day 15 within the 2 days allowable window,
nab-paclitaxel may be delayed: this dose will be considered as delayed Day 15 (up to 
Day 1 of the next cycle); CC-486 may be started on Day 1 as planned&(/*(1(35235,(7$5<,1)250$7,21a a 
isit date, isit date, IPIP
te, do not dte, do not d
allllowable wowab
ilybe pushbe pushy
to CCto CC --486 486
ssessed at sessed at t
d on Don D ayy8
yed (yed eg,g,fof
dose (Ddose (D ayay
ximatelyximately 202
l may may bbyye e sk
15 dose 15 dose 
DDayay8 is gi8 is 
dered as dedered as de
esuming treesuming tr
itaxel resumitaxel resum
!!DayDa
ffnabnab
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 58 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016If the nab-paclitaxel dose cannot be administered within 14 days from the last dose, it 
will be considered as skipped
nab-Paclitaxel/Durvalumab Combination Arm
No dose reductions of durvalumab are allowed. In case of doubt , the Investigator s hould consult 
with the Study Physician.
If, for administrative reasons, treatment cannot be administered on the planned visit date, IP may 
be administered plus or minus 2 days from the scheduled date.
!Day 1 Dose Missed
If nab-paclitaxel cannot be administered on Da y 1 within the 2 days allowable window,
nab-paclitaxel may not be skipped but only delayed 
Delay of Day 1 will automatically shift the following visit for this cycle 
!Day 8 Dose Missed
If the nab-paclitaxel dose for Day 8 is given > 9  days from Day 1, the Day 8 nab-paclitaxel dose 
should be skipped
!Day 15 Dose Missed
If durvalumab cannot be administered on Day 15 within the 2 days allowable window,
Durvalumab may be delayed: this dose will be considered as delayed Day 15 
If the durvalumab dose cannot be administered w ithin 14 days from the last dose, it will 
be considered as skipped
8.3.2. Rules for Dose Modifications
Subjects who experience any of the adverse drug reactions in Table 6 will be dose reduced as per 
Table 6 during tr eatment. 
nab-Paclitaxel Monotherapy Arm
!Do not administer nab-paclitaxel on Day 1 of a cycle until ANC is at least 
1500 cells/mm3and platelet count is at least 100,000 cells/mm3.
!In subjects who develop severe neutropenia or thrombocytopenia withhold treatment until 
counts recover to an absolute neutrophil count of at least 1500 cells/mm3and platelet 
count of at least 100,000 cells/mm3on Day 1 or to an absolute  neutrophil count of at least 
500 cells/mm3and platelet count of at least 50,000 cells/mm3on Day 8 of the cycle. 
Upon resumption of dosing, permanently reduce nab-paclitaxel doses as outlined in 
Table 6 .
!Withhold nab-paclitaxel for Grade 3 or 4 peripheral neuropathy. Resume nab-paclitaxel 
at reduced doses ( Table 6 ) when peripheral neuropathy improves to Grade 1 or 
completely resolves.
!For Grade 2 or 3 cutaneous toxicity, Grade 3 mucositis, or Grade 3 diarrhea, interrupt 
treatment until the toxicity improves to â‰¤Grade 1, then restart treatment according to &(/*(1(35235,(7$5<,1)250$7,21,,
e 
DayDay 88yynabnab
e 2 days al2 days a
consideredconsidered
ered withinered within
dverse drugdverse drug
Armrm
nabab--paclitapaclita
and plateland plate
who develowho develo
cover to ancover to a
of at least of at least 
0 cells/mmcells/mm33
Upon resumUpon resu
TableTable 66
!!WitWit
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 59 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016the guidelines in Table 6 . For any other Grade 3 or 4 nonhematologic toxicity or other 
Investigator defined unacceptable toxicity, interrupt treatment until the toxicity 
improves to â‰¤Grade 2, then restart treatment according to the guidelines in Table 6 .
Re-escalation is not permitted at any time. 
nab-Paclitaxel/CC-486 Combination Arm
!Do not administer nab-paclitaxel on Day 8 or CC-486 on Day 1 or 8 of a cycle until ANC 
is at least 1500 cells/mm3and platelet count is at least 100,000 cells/mm3.
!In subjects who develop severe thrombocytopenia, withhold treatment until counts 
recover to a platelet count of at least 100,000 cells/mm3on Days 1 and 8 for CC-486 and 
Day 8 for nab-paclitaxel or to a platelet count of at least 50,000 cells/mm3on Day 15 of 
the cycle for nab-paclitaxel. Upon resumption of dosing, permanently reduce nab-
paclitaxel and/or CC-486 doses as outlined in Table 6 .
!In subjects who experience Grade â‰¥3 neutropenia, withhold treatment and start G-CSF 
treatment daily until the ANC â‰¥ 2000/mm3(please refer to Section 9.3for G-CSF 
administration). Upon resumption, permanently reduce nab-paclitaxel and/or CC-486 
dose as outlined in Table 6 .
!Withhold nab-paclitaxel for Grade 3 or 4 peripheral neuropathy (CC-486 does not need 
to be withheld). Resume nab-paclitaxel at reduced doses ( Table 6 ) when peripheral 
neuropathy improves to Grade 1 or completely resolves. 
!For Grade 2 or 3 cutaneous toxicity, Grade 3 mucositis, or Grade 3 diarrhea, interrupt 
treatment until the toxicity improves to â‰¤Grade 1, then restart treatment according to the 
guidelines in Table 6 . For any other Grade 3 or 4 nonhematologic toxicity or other 
Investigator defined unacceptable toxicity, in terrupt treatment until the toxicity improves 
to â‰¤Grade 2, then restart treatment according to the guidelines in Table 6 .
Re-escalation is not permitted at any time. 
nab-Paclitaxel/Durvalumab Combination Arm
Guidelines for the management of toxicities for durvalumab and nab-paclitaxel are provided in 
Appendix C .
In addition:
!Do not administer nab-paclitaxel on Day 1 of a cycle until ANC is at least 
1500 cells/mm3and platelet count is at least 100,000 cells/mm3.
!In subjects who develop severe neutropenia or thrombocytopenia withhold treatment until 
counts recover to an absolute neutrophil count of at least 1500 cells/mm3and platelet 
count of at least 100,000 cells/mm3on Day 1 or to an absolute neutrophil count of at least 
500 cells/mm3and platelet count of at least 50,000 cells/mm3on Day 8 of the cycle. 
Upon resumption of dosing, permanently reduce nab-paclitaxel doses as outlined in 
Table 6 .&(/*(1(35235,(7$5<,1)250$7,21486 and 86 and
n DayDay 15 of 15 ofyy
uce ce nabnab--
ent and staent and sta
on 9.39.3fofor G
paclitaxel anaclitaxel a
europathyeuropathy (
doses (oses ( TabTab
esolves. esolves. 
3 m3 mucosiucosim titiii
Grade 1, tGrade 1, t
Grade 3 or 4Grade 3 or 4
toxicitoxicit yy, int,i n t
ment accordint accord
ny ttime. ime. 
Combinatioombinati
ment ent ofotoxto
administer administ
cells/mmcells/mm33
In subjects In subjects
counts recounts 
countcount
5050
EDMS Doc. Number:nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 60 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016!Withhold nab-paclitaxel for Grade 3 or 4 peripheral neuropathy. Resume nab-paclitaxel 
at reduced doses ( Table 6 ) when peripheral neuropathy improves to Grade 1 or 
completely resolves. 
!For Grade 2 or 3 cutaneous toxicity, Grade 3 mucositis, or Grade 3 diarrhea, interrupt 
treatment until the toxicity improves to â‰¤Grade 1, then restart treatment according to the 
guidelines in Table 6 . For any other Grade 3 or 4 nonhematologic toxicity or other 
Investigator defined unacceptable toxicity, interrupt treatment until the toxicity improves 
to â‰¤Grade 2, then restart treatment according to the guidelines in Table 6 .
Following the first dose of IP, subsequent administration of durvalumab can be modified based 
on toxicities observed as described in the Dosing Modification and Toxicity Management 
Guidelines.  These guidelines have been prepared by the Sponsor to assist the Investigator in the 
exercise of his/her clinical judgment in treating these types of toxicities.  These guidelines apply 
to AEs considered causally related to the durvalumab containing regimen by the reporting 
Investigator.
Treatment modifications referring to â€˜study regimen or treatmentâ€™ would apply to both nab-
paclitaxel and durvalumab unless AEs are not considered causally related to nab-paclitaxel by 
the reporting Investigator. In that case nab-paclitaxel or durvalu mab treatment may be continued 
alone if deemed beneficial to the patient per Investigatorâ€™s assessment.
Re-escalation is not permitted at any time. 
&(/*(1(35235,(7$5<,1)250$7,21based based 
ent ent 
tigator in thtigator in t
guidedelines alines a
he reportine reportin
d apply to d apply t
elated to ated to na
mabbtreatmatm
essment.essment
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 61 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Table 6: Permanent Dose Reductions for Hematologic and Nonhematologic Toxicities and Dosing on the Study
Dose Modification During Treatment
Adverse Drug Reaction OccurrenceMonotherapy Arm: nab-
paclitaxel Dose (mg/m2)Combination Arm: nab-
paclitaxel Dose (mg/m2) / 
CC-486 Dose (mg)
Neutropenic Fever (ANC < 500/mm3with fever >38Â°C)
OR
Delay of next cycle by > 7 days for ANC < 1500/mm3
ORANC < 500/mm
3for > 7 daysFirst 75 100/100
Second 50 75/100
Third Discontinue Treatment* 50/100
Fourth NA Discontinue Treatment*
Platelet count < 50,000/mm3First 75 100/100
Second Discontinue Treatment* 75/100
Third NA Discontinue Treatment*
Peripheral Neuropathy Grade â‰¥3First 75 75/200
Second 50 50/200
Third Discontinue Treatment*
Grade 2 or 3 Cutaneous toxicity
Grade 3 Diarrhea
Grade 3 Mucositis
Any other Grade 3 or 4 nonhematologic toxicity or other 
Investigator defined unacceptable toxicityFirst 75 100/100
Second 50 75/100
Third Discontinue Treatment* 50/100
Fourth NA Discontinue Treatment*
Grade 4 Cutaneous toxicity, Diarrhea or Mucositis First Discontinue Treatment*
ANC = absolute neutrophil count; AUC = area under the curve; NA = not applicable.
* If an adverse event that requires dose reduction recurs after the dose has been reduced according to the table above, the subje ct should generally have treatment 
discontinued unless, at the discretion of the Investigator, there is evidence of continuing benefit to the subject that outweigh s the risk of recurrent toxicity.
&(/*(1priprietet1(35235,(7$5<,1)250$7,21e Corporae Corpora
21StudyStudy
7,2
))CombinaCombina
paclitapaclit
CC$7
5050505050
500)2ontinue Treontinue Tre1)
NN<,5<$5D$5$5$5$57$$$$
stt(7 SecondSecond,(
ThirdThird5,
er er Fi3523555235353535tistis(31(ea under the cea under the 
duction recurduction recur
of the f the InvestInves
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 62 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 20168.4. Method of Treatment Assignment
The Treatment Period of the study is open-label. Randomization/treatment assignment has been 
and will be carried out centrally using an IRT system.
8.5. Packaging and Labeling
The label(s) for all IP will include Sponsor name, address and telephone number, the protocol number, IP name, dosage form and strength (where applicable), amount of IP per container, lot number, expiry date (where applicable), medication identification/kit number, dosing 
instructions, storage conditions, and required caution statements and/or re gulatory statements as 
applicable. Additional information may be included on the label as applicable per local regulations.
8.6. Investigational Product Accountability and Disposal
The Sponsor (or its designee) will review with the Investigator and relevant site personnel the 
process for IP return, disposal, and/or destruction including responsibilities for the site versus the 
responsibilities of the Sponsor (or designee).
The Sponsor w ill instruct th e Investigator on the ret urn, disposal and/or destruction of IP. Only 
completely unused IP vials should be retained by the site until a representative from the Sponsor
or other Sponsor-designated personnel have completed an inventory. Partially used and
completely used vials should be destroyed accordi ng to local guidelines, and disposition should 
be recorded on the Investigational Drug Accountability Record Form.
The Investigator(s) or designee(s) is responsible for accounting for all IP that is issued to and
returned by the subject during the course of the study according to applicable regulatory
requirements. Any unused CC-486 must be returned by a study subject and retained by the
investigative site for accountability to be conducted  by a Sponsor representative (or its designee). 
If any IP is lost or damaged, its disposition should be documented. At the periodic monitoring
visits, a Sponsor representative (or its designee)  will conduct IP accoun tability and address any
discrepancies. Upon satisfactory reconciliation of all IP, ret urned IP may be destroyed. At the
conclusion of the study, all remaining IP will be  counted, reconciled with dispensing records, 
documented, and destroyed at the clinic site or allocated drug destruction location after
completion of drug accountability by a Sponsor representative (or its designee). The Sponsor
representative (or its designee) will ensure that  a final report of drug accountability to the unit 
dose level (ie, tablet) is prepared and placed in both the Investigator study file and the central 
clinical study file.
Investigational product will not be loaned or dispensed by the Investigator to another 
Investigator or site. Under certain circumstances , and with Sponsor permission, cooperative 
groups may manage IP between locations within their network as clinical trial agreement and 
local guidelines permit.&(/*(1(35235,(7$5<,1)250$7,21ot 
ments as nts as
cal cal 
vant site pent site 
bilitilities ies fofor trt
sal and/orsal and/o d
ntil a represil a repr
an inventorinvento
to local guito local gu
bilitbility yRecorRecor
le for accoule for acco
the studythe study ay
be be returnedreturned
be conducbe conduc
posiostiion shon sh
(or (or ititssdesigdesig
oryoryreconcireconcyy
l remainingemaining
oyoyed at the ed at the
accountabilccountabi
ittssdesidesignegne
tablet) is prablet) is 
dyyffyyile.ile.fff
gatgaional pronal pro
ttigatorigator or sor
oups moups m ayayy
&loocal guidcal guid
EDMS Doc. Number:nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 63 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 20168.7. Investigational Product Compliance
All IP will be administered only by study site personnel and accurate recording of all IP 
administration will be made in the appropriate section of the subjectâ€™s eCRF and source 
documents.
8.8. Overdose
Overdose, as defined for this protocol, refers to nab-paclitaxel, CC-486, or durvalumab dosing.
On a per dose basis, an overdose is defined as 10% over the protocol-specified dose of nab-
paclitaxel, durvalumab or CC-486 to a given subject, regardless of any associated adverse events 
or sequelae. 
On a schedule or frequency basis, an overdose is defined as anything more frequent than the 
protocol required schedule or frequency.
On an infusion rate basis, an overdose is defined as any rate faster than the protocol-specified 
rate. For nab-paclitaxel, an infusion completed in less than 25 minutes may increase C maxby 
approximately 20%, therefore a nab-paclitaxel infusion completed in less than 25 minutes will 
meet the infusion rate criterion for an overdose.
Complete data about drug administration, including any overdose, regardless of whether the 
overdose was accidental or intentional, should be reported in the AE case report form. See 
Section 11.1 for the reporting of adverse events associated with overdose.
&(/*(1(35235,(7$5<,1)250$7,21e events events 
nt than the t than the
protocol-protocol- sps
mayayiiyyncreasncr
less than 2less than 
dose, regarddose, rega
in the n the AE AE
ed with oved with o
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 64 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 20169. CONCOMITANT MEDICATIONS AND PROCEDURES
9.1. Permitted Concomitant Medications and Procedures
Over the course of this study, additional medications may be required to manage aspects of the 
disease state of the subjects, including side effects from study treatments or disease recurrence. 
All supportive care (including but not limited to growth factors, antiemetics, analgesics, 
zoledronic acid, denosumab) is permitted as per t he Investigatorâ€™s disc retion and should be 
administered according to local institutional practice. All concomitant treatments, including 
blood and blood products, must be reported on the eCRF.
!Antiemetics are not required during the study; however, it is strongly recommended 
that all subjects receive a dose of a prophylactic antiemetic, preferably a 5-HT3 
antagonist, approximately 30 minutes prior to each dose of CC-486.
!Stable, therapeutic doses of anticoagulants are permitted; however, subjects on 
warfarin should have prothrombin t ime (PT) or international norm alized ratio (INR)
and partial thromboplastin time (PTT) monitored as clinically indicated.
!Subjects on eryth ropoietin or darbepo etin alfa for at least 4 weeks prior to starting the 
IP may continue their pretreatment doses throughout the study.
#Note: If the subject is not on a stable dose of an erythropoiesis-stimulating agents 
(ESA) prior to study entry, the subject may not start an ESA during Cycle 1. However, medications such as ESAs, granulocyte colony-stimulating factors (G-
CSFs), etc., may be administered according to standard of care after Cycle 1.
!Use of white blood cell growth f actors (eg, filgrastim, G-CSF for the treatment of 
subjects with neutropenic fever is permitted at the Investigator â€™s discretion. Use of 
filgrastim rather than pegylated-filgrastim is indicated, because of the 14 day delay of 
the next cycle following treatm ent with peg-filgrastim.
!Use of white blood cell growth factors (e g, filgrastim, G-CSF) for secondary
prophylaxis in subjects who experienced  a neutropenic complication from a prior
cycle of chemoth erapy (for which primary prophylaxis was not received) is permitted.
!Flu vaccination with inactivated virus is permitted.
!Routine infectious disease prophylaxis is not recommended, however, antibiotic,
antiviral, antipneumocystis, antifungal, or other prophylaxis may be implementedduring the study at the discretion of the Investigator.
!Treatments with bisphosphonates (eg, p amidronate, zoledronate), or other agents (eg, 
denosumab) to prevent or delay progression of bone metastases are permitted.
Maintenance of a stable dosing regimen throughout the study is recommended.
!Subjects may receive physiologic repl acement doses of glucocorticoids as
maintenance therapy for adrenal insufficiency. Glucocorticoids may be administeredas an antiemetic with IV chemotherapy, if directed by local standard of care. Use of 
immunosuppressive medications for the management of durvalumab-related AEs, or &(/*(1(35235,(7$5<,1)250$7,21mended mended 
-HT3 HT3 
r, subjects or, subjects o
rmrmalized ralized r
ly indicatedly indicat
st 4 weeks pst 4 week
the study.the study.
an erytan eryt hrophro
yynnyyot start ot start 
ranulocyranulocy teteyyy
cording to cording to
ors (rs (egeg, filg fil
s permitteds permitted
eded--filgrastfilgra ii
eatmeatm ent wient wi
l l growth fgrowth f
ects who exects who 
herapy (forerapy (fo
ioion nwiwthhiiihhn
e infectiousinfectious
irirala, anti, anti pnpnii
uring the uring the stust
TreatmeTreatm
denosenos
MaM
!!
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 65 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016in subjects with contrast allergies is acceptable.  In addition, use of inhaled, topical, 
and intranasal corticosteroids is permitted.
!Treatment with antidiarrheal medications is recommended at the first sign of diarrhea
as per the guidelines in Appendix B . Pre-medication with an tidiarrheal medication for 
subsequent doses of CC-486 may be appropriate.
!The potential drug-drug interactions precautions contained in the nab-paclitaxel 
prescribing information will be applied to this study, unless otherwise specified in the 
protocol. Specifically, the metabolism of paclitaxel is catalyzed by cytochrome P450 isozymes CYP2C8 and CYP3A4. Caution is recommended when administering nab-
paclitaxel concomitantly with medicines known to inhibit (eg, ketoconazole and other 
imidazole antifungals, erythromycin, fluoxetine, gemfibrozil, cimetidine, ritonavir, saquinavir, indinavir, and nelfinavir) or induce (eg, rifampicin, carbamazepine, 
phenytoin, efavirenz, nevirapine) either CYP2C8 or CYP3A4. For information 
regarding other drugs that may interact with either nab-paclitaxel or durvalumab and 
affect their metabolism, pharmacokinetics, or excretion, please see the respective IP 
product information (refer to Prescribing Information and/or IB).
!Antiepileptic treatment is permitted, in the context of prophylaxis for seizures, for 
subjects with prior evidence of brain metastasis (asymptomatic and clinically stable for at least 8 weeks following complet ion of therapy for brain metastasis).
9.2. Prohibited Concomitant Medications and Procedures
Other investigational therapies must not be used while the subject is enrolled in the study.
Anticancer therapy (chemotherapy, biologic or i nvestigational therapy, and surgery) other than
the study treatments must not be given to sub jects during the study. If such treatment is required,
the subject must be discontinued from the study . Focal palliative radiotherapy for treatment of
cancer-related symptoms is allowed during study treatment at the discretion of the Investigator.
The administration of either Î±-interferon and/or ribavirin, or drugs with known renal toxicity is
prohibited during study tr eatment. Monoclon al antibodies against CTLA-4, PD-1 or PD-L1 
should not be given concomitantly.
Immunosuppressive medications including, but not limited to, systemic corticosteroids at doses 
exceeding 10 mg/day of prednisone or equivalent, methotrexate, azathioprine, and tumor 
necrosis factor- Î± blockers should not be given during the study unless required for management 
of immune-related toxicities ( Appendix C ).
Live attenuated vaccines should not be given through 30 days after the last dose of IP.
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) EGFR TKIs should 
not be given concomitantly with durvalumab, and should be used with caution in the 90 days 
post last dose of durvalumab. Increased incidences of pneumonitis (with third generation EGFR 
TKIs) and increased incidence of transaminase incr eases (with first generation EGFR TKIs) has 
been reported when durvalumab has been given concomitantly.t ll(/*(1(35235,(7$5<,1)250$7,21e e 
50 0
ggnabab--
and other d othe
riritontoniiavir, avir, 
mazepine, zepine, 
nformationnformatio
l or durvalul or durva
e see see ththe re
or IB).or IB).
prophylaxisophylaxi
ymptomatymptom ic
apyapy ffyor braor brafff
ns and Prns and P
hile the subhile the sub
nvestinvesti gatigato
jects duringjects durin
studystudy . Foca. Foc
ring studyng study ty
fferon and/oeron andfff
MoMonoclonnoclo
ntly.tly.
cations incltions incl
 prednison prednisof
ckers shoulkers shou
d toxitoxicicititiiiies es 
d vaccinesvaccine
al growth fagrowth fa
given concgiven conc
ast dose oast dose o
TKIs) and inTKIs) and i
been repobeen repo
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 66 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 20169.3. Required Concomitant Medications and Procedures for Subjects 
Receiving CC-486
Data regarding G-CSF administration should be  recorded on the e CRF provided for G-CSF 
administration.
9.3.1. Description of G-CSF
This medication stimulates the blood system (bone marrow) to make white blood cells, helping
fight infections. This medication is given to those whose ability to make white blood cells has
been reduced. Filgrastim (also known as G-CSF, or granulocyte colony stimulating factor) is a
man-made version of a certain natural substance found in the body. It is produced using a certain
bacteria. It will be obtained commercially and relabeled as clinical supplies. It should be stored,
and administered according to the manufacturer â€™s recommendation.
9.3.2. Administration of G-CSF
For subjects who experience Grade â‰¥3 neutropenia, G-CSF 5 âˆ€g/kg daily will be administered
subcutaneously. During any cycle when Grade â‰¥3 neutropenia occurs, CC-486 and other 
cytotoxic agents will be held, and G-CSF will begin immediately (a minimum of 24 hours after the last dose of CC-486 and chemotherapy). In subsequent cycles, G-CSF will begin on Day 16. 
G-CSF will continue daily until the ANC â‰¥2000/mm
3. In subjects receiving G-CSF, the next 
cycle should begin no sooner than 48 hours after discontinuation of G-CSF. 
For complete details on drug administration, storage , clinical pharmacology, and the human PK 
of G-CSF (filgrastim), please see the G-CSF (filgrastim) package insert.
&(/*(1(35235,(7$5<,1)250$7,21 is ais a
g a certaing a certain
d be storedd be stored
ily will beily will b
rs, CCs, CC -486486
(a minimuma minimu
les, Gles, G --CSF
ubjectsbjects recerece
inuation ofnuation 
 clinical phclinical 
rastim) pacrastim) pa
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 67 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 201610. STATISTICAL ANALYSES
Statistical analyses for the primary and key s econdary endpoints of the study are described 
below.  Additional analyses of these endpoin ts as well as exploratory endpoints or subgroup 
analyses will be described in detail in the statistical analysis plan (SAP).  The SAP supersedes 
the analyses described in the protocol should there be differences between the two.
Evaluations of the study endpoints will be based primarily on the point estimates and the 
associated 95% confidence intervals of the within- and between-treatment differences. 
10.1. Overview
Approximately 240 subjects will be assigned 1:1:1 to one of the three treatment arms 
(approximately 80 subjects per group). The combination arms will receive nab-paclitaxel with 
epigenetic modifying therapy of CC-486 or nab-paclitaxel with immunotherapy of durvalumab,
and the monotherapy arm will receive nab-paclitaxel alone.  All regimens will be administered 
in 21-day cycles. All subjects will receive the assigned study treatment until disease progression, 
unacceptable toxicity, death, lost to follow-up, withdrawal of consent, or termination of the 
study by the Sponsor, in accordance with lo cal standard of care. Treatment beyond progression 
defined by RECIST 1.1 will be permitted per irRECIST criteria for those subjects in the nab-
paclitaxel/durvalumab arm (see Section 4.1.2.1 ).
Prior to Protocol Amendment 4.0, all subjects were randomized 1:1 to the nab-paclitaxel/CC-
486 combination therapy and nab-paclitaxel monotherapy arms using a permuted-block 
randomization met hod with the following baseline stratification factors: 
!ECOG performance status (0 versus 1)
!Gender (males versus females)
!Smoker (yes versus no)
Randomization was carried out centrally using an  IRT system. As Protocol Amendment 4.0 
implementation was in effect after enrollment completed in the nab-paclitaxel/CC-486 
combination therapy and nab-paclitaxel monothera py arms (with each arm reaching a total of 
approximately 80 subjects), all subjects enrolled wh ile Protocol Amendment 4.0 is in effect and 
at the time of Protocol Amendment 5.0 implementation will be assigned to the nab-
paclitaxel/durvalumab combination therapy arm until approximately 80 subjects have been enrolled in that arm. Hence, treatment assignment of subjects to the nab-paclitaxel/CC-486 
combination therapy and nab-paclitaxel monotherapy arms was in effect conducted completely 
in a randomized fashion and randomization between the nab-paclitaxel/durvalumab combination 
and nab-paclitaxel monotherapy arms will not apply.
A data monitoring committee (DMC) will be used to review the safety a nd efficacy data during 
the study.&(/*(1(35235,(7$5<,1)250$7,21 
aclitaxel clitaxel wiw
yyofofyy durval durvff
will be admwill be adm
ntntil diseaseil dis
 or terminaor termin
eatment beeatment b
for those sr those s
domized 1:domized 1
erapy armserapy arms
e stratificatstratificat
us 1)us 1)
))
centrallycentrally usuyy
t after enrolafter enro
abb--paclitapaclita
ectscts)), all,  subsul
col Amendml Amend
umab coumab co mbmb
at arm. Henarm. He
n therapyn therapy aayy
omized fasized fa
abab-paclitpaclit axax
A A data mdata m onon
thhe stude stud
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 68 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 201610.2. Study Population Definitions
10.2.1. Intent-to-treat Population
The primary efficacy analysis will be performed on the intent-to-treat (ITT) population, which 
includes all randomized (assigned) subjects regardle ss of whether the subject receives any IP or 
has any efficacy assessments performed. 
10.2.2. Per-protocol (PP) Population
The PP population is defined as all eligible subjects randomized/assigned who receive at least 
one dose of the IP, have been treated in the arm they were assigned and meet the major eligibility
criteria of the protocol.  Additional analyses utilizing the PP population will be described in the 
SAP.
10.2.3. Treated Population
The treated population will consist of all randomized/assigned subjects who receive at least one 
dose of IP. The safety analyses will be based on the treatment as received if different from the 
assigned treatment by rando mization/tr eatment assignment.
10.3. Sample Size and Power Considerations
The primary objective of this study is to estimate the efficacy of the nab-paclitaxel/CC-486 
combination therapy, that of the nab-paclitaxel/durvalumab combination therapy, and that of the 
nab-paclitaxel monotherapy.
A secondary efficacy objective is to estimate th e relative efficacy of each of the combination 
regimens to the nab-paclitaxel monotherapy regimen. 
The effect of the treatment regimens with respect to  the efficacy endpoints will be based on the 
point estimates and the associated 95% confidence intervals. The sample size was chosen to support the estimation of the within- treatmen t effects with reasonable precision. In the 
durvalumab arm, a sample size of 80 subjects will further allow the estimation of the treatment 
effect with reasonable precision when stratification by prior checkpoint inhibitor exposure (checkpoint naÃ¯ve and prior exposure to checkpoint inhibitors) is performed. 
No inferential statistical tests will be performed and no multip licity adjustments are planned for 
the statistical analyses.
Table 7 below summarizes the two-sided 95% confidence intervals for a range of hypothetical 
observed disease control rates given a sample size of 80 subjects in a treatment arm. If the 
observed disease control rate is 0.30, then the actual width of the 2-sided 95% confidence interval is 0.21 (95% CI is [0.20, 0.41]).
&(/*(1(35235,(7$5<,1)250$7,21ast st 
eligibilitgibilit y
bed in the ed in the 
who receiveho rece
ved if diffeved if diffe
cacyacyofofythe
umabumab cocombm
e relate relat ive eive 
yregimenregimen .
th respect th respect
% confiden% confid
n-treatmtreatm en
of 80 of 80 subjesubj
siosion when n whe
or exposuror expo
cal tests wical tests w
yses.ses.
summarizsummari
sease contsease cont
d disease cosease c
alaliills s0.210.21 (
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 69 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Table 7: Disease Control Rate â€“Two-Sided 95% Confidence Interval of Hypothetical 
Disease Control Rate with a Sample Size of 80 Subjects in a Treatment Arm
Hypothetical Observed 
Disease Control RateActual Width of 95% 
Confidence Interval95% Confidence Intervala
0.20 0.186 (0.119, 0.304)
0.25 0.199 (0.16, 0.359)
0.30 0.21 (0.203, 0.413)
0.35 0.218 (0.247, 0.465
0.40 0.224 (0.292, 0.516)
0.45 0.227 (0.338, 0.565)
0.50 0.228 (0.386, 0.614)
aBased on the Clopper-Pearson exact method.
The between-treatment effect with respect to PFS can be estimated based on the point estimate of 
the hazard ratio and the associated 95% confidence interval. Table 8 below summarizes the 
precision that can be achieved given different scenarios of hypothetical observed hazard ratios 
between the treatment arms for PFS events, assuming a total of 120 events are observed. 
Table 8: Progression-Free Survival â€“ Two-Sided 95% Confidence Interval of 
Hypothetical Observed Hazard Ratio between Treatment Arms
Hypothetical Number of 
Events ObservedHypothetical Observed 
Hazard Ratio of PFS Events95% Confidence Interval of 
Hazard Ratioa
1200.60 (0.42, 0.86)
0.65 (0.45, 0.93)
0.70 (0.49, 1.00)
a Assuming a standard error of 0 .18 [es timated based on (4/120)1/2] for the log hazard ratio.
Assuming the median times of PFS are 4.17 and 2.5 months, respectively, for the nab-
paclitaxel/CC-486 combination therapy and nab-paclitaxel monotherapy arms, and an 
approximate 23 months accrual period for a total of 160 subjects, it is estimated that a total of 
120 PFS events will have been observed approx imately 2 months after the last subject is 
randomized to these 2 arms, assuming an e xponential distribution for PFS. The final analysis of 
the nab-paclitaxel/CC-486 combination and nab-paclitaxel monotherapy arms  will be performed 
when a total of approximately 120 PFS events have been observed between these two arms.
While there is published data demonstrating efficacy of nab-paclitaxel as monotherapy in a 
second line setting in advanced NSCLC with ORR ranging from 16.1 to 33% and a median PFS 
of up to 5 months, it is difficult to place an assumed treatment effect on nab-paclitaxel as a 
monotherapy ( Chen, 2012; Saxena, 2012; Yuan, 2012 ).  The assumption of 2.5 months PFS in 
the monotherapy arm is in line with this d ata and other efficacy data previously observed 0.600.5,(7$5<,1)250$7,21777$7$7$7$76))0$$$
0.565).565)50 386, 0.614)386, 0.614)25)2
based on thsed on th
e88below w
pothetipotheti calcao
al of 120 evof 120 
ed 95% Cod 95% Co
tio betweetio betwe
cal Observal Observ
atio of PFSatio of PFS(7532
35535358 8 [estimated[estima
timeimessofPFPF
ombinatmbinat ioio
momontnths acchs ac
ts will  will havhav
dto these 2to these 2
paclitaxel/paclitaxel
n a total of n a total of
While thereWhile there
second liecond
up
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 70 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016following monotherapy treatment of advanced disease with other agents ( Shepherd, 2000; 
Hanna, 2004; Reck, 2014; Garon, 2014 ).
[Of note, with 120 PFS events, this study has an 80% power (1-sided, Type-1 error of 2.5%) to 
detect a HR of 0.60 for PFS between two treatment arms.]
Assuming the median time of PFS is 4.25 months for the nab-paclitaxel/durvalumab 
combination therapy, and an approximate 13 months accrual period for a total of approximately
80 subjects, it is estimated that a total of approximate 50 PFS events will have been observed at approximately 3 months after the last subject is assigned to this arm, assuming an exponential
distribution for PFS. The final analysis for PFS for the nab-paclitaxel/durvalumab arm will be 
performed when approximately 50 PFS events have been observed in this arm.
One nonbinding interim analysis for PFS with an early st opping rule for futility between the nab-
paclitaxel/CC-486 combination and nab-paclitaxel monotherapy arms will be conducted when 
approximately 60 events have been observed. The nab-paclitaxel/CC-486 combination arm may 
be stopped early for fu tility if the observed HR is > 1.10, and/or if recommended by the DMC 
based on the safety profile of this combination regimen. A HR> 1.10 when half of the target 
events of 120 have occurred signals a low probability for observing a meaningful difference in favor of the nab-paclitaxel/CC-486 combination therapy s hould the study cont inue to the end. 
With the assumptions stated above, it will take approximately 15 months from the first subject 
randomized to observe approximately 60 PFS events for the interim analysis.
An additional interim analysis for fut ility with the PFS endpoint between the nab-
paclitaxel/durvalumab combination therapy and nab-paclitaxel monothe rapy arms will be 
conducted when approximately 30 PFS events have been observed in the nab-paclitaxel/
durvalumab combination arm. It is projected that 60 or more PFS events will have been observed 
in the nab-paclitaxel monotherapy arm at that point. The nab-paclitaxel/durvalumab combination 
arm may be stopped early for fut ility if the observed HR is â‰¥ 1.10, and/or if recommended by the 
DMC based on the safety profile of this combination regimen. With the assumptions stated 
above, it will take approximately 13 months from the first subject randomized to the nab-
paclitaxel/durvalumab arm to observe the events needed for this interim analysis. As the enrollment in the nab-paclitaxel/durvalumab combination arm started after the enrollment in the 
nab-paclitaxel/CC-486 and nab-paclitaxel monotherapy arms ended, randomization between the 
nab-paclitaxel monotherapy and nab-paclitaxel/durvalumab arms does not apply.  Nevertheless, 
the futility boundary for the interim analysis between the two arms will st ill be ut ilized as a 
guidance to the DMC for their recommendations.
At the interim analysis data review on , based on the recommendation of the DMC, 
treatment with CC-486 was discontinued in the nab-paclitaxel/CC-486 combination arm; 
subjects in this arm may be allowed to continue on nab-paclitaxel single agent, at the 
Investigatorâ€™s discretion.  
Similarly, following the outcome of the interim analysis between nab-paclitaxel/durvalumab 
combination and nab-paclitaxel monotherapy arms, and taking into account the DMC 
recommendations, subjects may be allowed to remain on either nab-paclitaxel or durvalumab as 
a single agent or both agents, at the Investigatorâ€™s discretion.
Disease control rate, OS, and ORR within and the difference between the 
nab-paclitaxel/CC-486 
combination and nab-paclitaxel monotherapy treatment arms will be estimated at the time of the &(/*(1(35235,(7$5<,1)250$7,21be e 
ween the ween the nan
nducted whducted w
mbinatinioion naa
ended by thended by t
hen half of n half 
a meaningfumeaningf
he studye study concoyy
55momontnhs f
interim aninterim an
endpoendpo intint be b
paclitaxel mpaclitaxel m
ve been obsve been obs
at 60 or mot 60 or m
at point. That point. Th
e observede observed
s combinatcombina
3 months frmonths f
serve the evserve the e
xel/durvalumxel/durvalu
nabnab--paclitpacli
rapyrapy and nd y na
ffor the inteor the infff
MC for theMC for the
analysis danalysis d
wiiththii CCCChh --4848
in this armin this arm
ttigatorâ€™s diigatorâ€™s d
iimilarly, fomilarly, f
combinatombinat
comcom
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 71 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016final analysis of the PFS endpoint when approximately 120 PFS events have been observed
between these two arms. The same endpoints will be estimated within the nab-
paclitaxel/durvalumab arm and between this and the nab-paclitaxel monotherapy arms when 
approximately 50 PFS events have been observed in the nab-paclitaxel/durvalumab arm. 
All subjects in the nab-paclitaxel/CC-486 combination and nab-paclitaxel monotherapy arms 
will continue to be followed for OS for at least 12 months after the last subject is randomized to
either of these two arms or 120 PFS events have been observed between these two arms, whichever comes later. All subjects in the nab-paclitaxel/durvalumab arm will be followed for 
OS for at least 12 months after the la st subject is assigned to this arm.
The study milestones for the scenario that all 3 arms proceed to the end of the study are
summarized in the table below:
Study MilestoneTime from First Subject 
Randomized (Day 1)
First subject randomized to either the nab-paclitaxel/CC-486 and nab-
paclitaxel monotherapy arms (1:1 randomization ratio) Day 1
Interim analysis for nab-paclitaxel/CC-486 vs. nab-paclitaxel 
monotherapy (~60 PFS events total) ~ 15 months
Addition of the nab-paclitaxel/durvalumab arm to the study; 
randomization in a 1:1:1 ratio to the nab-paclitaxel/CC-486, nab-
paclitaxel/durvalumab, and nab-paclitaxel arms begins. ~ 15 months
Last subject randomized to the nab-paclitaxel/CC-486 and nab-
paclitaxel arms ~ 23 months
Assignment of all incoming subjects to the durvalumab arm begins. ~ 24 months
Final analysis for nab-paclitaxel/CC-486 vs. nab-paclitaxel (~120 PFS 
events total) ~25 months
Last subject assigned to the nab-paclitaxel/durvalumab arm ~ 28 months
Interim analysis for nab-paclitaxel/durvalumab vs. nab-paclitaxel (~30 
PFS events from nab-paclitaxel/durvalumab, â‰¥60 from nab-paclitaxel 
monotherapy) ~28 months
Final analysis for nab-paclitaxel/durvalumab vs. nab-paclitaxel (~50
PFS events have been observed in the nab-paclitaxel/durvalumab arm) ~ 31 months
End of OS Follow-up for subjects in nab-paclitaxel/CC-486 and nab-
paclitaxel arms ~ 35 months
End of OS Follow-up for durvalumab subjects ~40 months
10.4. Background and Demographic Characteristics
The baseline char acteristics of all randomized /assigned sub jects will be summarized. Subjectâ€™s 
age, height, weight, and baseline characteristics will be summarized using descriptive statistics, while gender, race and other categorical variables will be provided using frequency tabulations. &(/*(1ollowollow --up foup fo(1(35235,(7$5<,1)250$7,21ee
ommFirst SuFirst Smm
ndomized (Dndomized 25)2,1<
,nabnab--5<<<<
6 and 6 and nabab(7$
urvalumab avalumab a5,( vs. s. nabnab-pacpa35
aclitaxel/duaclitaxel/du52itaxel/durvataxel/durv
itaxel/durvataxel/du5
abab-paclitaxepaclitax
been obserbeen obser1(
l armsrms(1
of OS Folloof OS Fol/*(/ 10.4.10
ebb
EDMS Doc. Number:nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 72 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Selected medical history data will be summarized using frequency tabulations by system organ 
class and preferred term.
10.5. Subject Disposition
Subject disposition (analysis population allocat ion, entered, discontinued, along with primary 
reason for discontinuation) will be summarized using frequency and percent for both Treatment and Follow-up Periods. A summary of subjects enrolled by site will be provided. Protocol 
deviations will be summarized using frequency tabulations.
10.6. Efficacy Analysis
10.6.1. Primary Efficacy Endpoints 
The primary efficacy endpoint is progression-free s urvival, which is defined as the time from the 
date of rando mization/tr eatment assignment to the date of disease progression or death (any 
cause) on or prior to the data cutoff date for an alyses, whichever occurs first, based on the 
Investigatorâ€™s assessment of the data from CT scans using RECIST 1.1 guidelines. Baseline 
tumor measurements will be determined from the radiologic evaluation performed within 28 days before the start of study therapy. 
Subjects who do not have disease progression and are alive as of the data cutoff date for the 
statist ical analysis w ill be censored at the date of the last ra diologic assessment prior to the data 
cutoff date.  Similarly, subjects who discontinue from the study prior to disease progression or 
death will be censored at the date of the last radiologic assessment prior to the data cutoff date.  
In the event that a new anticancer treatment occurs prior to documented progression, the subject will be censored at the date of the last radiologic assessment where the subject was documented 
to be progression-free prior to the new anticancer treatment. Subjects with a single missing 
radiologic assessment prior to a visit with documented disease progression (or death) will be analyzed as a PFS event at the date of the radiologic assessment that shows progression or death 
(whichever is earlier). Subjects with two or more missing radiologic assessments prior to a visit 
with documented disease progression (or death) will be censored at the date of the last radiologic assessment where the subject was documented to be progression-free prior to the first of the two 
missing visits.  Subjects who are alive and drop out  early without any post baseline radiologic 
tumor assessment will be censored on the date of rando mization/tr eatment assignment. 
Progression-free survival will be summarized us ing Kaplan-Meier methods with median PFS 
time (including two-sided 95% CI) for each treatment arm. The Kaplan-Meier curve for PFS will 
be presented graphically for each treatment ar m. The relative treatment effect between the 
combination and monotherapy arms on PFS will be estimated by the hazard ratio (HR) and the 
associated two-sided 95% CIs using the stratified Cox proportional hazard model with ECOG 
performance status (0 versus 1), gender (males versus females), and smoker (yes versus no) as the stratification factors, given the number of events in each cell is adequate. No statist ical 
inferential tests will be performed.
To assess the impact on PFS of radiologic assessments not occurring at the regularly scheduled 
assessment times, the frequency of these unscheduled/off-scheduled assessments will be 
presented for each treatment arm. In addition, confirmatory and sensitivity analyses may be &(/*(1(35235,(7$5<,1)250$7,21the time frthe time 
n or death n or death
rst, based orst, based o
 guidelinesguideline
ion performn perform
s of the das of the d
radioadiolologigic aca
the studythe study prpyy
gic assessmgic assess
rs prior to drs prior to 
gigc assessmc assessm
cancer treaancer trea
th documenh docum
f the radiof the rad lo
th two or mth two or m
ession (or dession (or d
t was docut was docu
who are alivare 
be censorebe censore
urvival willurvival wil
twotwo-sidsided d
graphicallygraphically
on and mn and m oo
tededtwwo-o-sidsid
formormance stance st
hhe stratificae stratific
inferentianferentia
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 73 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016performed to further assess the impact of missed radiologic assessments. An additional analysis 
of PFS, where death or new treatment will be considered as an event, will be conducted to 
address the impact of next line therapy. 
To explore the effect of treatment post initial progression, PFS defined by irRECIST criteria may
be estimated for the subjects in the nab-paclitaxel/durvalumab arm.  
10.6.2. Secondary Efficacy Endpoints
10.6.2.1. Disease Control Rate
Disease control rate is defined as the per cent of subjects who have a radiologic complete 
response, partial response, or stable diseas e according to RECIST 1.1 guidelines, as determined 
by the Investigator.
Disease control rate for each treatment arm will be  summarized by the observed DCR rate and 
the associated two-sided 95% CI. The relativ e treatment effect will be summarized by the 
absolute difference and ratio of the res ponse rates and the associated two-sided 95% CI.
10.6.2.2. Overall Survival
Overall survival is defined as the time betw een randomizatio n/treatment assignment and death. 
All deaths, regardless of the cause of death, will be included. All subjects who are lost to follow-
up prior to the end of the study or who are with drawn from the study will be censored at the time 
of last contact. Subjects who are still receiving treatment as of the data cutoff date will be censored at the cutoff date. Overall survival will be analyzed in a similar manner as that for PFS.
10.6.2.3. Overall Response Rate 
Overall response rate is defined as the percen t of subjects who have a radiologic complete or 
partial response according to RECIST 1.1 guidelines determined by the Investigator.  
Overall response rate will be assessed using the same statist ical methods as those for the DCR 
endpoint.
10.6.3. Exploratory Endpoints
10.6.3.1. HealthCare Utilization 
Healthcare utilization will be summarized by treatment. Additional analyses w ill be described in 
detail in the SAP.
10.6.3.2. Quality of Life Questionnaires
The score or VAS value and the corresponding change from baseline at each timepoint will be 
summarized by treatment for the EQ-5D-5L, EORTC QLQ C30 and LCSS questionnaires. 
Additional analyses will be described in detail in the SAP. 
10.6.3.3. Biomarker, Tumor Characteristics, and Genomic Analyses 
Statistical analysis of the biomarkers, tumor characteristics, and genomic correlates will be 
described in a SAP separate from that described above.&(/*(1(35235,(7$5<,1)250$7,21e 
determineddetermined
ved DCR raed DCR ra
mmarized bymarized by
o-sided 95%sided 9
/treatmtreatm ent e
d. All. All subjesubll
om m ththe stude stu
ment as of thment as of th
e e analyzed analyzed 
rcent of surcent of su
 1.1 guidel 1.1 guidel
ssed using ssed using
EndpointsEndpoi
are Utilizare Utiliz
zatatioion will n will 
SAP.AP.
..QualityQualit
e score or Vscore or V
summarizedummarize
AdditAddit ioion
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 74 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 201610.6.3.4. Anti-tumor Activity and PD-L1 Expression ( nab-Paclitaxel/Durvalumab Arm)
An exploratory analysis of PFS and DCR using investigatorâ€™s assessments based according to 
irRECIST criteria, and their association with PD-L1 expression will be performed for subjects in 
the nab-paclitaxel/durvalumab arm.  
10.7. Safety Analysis
The treated population, which includes all subjects who receive at least one dose of IP, will be 
the analysis population for all safety analyses.
The safety/tolerability of the treatment arms will be monitored through continuous reporting and 
evaluated by adverse events and serious adverse events, and incidence of subjects experiencing 
dose modifications, dose interruptions, and/or premature discontinuation of IP.
10.7.1. Adverse Events
TEAEs will be defined as any AE or SAE occurring or worsening on or after the day of the first 
dose of the IP through 28 days after the last dose of IP for the monotherapy arm and the nab-
paclitaxel/CC-486 combination arms, or 90 days after last dose of IP in the nab-
paclitaxel/durvalumab combination arm.  In addition, any serious AE with an onset date more 
than 28 days after the last dose of IP that is assessed by the Investigator as related to IP w ill be 
considered a TEAE. TEAEs occurring up to 28 days after the last dose of IP will be summarized. 
In addition, for the nab-paclitaxel/durvalumab arm, AEs with an onset from 29 days up to 90 
days after the last dose of IP will be summarized separately.
Adverse events will be coded according to the Medical Dictionary for Regulatory Activities 
(MedDRA). The severity of AEs will be graded based on NCI CTCAE, Version 4.0; 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40.
Treatment-emergent adverse events, Grade 3 or higher TEAEs, serious AEs, TEAEs leading to 
dose reduction, and dose interruption, TEAEs leading to treatment discontinuation, and TEAEs 
with an outcome of death will be summarized per treatment arms by MedDRA system organ class and preferred terms. 
Adverse events of special interest relevant to the nab-paclitaxel/CC-486 combination, nab-
paclitaxel/durvalumab combination, and nab-paclitaxel monotherapy regimens observed in 
previous studies in a similar population may be identified and summarized by worst NCI 
CTCAE grade, and MedDRA preferred terms.
By-subject listings will be provided for all relevant safety data. Graphical displays and figures 
will be provided where useful to assist in the interpretation of results.
10.7.2. Laboratory Assessments
Treatment group differences in each laboratory parameter with respect to the NCI CTCAE 
grades will be summarized by the frequency distribution of subjects with the AE grades.  
All laboratory parameters will be summarized by de scriptive statistics within each treatment arm, 
as appropriate. &(/*(1(35235,(7$5<,1)250$7,21ing and ng and 
eriencing riencing 
fter thefter the dayday
rapyrapy armarmyy  an mm
P in the n the nabnab
AE with aAE with a
estestigatorigato a
he last dosee last dose
with an onwith an o
rately.rately.
edical Dictedical Dic i
d based ond based on
t/electronic/electronic
rade 3 or hiade 3 or h
n, TEAEs le, TEAEs
summarizesummariz
interestterest releel
cocombinationmbinati
similar popsimilar po
nd MedDRAd MedDRA
tings will bngs will 
vided whervided wher
2.2. LaboLab
Treatment gTreatment g
grades wgrades w
l
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 75 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 201610.7.3. IP Exposure
The extent of exposure to the IPs will be asse ssed based on the descriptive statistics on the 
number of cycles and IP doses administered, cumulative dose, average dose intensity, and 
percentage of protocol dose administered.  The incidences of CC-486, nab-paclitaxel, and 
durvalumab dose reductions (although not expected for durvalumab) and dose interruptions will 
be summarized by treatment arm.  
10.8. Study Therapy Termination
Reasons for stopping study therapy will be prese nted in listings and summarized by frequency of 
occurrence and corresponding percentage of occurrence.
10.9. Deaths
Deaths reported during treatment (defined as deaths from the first administration of the IP
through 28 days post last dose of the IP w ill be su mmarized by frequency of occurrence and 
corresponding percentage by cause of death per period (during treatment or follow-up). In 
addition, deaths that occur from 29 to 90 days post last dose will be summarized in a similar manner for the nab-paclitaxel/durvalumab combination therapy arm.
10.10. Interim Analysis
One nonbinding interim analysis for PFS with an early st opping rule for futility will be 
conducted when approximately 60 events have been observed between the nab-paclitaxel/CC-
486 combination and nab-paclitaxel monotherapy arms. The nab-paclitaxel/CC-486 combination 
arm may be stopped early for fut ility if the observed HR is â‰¥1.10 given the assumed number of 
PFS events above, and/or if recommended by the DMC based on the safety profile of this combination regimen.   
An additional interim analysis for fut ility with the PFS endpoint between the nab-
paclitaxel/durvalumab combination therapy and nab-paclitaxel monotherapy arms will be 
conducted when approximately 30 PFS have been observed in the nab-paclitaxel/durvalumab 
combination arm. This is similar to approximately half of the number of events that are planned 
for the interim analysis between the nab-paclitaxel/CC-486 combination and nab-paclitaxel 
monotherapy arms mentioned above. At this time point, it is projected that approximately â‰¥ 60 
PFS events will have been observed in the nab-paclitaxel monotherapy arm. The nab-
paclitaxel/durvalumab combination therapy arm may be stopped early for fut ility if the observed 
HR is â‰¥ 1.10, and/or if recommended by the DMC based on the safety profile of this 
combination regimen. Should th is occur, enrollment in the study may discontinue. The fut ility 
boundary for the interim analysis between the two arms is provided as a guidance to the DMC for their recommendations.
At the interim analysis data review on , based on the recommendation of the DMC, 
treatment with CC-486 was discontinued in the nab-paclitaxel/CC-486 combination arm; 
subjects in this arm may be allowed to continue on nab-paclitaxel single agent, at the 
Investigatorâ€™s discretion.  
Similarly, following the outcome of the interim analysis between nab-paclitaxel/durvalumab 
combination and nab-paclitaxel monotherapy arms, and taking into account the DMC &(AtAt&(/*(1(35235,(7$5<,1)250$7,21ncy oncy o f f 
on of the n of the II
ff occurren occurrenff
t or foor fo llollw
ummarizedummarize
m.m.
toppitoppi ng rulng riii
observedobserved bb
armarms. The The 
rved HR isrved HR 
y the DMCy the DMC
litlity wiy withtiithh
nthherapyerapy a
30 P30 PFS haFS ha
milar to appmilar to app
etween the etween t
ntntioioned aboned abo
e been obsbeen obs
umab umab cocombmb
and/or if rend/or if r
n regimenn regimen
yyfyor the inr the inf
eieir recommr recomiii
 the interi the inter
treatmreatm enten
bjecbjec
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 76 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016recommendations, subjects may be allowed to remain on either nab-paclitaxel or durvalumab as 
a single agent or both agents, at the Investigatorâ€™s discretion.
10.11. Data Monitoring Committee
An independent DMC will be established with the responsibilities for safeguarding the interests of study subjects and monitoring the overall conduct of the study. Final reco mmendations of the 
DMC will reflect the judgment of the DMC members and will be considered advisory in nature 
to the Sponsor. The decision to implement the recommendations of the DMC will be made by
the Sponsor, following consultation with the coordinating Investigator and Steering Co mmit tee.
Operational details for the DMC will be detailed in the DMC charter. 
10.12. Scientific Steering Committee
The conduct of this study will be overseen by a Steering Committee. The Steering Committee 
will serve in an advisory capacity to the Sponsor.
&(/*(1(35235,(7$5<,1)250$7,21tee.ee.
ering Commering Comm
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 77 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 201611. ADVERSE EVENTS
11.1. Monitoring, Recording and Reporting of Adverse Events
An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may 
appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a 
worsening concomitant illness, an injury, or any concomitant impairment of the subjectâ€™s health, 
including laboratory test values (as specified by the criteria in Section 11.3), regardless of 
etiology. Any worsening (ie, any clinically significant adverse change in the frequency or 
intensity of a pre-existing condition) should be  considered an AE. A diagnosis or syndrome 
should be recorded on the AE page of the eCRF rather than the individual signs or symptoms of the diagnosis or syndrome. 
For the purposes of this study, progressive disease (PD) of NSCLC will not require reporting as 
an adverse event. However, signs and symptoms (events) related to disease progression may be reported as adverse events. If reported, events of disease progression for NSCLC (including 
deaths due to disease progression for indications that are considered to be fatal) will be assessed 
as expected adverse events and will not be reported as expedited safety reports to regulatory authorities.
Abuse, withdrawal, sensitivity or toxicity to an investigational product should be reported as an 
AE. Overdose, accidental or intentional, whether or not it is associated with an AE should be reported as an AE. (See Section 8.8for the definition of overdose.) Any sequela of an accidental 
or intentional overdose of an investigational product should be reported as an AE on the AE 
CRF. If the sequela of an overdose is an SAE, then the sequela must be reported on an SAE report form and on the AE CRF. The overdose resulting in the SAE should be identified as the 
cause of the event on the SAE report form and CRF but should not be reported as an SAE itself.
In the event of overdose, the subject should be monitored as appropriate and should receive 
supportive measures as necessary. There is no known specific antidote for nab-paclitaxel,
CC-486 or durvalumab overdose. Actual treatment should depend on the severity of the clinical 
situation and the judgment and experience of the treating physician.
All subjects will be monitored for AEs during the study. Assessments may include monitoring of 
any or all of the following parameters: the subjectâ€™s  clinical symptoms, laboratory, pathological, 
radiological or surgical findings, physical examination findings, or findings from other appropriate tests and procedures.
All AEs will be recorded by the Investigator from the time the subject signs informed consent to
28 days after the last dose of IP for the monothera py and CC-486 combination arms or to 90 days 
for the durvalumab combination arm, and thos e SAEs made known to the Investigator at any 
time thereafter that are suspected of being related to IP. AEs and serious adverse events (SAEs) 
will be recorded on the AE page of the eCRF and in the subjectâ€™s source documents. All SAEs must be reported to Celgene Drug Safety within 24 hours of the Investigatorâ€™s knowledge of the 
event by facsimile, or other appropriate method, using the SAE Report Form, or approved 
equivalent form.
11.2. Evaluation of Adverse Events
A qualified Investigator w ill evalu ate all adverse events as to: &(/*(1(35235,(7$5<,1)250$7,21toms of ms of 
re reportingreportin
ogression mgression 
CLCCLC (i(incluncl
e fatal) willfatal) 
y yreports toreports to
product shproduc
associatedassociated
overdose.) verdose
hould be rehould be re
the sequelthe sequel
esultesult ing ing in in 
d CRF but d CRF but 
uld be moniuld be mon
ere is no knere is no kn
Actual treatmtual trea
experience xperience 
ed for AEs ed for AE
g parameteg param
al findings, findings, l
d procedurd procedur
e recorded be recorde
the lthe last doast d
rvalalumab cmab cl
hereafter thhereafter th
be recordebe recorde
must be repmust be rep
event byvent b
uivi
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 78 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 201611.2.1. Seriousness 
A serious adverse event (SAE) is any AE occurring at any dose that:
!Results in death;
!Is life-threatening (ie, in the opinion of the Investigator, the subject is at immediate 
risk of death from the AE);
!Requires inpatient hospitalization or prolongation of ex isting hospitalization 
(hospitalization is defined as an inpatient admission, regardless of length of stay);
!Results in persistent or significant disability/incapacity (a substantial disruption of the 
subjectâ€™s ability to conduct normal life functions);
!Is a congenital anomaly/birth defect;
!Constitutes an important medical event.
Important medical events are defined as those occurrences that may not be immediately life 
threatening or result in death, hospitalization, or disability, but may jeopardize the subject or 
require medical or surgical intervention to pre vent one of the other outcomes listed above.
Medical and scientific judgment should be exercised in deciding whether such an AE should be 
considered serious.
Events not considered to be SAEs are hospitalizations for:
!A standard procedure for protocol therapy administration. However, hospita lization 
or prolonged hospitalization for a complication of therapy administration will be 
reported as an SAE. 
!Routine treatment or monitoring of the studi ed indication not associated with any 
deterioration in condition.
!The administration of blood or platelet transfusion as routine treatment of studied 
indication. However, hospitalization or prolonged hospitalization for a complication of such transfusion remains a reportable SAE.
!A procedure for protocol/disease-related investigations (eg, surgery, scans, 
endoscopy, sampling for laboratory tests, bone marrow sampling). However, 
hospitalization or prolonged hosp italization for a complication of such procedures 
remains a reportable SAE.
!Hospitalization or prolongation of hospitalization for technical, practical, or social 
reasons, in absence of an AE.
!A procedure that is planned (ie, planned prior to starting of treatment on study); must 
be documented in the source document and the eCRF. Hospitalization or prolonged hospitalization for a complication remains a reportable SAE.
!An elective treatment of or an elective pr ocedure for a pre-existing condition 
unrelated to the studied indication. 
!Emergency outpatient tr eatment or observation that does not result in admission, 
unless fulfilling other seriousness criteria above.&(/*(1(35235,(7$5<,1)250$7,21n of the n of the 
e immediate immediat
opardipardi ze theze th
outcomes litcomes li
whether suhether s
r::
administraadministra
plicatlicaioon of n of
g oof fththe stude stud
ood or plaod or pla te
hospitalizathospitaliza
remains a remains a
or protocol/protocol/
samsampling fpling mm
zatiation or pron or p
ns a reportans a reporta
ospitalizatiospitalizati
reasons, ireasons, i
!!A proA pro
bebe
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 79 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016If an AE is considered serious, both the AE page/screen of the eCRF and the SAE Report Form 
must be completed.
For each SAE, the Investigator will provide information on severity, start and stop dates, 
relationship to IP, action taken regarding IP, and outcome.
11.2.2. Severity / Intensity
For both AEs and SAEs, the Investigator must assess the severity/intensity of the event. The severity/intensity of AEs will be graded based upon the subjectâ€™s symptoms according to the 
current active minor version of NCI CTCAE, Version 4.0
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40.
Adverse events that are not defined in the NCI CTCAE should be evaluated for severity/intensity 
according to the following scale:
!Grade 1 = Mild â€“ transient or mild discomfort; no limitation in activity; no medical 
intervention/therapy required
!Grade 2 = Moderate â€“ mild to moderate limitation in activity, some assistance may be 
needed; no or minimal medical intervention/therapy required
!Grade 3 = Severe â€“ marked limitation in activity, some assistance usually required; 
medical intervention/therapy required, hospitalization is possible
!Grade 4 = Life threatening â€“ extreme limitation in activity, significant assistance 
required; significant medical intervention/therapy required, hospitalization or hospice care probable
!Grade 5 = Death â€“ the event results in death
The term â€œsevereâ€ is often used to describe th e intensity of a specific event (as in mild, moderate 
or severe myocardial infarction); the event itself, however, may be of relatively minor medical 
significance (such as severe headache). This criterion is notthe same as â€œseriousâ€ which is based 
on subject/event outcome or action criteria associated with events that pose a threat to a subjectâ€™s 
life or functioning.
Seriousness, not severity, serves as a gui de for defining regulatory obligations.
11.2.3. Causality 
The Investigator must determine the relationship between the administration of IP and the 
occurrence of an AE/SAE as Not Suspected or Suspected as defined below:
Not suspected: Means a causal relationship of the adverse event to IP
administration is unlikely or remote , or other medications, 
therapeutic interventions, or underlying conditions provide a 
sufficient explanation for the observed event.
Suspected: Means there is a reasonable possibility that the administration 
of IP caused the adverse event.  â€˜Reasonable possibilityâ€™ means &(/*(1(35235,(7$5<,1)250$7,21o the o the
veriterity/y/intintee
actactivitivity; y;nn
ivitivity,y,somsom
requiredrequi
,somsome assie assi
alizatiolizatio n nis 
tatatition in acon in
oon/therapyn/therap
ults in dealts in dea
cribe the inibe the in
e event itseevent its
dache).dache). ThiTh
ction ction critercrite
tty,y, serves a serves 
ality ality 
atoratormumust dst d
e of an AE/of an AE
Not susNot su
EDMS Doc. Number:nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 80 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016there is evidence to suggest a causal relationship between the IP
and the adverse event.
Causality s hould be a ssessed and provided for every AE/SAE based on currently available 
information.  Causality is to be reassessed and provided as additional information becomes available.
If an event is assessed as suspected of being related to a comparator, ancillary or additional IP
that has not been manufactured or provided by the Sponsor, please provide the name of the 
manufacturer when reporting the event.
11.2.4. Duration
For both AEs and SAEs, the Investigator will provide a record of the start and stop dates of the 
event.
11.2.5. Action Taken
The Investigator will report the action taken with IP as a result of an AE or SAE, as applicable 
(eg, discontinuation or reduction of IP, as  appropriate) and report if concomitant and/or 
additional treatments were  given for the event. 
11.2.6. Outcome
The Investigator will report the outcome of the event for both AEs and SAEs. All SAEs that have 
not resolved upon discontinuation of the subjectâ€™s participation in the study must be followed until recovered, recovered with sequelae, not recovered or death (due to the SAE). 
11.3. Abnormal Laboratory Values
An abnormal laboratory value is considered to be an AE if the abnormality:
!results in discontinuation from the study;
!requires treatment, modification/ interruption of IP dose, or any other therapeutic 
intervention; or
!is judged to be of significant clinical importance by the Investigator.
Regardless of severity grade, only laboratory abnormalities that fulfill a seriousness criterion 
need to be documented as a serious adverse event.
If a laboratory abnormality is one component of a diagnosis or syndrome, then only the diagnosis 
or syndrome should be recorded on the AE page/screen of the eCRF. If the abnormality was not 
a part of a diagnosis or syndrome, then the labor atory abnormality should b e recorded as the AE.
If possible, the laboratory abnormality should be recorded as a medical term and not simply as an 
abnormal laboratory result (eg, record throm bocytopenia rather than decreased platelets).
11.4. Pregnancy
All pregnancies or suspected pregnancies occurring in either a female subject or partner of a 
male subject are immediately reportable events.&(/*(1(35235,(7$5<,1)250$7,21dadates of thtes of tha
AE or SAE, E or SAE
f concoconco mitma
or both AEor both AE
articipatarticipat ioion
overed or dvered or d
aluesues
ered to be ered to be
n from thefrom the
mmodificatodificat io
be of signibe of sign
rity ygrade, grade, 
mented as amented as 
oryryabnormabnormyy
ome shoulde should
of a diagnoof a diagno
possible, theossible, th
abnormbnorm alalllll
44
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 81 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 201611.4.1. Females of Childbearing Potential
Pregnancies and suspected pregnancies (including a positive pregnancy test regardless of age or 
disease state) of a female subject occurring while the subject is on IP, or within 3 months of the 
subjectâ€™s last dose of IP, are considered immediately reportable events. IP is to be discontinued immediately. The pregnancy, suspected pregnancy, or positive pregnancy test must be reported 
to Celgene Drug Safety immediately by facsimile, or other appropriate method, using the 
Pregnancy Initial Report Form, or approved equiv alent form. The female subject should be 
referred to an obstetrician-gynecologist or another appropriate healthcare professional for further 
evaluation.
The Investigator will follow th e female subject until completion of the pregnancy, and must 
notify Celgene Drug Safety immediately about the outcome of the pregnancy (either normal or 
abnormal outcome) using the Pregnancy Follow -up Report Form, or approved equivalent form.
If the outcome of the pregnancy was abnormal (eg, spontaneous abortion), the Investigator
should report the abnormal outcome as an AE. If the abnormal outcome meets any of the serious 
criteria, it must be reported as an SAE to Celgene Drug Safety by facsimile, or other appropriate 
method, within 24 hours of the Investigatorâ€™s know ledge of the event using the SAE Report 
Form, or approved equivalent form.
All neonatal deaths that occur within 28 days of birth should be reported, without regard to 
causality, as SAEs. In addition, any infant death  after 28 days that the Investigator suspects is 
related to the in utero exposure to the IP should also be reported to Celgene Drug Safety by 
facsimile, or other appropri ate method, within 24 hours of the Investigatorâ€™s knowledge of the 
event using the SAE Report Form, or approved equivalent form.
11.4.2. Male Subjects
If a female partner of a male subject becomes pregnant while the subject is receiving IP or within 
6 months of the last dose of IP, the male subject  taking IP should notify the Investigator, and the 
pregnant female partner should be advised to call her healthcare provider immediately. If the 
male subject is receiving IP, the IP may need to be discontinued in the male subject, but may be resumed later at the discretion of the Investigator and medical monitor.
11.5. Reporting of Serious Adverse Events
Any AE that meets any criterion for an SAE requires the completion of an SAE Report Form in 
addition to being recorded on the AE page/scr een of the eCRF. All SAEs must be reported to 
Celgene Drug Safety within 24 hours of the Investigatorâ€™s knowledge of the event by facsimile, 
or other appropriate method, using the SAE Report Form, or approved equivalent form. This 
instruction pertains to initial SAE report s as well as any follow-up reports.
The Investigator is required to ensure that the data on these forms are accurate and consistent.
This requirement applies to all SAEs (regardless of relationship to IP) that occur during the study 
(from the time the subject signs informed consent to at least 28 days after the last dose of IP for 
the monotherapy and CC-486 combination arms or 90 days after the last dose of IP for the 
durvalumab combination arm) and those made known to the Investigator at any time thereafter 
that are suspected of being related to IP. SAEs occurring prior to treatment (after signing the ICF) will be captured.&(/*(1(35235,(7$5<,1)250$7,21er er 
muststm
normnorm alal or  or ll
uivalent forvalent fo
Investnvest igatiga
eets any oets any o ff
mile, or othele, or o
t using the using the 
be reportedbe reporte
ayys that the s that th
reported ported to t
rs of the rs of the In
uivalent fouivalent fo
omemes pregns pregn
ale subject ale subject 
advised to dvised to 
IPIPmamay ynene
n of the n of the InvI
g of Seriog of Serio
any criteriany criteri
g recorded g recorded 
g Safetg Safet y ywiwi
ppropriate mropriate m
iion pertainon pertain
InvestiInvesti gaga
This requirThis requir
(frofrom m tht
m
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 82 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016The SAE report should provide a detailed description of the SAE and include a concise summary
of hospital records and other relevant documents. If a subject died and an autopsy has been 
performed, copies of the autopsy report and d eath certificate are to be sent to Celgene Drug 
Safety as soon as these become available. Any fo llow-up data will be detailed in a subsequent 
SAE Report Form, or approved equivalent form, and sent to Celgene Drug Safety.
Where required by local legislation, the Investigator is responsible for informing the Independent 
Review Board/Ethics Committee (IRB/EC) of the SA E and providing them with all relevant 
initial and follow-up information about the event. The Investigator must keep copies of all SAE 
information on file including correspondence with the Sponsor and the IRB/EC.
11.5.1. Safety Queries
Queries pertaining to SAEs w ill be commun icated from Celgene Drug Safety to the site via 
facsimile or electronic mail. The response t ime is exp ected to be no more than five (5) business 
days. Urgent queries (eg, missing causalit y assessment) may be handled by phone.
11.6. Expedited Reporting of Adverse Events
For the purpose of regulatory reporting, Celgene Drug Safety will determine the expectedness of 
events suspected of being related to nab-paclitaxel, CC-486 or durvalumab based on the
Investigator Brochures of the respective IPs.
In the US, all suspected unexpected serious adverse reactions (SUSARs) will be reported in an 
expedited manner in accordance with 21 CFR 312.32.
For countries within the European Economic Area (EEA), the Sponsor or its authorized 
representative will report in an expedited manner to Regulatory Authorities and Ethics 
Committees concerned, suspected unexpected serious adverse reactions (SUSARs) in accordance with Directive 2001/20/EC and the Detailed Guidance on collection, verification and 
presentation of adverse reaction reports arising from clinical trials on investigational products for 
human use (ENTR/CT3) and also in accordance with country-specific requirements.
The Sponsor or its authorized representative shall notify the Investigator of the following
information: 
!Any AE suspected of being related to the use of IP in this study or in other studies
that is both serious and unexpected (ie, SUSAR);
!Any finding from tests in laboratory animals that suggests a significant risk for 
human subjects including reports of mutagenicity, teratogenicity, or carcinogenicity.
Where required by local legislation, the Investigator shall notify his/her IRB/EC promptly of 
these new serious and unexpected AE(s) or significant risks to subjects.
The Investigator must keep copies of all pe rtinent safety information on file including 
correspondence with the Sponsor and the IRB/EC. (See Section 15.3 for record retention 
information).
Celgene Drug Safety Contact Information:
For Celgene Drug Safety contact i nformation, please refer to the Serious Adverse Event Report 
Form/Completion Guidelines or to the Pre gnancy Report Form/Com pletion Guidelines.&(/*(1(35235,(7$5<,1)250$7,21E 
e sie site vite viii a a
five (5) busive (5) b
phone.phone
determine tdetermine
durvalumaburvalumab
tions (SUSons (SU
a (EEA), a (EEA), tht
ner to Reguner to Regu
ed serious ed serious 
iled Guidanled Guidan
ts arits ari sing frsin
n accordanaccordan
representatipresentat
pected of bpected of 
th serious ah serious 
finding frofinding fro
uman subjeuman subje
quired byired by lly
new seriousnew serious
he InvestiInvesti g
corresponorrespon
nformnform
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 83 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 201611.7. Definition of Adverse Events of Special Interest
An adverse event of special interest (AESI) is one of scientific and medical interest specific to 
the understanding of the IP and may require clos e monitoring and rapid communication by the 
Investigator to the Sponsor. An AESI may be serious or nonserious. The rapid reporting of 
AESIs allows ongoing surveillance of these events in order to characterize and understand them in association with the use of this IP. Furthe r information on risks (eg, presenting symptoms) can
be found in the current version of the Investigator Brochure, including guidelines for their 
evaluation and treatment.
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 84 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 201612. DISCONTINUATIONS
12.1. Study Treatment Discontinuation
The following events are considered sufficient reasons for discontinuing a subject from the IP:
!Adverse Event(s)
!Disease progression
!Withdrawal of consent
!Death
!Lost to follow-up
!Protocol violation
The reason for discontinuation should be recorded in the eCRF and in the source documents.The decision to discontinue a subject remains the responsibility of the treating physician, which
will not be delayed or refused by the Sponsor. However, prior to discontinuing a subject, the
Investigator may contact the Medical Monitor and forward appropriate supporting documents for 
review and discussion.
All subjects discontinued from IP for any reason will have a treatment discontinuation visit at the 
time of discontinuation and should undergo treatment discontinuation procedures.
All subjects discontinue d from IP will be followed for a period of 28 days after last dose of IP
for the monotherapy and CC-486 combination arms  or 90 days after the last dose of IP for the 
durvalumab combination arm for the collection of AEs.
Additionally subjects who withdraw from or discontinue treatment should be followed for 
progressive disease (if applicable), survival and any new anticancer therapy given.
12.2. Study Discontinuation
The following events are considered sufficient reasons for discontinuing a subject from the 
study:
!Withdrawal of consent
!Death
!Lost to follow-up
The following events may be considered sufficient reasons for discontinuing a subject from the 
study:
!Adverse events(s)
!Protocol violation
The reason for st udy discontinuation s hould be recorded in the eCRF and in the source 
documents. The Investigator must notify the Medical Monitor immediately when a subject has been discontinued/withdrawn due to an AE (any unacceptable toxicity). All subjects who are &(/*(1(35235,(7$5<,1)250$7,21urce documurce docu
eatiating phyng piii
continuing aontinuing
priate suppoiate supp
atreatmtreatm ene
scontcontinuatinua i
for a perifor a peri odo
ms or 90 dms or 90 d
n on of f AEs.AEs.
or orddiscontiscont i
vival and anval and a
ationation
nsidered sunsidered su
al ofofl consenconff
ost to followst to follow
wing eventng eve
!!AA
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 85 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016withdrawn from the study should complete all protoc ol-required evaluations scheduled for early 
termination at the time of withdrawal.
Since follow-up of subjects who discontinue prema turely is of particular importance, every 
attempt should be made to collect all survival i nformation and NSCLC treatment/therapy, unless 
the subject has specifically withdrawn consent from further follow-up. The Investigator must 
make every effort to obtain minimal information regarding the subjectâ€™s survival status before 
determining that the subject is lost to follow-up.
12.3. Subject Replacement
Subjects who discontinue will not be replaced.
&(/*(1(35235,(7$5<,1)250$7,21
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 86 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 201613. EMERGENCY PROCEDURES
13.1. Emergency Contact
In emergency situations, the Investigator s hould contact the responsible Clinical Research
Physician/Medical Monitor or designee by telephone at the number(s) listed on the Emergency 
Contact Information page of the protocol (after title page).
In the unlikely event that the Clinical Research Physician/Medical Monitor or designee cannot be 
reached, please contact the global Emergency Call Center by telephone at the number listed on 
the Emergency Contact Information page of the protocol (after title page). This global 
Emergency Call Center is available 24 hours a day and 7 days a week. The representatives are 
responsible for obtaining your call-back informatio n and contacting the on call Sponsor/Contract 
Research Organization (CRO) Medical M onitor, who will then contact you promptly.
Note: The back-up 24-hour global emergency contact call center should only be used if you are 
not able to reach the Clinical Research P hysician(s) or Medical Monitor or designee for 
emergency calls. 
13.2. Emergency Identification of Investigational Products
This is an open-label study; therefore, IP will be identified on the package labeling. 
&(/*(1(35235,(7$5<,1)250$7,21ee
n 
ves are ves are 
sorsor//ContraContra
ptly.ly.
bbe used if ye used if 
r designee fdesignee f
ProductsProduct
n the packagthe pack
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 87 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 201614. REGULATORY CONSIDERATIONS
14.1. Good Clinical Practice
The procedures set out in this study protocol pertaining to the conduct, evaluation, and 
documentation of this study are designed to ensure that the Sponsor, its authorized 
representative, and Investigator abide by Good Clinical Practice (GCP), as described in 
International Conference on Harmonization (ICH) Guideline E6 and in accordance with the general ethical principles outlined in the Declarati on of Helsinki. The study will receive approval 
from an IRB/EC prior to commencement. The I nvestigator will conduct all aspects of this study 
in accordance with applicable national, state, and local laws of the pertinent regulatory authorities.
14.2. Investigator Responsibilities
Investigator responsibilities are set out in the ICH Guideline for Good Clinical Practice and in the local regulations. The Sponsor staff or its authorized representative will evaluate and approve 
all Investigators who in t urn will select their staff.
The Investigator should ensure that all persons assi sting with the study are adequately informed 
about the protocol, amendments, study treatments, as well as study-related duties and functions. 
The Investigator should maintain a list of sub-Investigators and other appropriately qualified 
persons to whom he or she has d elegated significant study-related duties.
The Investigator is responsible for keeping a record of all subjects who sign an ICF and are 
screened for entry into the study. Subjects who fail screening must have the reason(s) recorded in 
the subjectâ€™s source documents.
The Investigator, or a designated member of the Investigatorâ€™s staff, must be available during 
monitoring visits to review data, resolve queries and allow direct access to subject records (eg, 
medical records, office charts, hospital charts, and study-related charts) for source data verification. The Investigator must ensure timely and accurate completion of eCRFs and queries.
The information contained in the protocol and amendments (with the exception of the 
information provided by the Sponsor on public regist ry websites) is considered the Sponsorâ€™s 
confidential information. Only information that is previously disclosed by the Sponsor on a 
public registry website may be freely disclosed by the Investigator or its institution, or as 
outlined in the Clinical Trial Agreement. The Sponsorâ€™s protocol, amendment and IB 
information is not to be made publicly available (for example on the Investigatorâ€™s or their 
institutionâ€™s website) without express written approval from the Sponsor. Information proposed 
for posting on the Investigatorâ€™s or their institutionâ€™s website must be submitted to the Sponsor
for review and approval, providing at least 5 business days for review. 
At the time results of this study are made available to the public the Sponsor will provide 
Investigators with a summary of the results that is written for the lay person. The Investigator is 
responsible for sharing these results with the subject and/or their caregiver as agreed by the 
subject.&(/*(1(35235,(7$5<,1)250$7,21valval
tudyudy
cal Practicecal Practic
will evaluatell eval
studyudare adare a
tudytudy--relatedre
and other aand other a
y-y-relrelated dated
of all subjeof all sub
il screeningil screenin
of the f the InvesInve
e queries anqueries 
alal charts, achartsll
t ensure timt ensure t
the protocothe protoc
e Sponsor Sponsor
n. Only infon. Only in
te maye may  be f bey
nical Trial nical Trial 
not to be mnot to be m
website) wwebsite) w
g on the Inon the In
iew and apiew and ap
the time rehe time re
Investnvest igatoigato
responsespons
j
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 88 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 201614.3. Subject Information and Informed Consent
The Investigator must obtain informed consent of the subject and/or the subjectâ€™s legal 
representative prior to any study-related procedures.
Documentation that informed consent occurred prior to  the subjectâ€™s entry into the study and of 
the informed consent process should be recorded in the subjectâ€™s source documents including the date. The original ICF signed and dated by the subject and by the person consenting the subject
prior to the subjectâ€™s entry into the study, must be maintained in the Investigatorâ€™s study files and 
a copy given to the subject. In addition, if a protocol is amended and it impacts the content of the informed consent, the ICF must be revised. Sub jects participating in the study when the amended 
protocol is implemented must be re-consented with  the revised version of the ICF. The revised 
ICF signed and dated by the subject and by the person consenting the subject must be maintained 
in the Investigatorâ€™s study files and a c opy given to the subject. Subjects in the nab-
paclitaxel/durvalumab arm who continue treatment beyond disease progression per RECIST 1.1 
will be requested to sign a consent form at time of progression and prior to treatment continuation.
14.4. Confidentiality
The Sponsor affirms the subject's right to protection against invasion of privacy and to be in compliance with ICH and other local regulations (whichever is most stringent). The Sponsorrequires the Investigator to permit the Sponsor's representatives and, when necessary, 
representatives from regulatory au thorities, to review and/or copy any medical records relevant 
to the study in accordance with local laws.
Should direct access to medical records require  a waiver or authorization separate from the 
subjectâ€™s signed ICF, it is the responsibility of the Investigator to obtain such permission in 
writing from the appropriate i ndividual.
14.5. Protocol Amendments
Any amendment to this protocol must be approved by the Sponsorâ€™s Clinical Research 
Physician/Medical Monitor. Amendments will be submitted to the IRB/EC for written approval.Written approval must be obtained before implementation of the amended version occurs. The 
written signed approval from the IRB/EC shoul d specifically referen ce the Investig ator name, 
protocol number, study title and amendment number(s) that is applicable. Amendments that are administrative in nature do not require IRB/IEC approval but will be submitted to the IRB/IEC 
for information purposes.
14.6. Institutional Review Board/Independent Ethics Committee Review 
and Approval
Before the start of the study, the study protoc ol, ICF, and any other appropriate documents will 
be submitted to the IRB/EC with a cover letter or a form listing the documents submitted, their 
dates of issue, and the site (or region or area of jurisdiction, as applicable) for which approval is 
sought. If applicable, the documents will also be submitted to the authorities in accordance with local legal requirements.&(/*(1(35235,(7$5<,1)250$7,21d d 
f the ft h e
mmended nded 
revised vised 
e maintainee maintaine
b--
n per RECIper REC
treatment treatment 
vasiovasio n of pn o
r ir is ms most stost st
ntatives andatives a
and/or copyand/or cop
e a waiver oa waiver 
ofof the theff InveInve
ntsts
ol must be al must be 
AmendmeAmendm
e obtained bobtaine
allffllromomff  the m
tudyudytitiyytltliiie ane an
n nature do n nature do
n purposen purpose
InstituInstit
anandd
Before the Before the 
be subme subm
es
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 89 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016IP can only be supplied to an Investigator by the Sponsor or its authorized representative after 
documentation on all ethical a nd legal requirements for starting the study has been received by 
the Sponsor or its authorized representative. This  documentation must also include a list of the 
members of the IRB/EC and their occupation and qualifications. If the IRB/EC will not disclose 
the names, occupations and qualifications of the committee members, it should be asked to issue 
a statement confirming that the composition of the committee is in accordance with GCP. For 
example, the IRB General Assurance Number may be accepted as a substitute for this list. 
Formal approval by the IRB/EC should mention the protocol title, number, amendment number 
(if applicable), study site (or region or area of jurisdiction, as applicable), and any other 
documents reviewed. It must mention the date on which the decision was made and must be 
officially signed by a co mmittee memb er. Before the first subject is e nrolled in the study, all 
ethical and legal requirements must be met.
The IRB/EC and, if applicable, the authorities, must be informed of all subsequent protocol 
amendments in accordance with local legal requirements. Amendments must be evaluated to 
determine whether formal approval must be sought and whether the ICF should also be revised.
The Investigator must keep a record of all comm unication with the IRB/EC  and, if applicable, 
between a coordin ating Investigator and the IRB/EC. This statement also applies to any 
communication between the Investigator (or coordinating Investigator, if applicable) and 
regulatory authorities.
Any advertisements used to recruit subjects for the study must be reviewed by the Sponsor and 
the IRB/EC prior to use.
14.7. Ongoing Information for Institutional Review Board / Ethics 
Committee
If required by legislation or the IRB/EC, the Investigator must submit to the IRB/EC:
!Information on serious or unexpected adverse events as soon as possible; 
!Periodic reports on the progress of the study;
!Deviations from the protocol or anything th at may involve added risk to subjects.
14.8. Closure of the Study
The Sponsor reserves the right to terminate this study at any time for reasonable medical or 
administrative reasons. Any premature disc ontinuation will be appropriately documented 
according to local requirements (eg, IRB /EC, regulatory authorities, etc).
In addition, the Investigator or the Sponsor has th e right to discontinue a single site at any time 
during the study for medical or administrative reasons such as:
!Unsatisfactory enrollment;
!GCP noncompliance;
!Inaccurate or incomplete data collection;
!Falsification of records;
!Failure to adhere to the study protocol.&(/*(1(35235,(7$5<,1)250$7,21e 
y, all all 
nt protocol nt protocol 
be evaluate evaluat
ould also bould also b
/EC and, if/EC and,
also appliealso appli
gatorato, if appif app
ust be revist be rev
utional Rutional R
he InvestigaInvestig
nexpected expected 
progress ofogress of
e protocole protocol l
the Studythe Stu
s the right tthe right
asons. Anysons. Any
cal requirecal requi
, the the InvestInvest
he studyhe study ffyyoff
!UnsUns
!!
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 90 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 201615. DATA HANDLING AND RECORDKEEPING 
15.1. Data/Documents
The Investigator must ensure that the records and documents pertaining to the conduct of the 
study and distribution of the IP are complete, accurate, filed and retained. Examples of source 
documents include: hospital records; clinic and office charts; laboratory notes; memoranda; 
subjectâ€™s diaries or evaluation checklists; dispensing records; recorded data from automated instruments; copies or transcriptions certifie d after verification as being accurate copies; 
microfiche; x-ray film and reports; and records kept  at the pharmacy and th e laboratories, as well 
as copies of CRFs or CD-ROM.
15.2. Data Management
Data will be collected via eCRF and entered into  the clinical database per the Sponsorâ€™s Standard 
Operating Procedures (SOPs). This data will be electronically verified through use of programmed edit checks specified by the clinical team. Discrepancies in the data will be brought 
to the attention of the clinical team, and investigational site personnel, if necessary. Resolutions 
to these issues will be reflected in the database. An audit trail within the system will track all 
changes made to the data.
15.3. Record Retention
Essential documents must be retained by the Inve stigator for a minimum of 2 years after the last 
approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketi ng applications in an ICH region, or at least 2 years have elapsed since the 
formal discontinuation of clinical development of the IP. The Investigator must retain these 
documents for the time period described above or according to local laws or requirements, whichever is longer. Essential documents include, but are not limited to, the following:
!Signed ICFs for all subjects;
!Subject identification code list, screening log (if applicable), and enrollment log;
!Record of all communications between the Investigator and the IRB/EC;
!Composition of the IRB/EC;
!Record of all communications betw een the Investigator, Sponsor, and their authorized 
representative(s);
!List of sub-Investigators and other appropriately qualified persons to whom the 
Investigator has delegated significant study-related duties, together with their roles in 
the study, curriculum vitae, and their signatures;
!Copies of CRFs (if paper) and of documentation of corrections for all subjects;
!IP accountability records;
!Record of any body fluids or tissue samples retained;
!All other source documents (subject records, hospital records, laboratory records, 
etc.); &(/*(1(35235,(7$5<,1)250$7,21s well well 
Sponsorâ€™s ponsorâ€™s S
ugh use of ugh use of 
the data wihe dat
, if necessa if necessa
in the systen the syst
atoratorfofor a mr a m
on and unton and unt i
region, or aregion, or a
nt of the nt of the IPIP
bove or accbove or acc
nts include,s include
ects;cts
on code listn code lis
ommummu nicatnicat
on ofn of the IR the IRff
d of all coof all co mm
resentative(esentativ
List of List of ssubub
Investnvest igi
ththe se 
!!
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 91 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016!All other documents as listed in Section 8 of the ICH consolidated guideline on GCP 
(Essential Documents for the Conduct of a Clinical Trial).
The Investigator must notify the Sponsor if he/she wishes to assign the essential documents to 
someone else, remove them to another location or is unable to retain them for a specified period.
The Investigator must obtain approval in writing from the Sponsor prior to destruction of any 
records. If the Investigator is unable to meet this obligation, the Investigator must ask the 
Sponsor for permission to make alternative arrangements. Details of these arrangements should 
be documented. 
All study documents should be made available if  required by relevant health authorities. The 
Investigator/Institution should take measures to prevent accidental or premature destruction of 
these documents.
&(/*(1(35235,(7$5<,1)250$7,21he 
tion of tion of 
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 92 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 201616. QUALITY CONTROL AND QUALITY ASSURANCE
All aspects of the study will  be carefully monitored by the Sponsor or its authorized 
representative for compliance with applicable government regulations with respect to current 
GCP and standard operating procedures.
16.1. Study Monitoring and Source Data Verification
The Sponsor ensures that appropriate monitoring procedures are performed before, during and 
after the study. All aspects of the study are reviewed with the Investigator and the staff at a study 
initiation visit and/or at an Investigator meeting. Prior to enrolling subjects into the study, a 
Sponsor representative or designee will review the protocol, eCRFs, procedures for obtaining 
informed consent, record keeping, and reporting of AEs/SAEs with the Investigator. Monitoring 
will include on-site visits with the Investigator and his/her staff as well as any appropriate 
communications by mail, email, fax, or telephone. During monitoring visits, the facilities, IP storage area, eCRFs, subjectâ€™s source documen ts, and all other study  documentation will be
inspected/reviewed by the Sponsor representative in  accordance with the Study Monitoring Plan.
Accuracy will be checked by performing source data verification that is a direct comparison of 
the entries made onto the eCRFs against the appropriate source documentation. Any resulting 
discrepancies will be reviewed with the Inve stigator and/or his/her staff. Any necessary 
corrections will be made directly to the eCR Fs or via queries by the Investigator and/or his/her 
staff. Monitoring procedures require that informed consents, adherence to inclusion/exclusion 
criteria and documentation of SAEs and their  proper recording be verified. Additional 
monitoring activities may be outlined in a study-specific monitoring plan.
16.2. Audits and Inspections
In addition to the routine monitoring proce dures, a Good Clinical Practice Quality Assurance 
unit exists within the Sponsor. Representatives of this unit will conduct audits of clinical research activities in accordance with the Sponsorâ€™s SOPs to evaluate compliance with Good 
Clinical Practice guidelines and regulations.
The Investigator is required to permit direct acce ss to the facilities where the study took place, 
source documents, eCRFs and applicable supporting records of subject participation for audits 
and inspections by IRB/IECs, regulatory authori ties (eg, FDA, European Medicines Agency 
[EMA], Health Canada) and company authorized representatives. The Investigator should make every effort to be available for the audits and/or inspections. If the Investigator is contacted by 
any regulatory authority regarding an inspection, he/she should contact the Sponsor immediately.udy udy
a a 
aining aining 
MoMonitnitoringorin
propriate opriate 
he fe faciliaciliff titiiiese
entatientati on on ww
StudyStudy Mony
t iis a dis a di recrecii
ocumentatioumentati
/her staff.her sta A
s by the s by the Inv
nts, adnts, ad hereh
ecording beecording b
ecific mecific m onion
cedures, a Gcedures, a G
entatives oentatives o
th h thte SponSpo
regulatregulat ioionn
to permit dto permi
s and applis and ap
B/IECs, regB/IECs, reg
nada) nada) and cand c
e available e available
yyauthoriauthoriy tytyii
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 93 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 201617. PUBLICATIONS
As described in Section 14.2, all protocol- and amendment-related information, with the 
exception of the information provided by the Sponsor on public registry websites, is considered 
Sponsorâ€™s confidential information and is not to be used in any publications. The Sponsor
protocol-related information proposed for use in a publication must be submitted to the Sponsor
for review and approval, and should not be  utilized in a publication without express written 
approval from the Sponsor, or as described in the Clinical Trial Agreement. 
The Sponsor will ensure sponsored studies are considered for publication in the scientific 
literature in a peer-reviewed journal, irrespective of the results. At a minimum, this applies to 
results from all Phase 3 clinical studies, and any other study results of significant medical 
importance. This also includes results relating to investigational medicines whose development programs have been discontinued. 
Study results may also be presented at one or more medical congresses, and may be used for 
scientific exchange and teaching purposes. Additionally, this study and its results may be submitted for inclusion in all appropriate health authority study registries, as well as publication 
on health authority study registry websites, as required by local health authority regulations. 
Eligibility for external authorship, as well as selection of first authorship, will be based on  
several considerations, including, but not limited to, contribution to protocol development, study 
recruitment, data quality, participation in data analysis, participation in study steering committee 
(when applicable) and contribution to abstract, presentation and/or publication development.
&(/*(1(35235,(7$5<,1)250$7,21s to s to 
al 
evelopmentvelopment
maymay byye usedused
resulresul ts mts mll ayay
es, as well aes, as we
h authorityh authority
thorship,thors ww
tion to protion to pro
rticipation icipation
tion and/ortion and/o
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 94 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 201618. REFERENCES
AbraxaneÂ®[package insert]. Summit, NJ:  Celgene Corporation; 2015. Available at:  
http://www.abraxane.com/wp-content/pi/prescribing-info.html.
Antonia SJ, Brahmer JR, Gettinger SN, Chow LQ, Juergens RA, Shepherd FA, et al. Nivolumab 
(anti-PD-1; BMS-936558, ONO-4538) in comb ination with platinum-based doublet 
chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC) [abstract] .J Clin 
Oncol 32:5s, 2014 (suppl; abstract 8113).
Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, et al. Safety and 
antitumour activity of durvalumab plus tremelimumab in non-small cell l ung cancer: a 
multicentre, phase 1b study. Lancet Oncol. 2016 Mar;17(3):299-308.
Azzoli CG, Baker Jr. S, Temin S, Pao W, Aliff T, Brahmer J, et al. American Society of Clinical 
Oncology clinical practice guideline update on chemotherapy for Stage IV nonâ€“small-cell lung 
cancer. J Clin Oncol 2009;27:6251-66.
Banissi C, Ghiringhelli F, Chen L, Carpentier AE . Treg depletion with a low-dose metronomic
temozolomide regimen in a rat glioma mode l. Cancer Immunol Immunother. 2009;58(10):1627-
34.
Belani CP, Ramalingam S, Perry MC, LaRocca RV, Rinaldi D, Gable PS, et al. Randomized, 
phase III study of weekly paclitaxel in co mbination with carboplatin versus standard 
every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated 
advanced non-small-cell lung cancer. J Clin Onc 2008;26:468-73.
Benson AB 3rd, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA Jr, et al.
Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol
2004 Jul 15;22(14):2918-2926.
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus 
docetaxel in advanced nonsquamous nonâ€“small-cell lung cancer. N Engl J Med 
2015;373(17):1627-39.
Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune -based mechanisms of cytotoxic 
chemotherapy: implications for the design of novel and rationale -based combined treatments 
against cancer. Cell Death Differ. 2014;21(1):15 -25.
Brahmer J, Reckamp KL, Baas P, CrinÃ² L, Eberhardt WE, Poddubskaya E, et al. Nivolumab 
versus docetaxel in advanced squamous-cell  nonâ€“small-cell lung cancer. N Engl J Med 
2015;373(2):123-35.
Buccheri G, Ferrigno D. Second-line weekly p aclitaxel in patients with inoperable non-small cell 
lung cancer who fail combination chemotherapy with cisplatin. Lung Cancer 2004;45:227â€“36.
Ceresoli GL, Gregorc V, Cordio S, Bencardino KB, Schipani S, Cozzarini C, et al. Phase II study 
of weekly paclitaxel as second- line therapy in patients with advanced non-small cell lung cancer. 
Lung Cancer 2004;44:231â€“9.
Chen G, Emens LA. Chemoimmunotherapy: ree ngineering tumor immunity. Cancer Immunol
Immunother. 2013a;62(2):203-16.&(/*(1(35235,(7$5<,1)250$7,21d d 
ietety y ofof Clin Cliff
smsmallall--cellce
lowow-ddoseo
unother. nother. 2020
D, Gable PSD, Gable 
arboplboplatatin vin
xel for patiel for pa
8;26:4688;26:468 -77
ng C, Kornng C, Korn
cancer treacancer trea
el DR, SteinDR, Ste
s nnononâ€“â€“nnnssmalm
gu u A, BelarA, Belar
ns for the dfor the d
ath Differ. ath Differ
mp KL, Baamp KL, Baa
l in advancl in advanc
123-35.3-35
G, Ferrign Ferrign
ancer who ancer who 
eresoresoli GL,li GL,
ofof weekly weeklyff
ung Cung C
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 95 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Chen DS, Mellman I. Oncology meets immunology: the cancer -immunity cycle. Immunity. 
2013;39(1):1 -10.
Chen X, Ren S, Li X, et al. Efficacy of nab-paclitaxel for advanced non-small cell lung cancer 
after failure of multi-line chemotherapy [Chinese]. Chinese Journal of Clinical Oncology 2012; 
39(22):1824-7.
Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, et al. Increased antitumor activity, intratumor 
paclitaxel concentrations, and endothelial cell tr ansport of cremophor-free, albumin-bound 
paclitaxel, ABI-007, compared with crem ophor-based p aclitaxel. Clin Cancer Res 
2006;12(4):1317-24.
Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, et al. Prognostic value of 
tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-
negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014;25(3):611-8.
Dumlao TL, Butler TW, Dyess DL, Khong HT. A phase I/II study of the hypomethylating agent 
azacitidine with th e nanoparticle albumin bound paclitaxel in the treatment of patients with 
advanced or metastatic solid tumors. J Clin  Oncol (Meeting Abstracts) May 2011;29(15) Suppl 
3095.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, et al. New 
response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J 
Cancer 2009 Jan;45(2):228-47. 
Garcia-Manero G, Gore SD, Cogle C, Ward R, Shi T, Macbeth KJ, et al. Phase I study of oral 
azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid 
leukemia. J Clin Oncol 2011 Jun;29(18):2521-2527.
Gardner ER, Dahut WL, Scripture CD, Jones J,  Aragon-Ching JB, Des ai N, et al.  Rando mized 
crossover pharmacokinetic study of solvent-ba sed paclitaxel and na b-paclitaxel. C lin Cancer Res 
2008;14(13):4200-5. 
Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, S yrigos KN, Goksel T, et al. Ramucirumab plus 
docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell 
lung cancer after disease progression on platinum -based therapy (REVEL): a multicentre, 
double-b lind, randomised phase 3 trial. Lan cet, 2014; 384(9944),665-73.
Gerber DE, Schiller JH. Maintenance chemotherapy for advanced non-small-cell lung cancer: 
new life for an old idea. J Clin Oncol 2013 Mar 10;31(8):1009-20.
Gordian E, Ramachandran K, Singal R. Methylation mediated silencing of TMSl in breast cancer 
and its potential contribution to docetaxel cytotoxicity. Anticancer Res 2009 Aug;29(8):3207-10.
Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized 
Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Nonâ€“Small-Cell Lung Cancer 
Previously Treated With Chemotherapy. J Clin Oncol 2004;22:1589-97.
Herr I, Ucur E, Herzer K, Okouoyo S, Ridder R, Krammer PH, et al. Glucocorticoid cotreatment 
induces apoptosis resistance toward can cer therapy in carcinomas. Cancer Res.
2003;63(12),3112-20.
Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007 Feb;128(4):683-92.&(/*(1(35235,(7$5<,1)250$7,21alue of lue of 
tripleriple-
:611:611-8.-8.
popometmehylatylai
nt of patientnt of patien
MayMay 2011201yy
D, Ford R, DD, Ford R, 
T guidelineT guidelin
Macbeth KMacbeth K
myelomyelo momonn
527.527.
es J, Aragos J, Arago
entnt-based p-based p
O, PrabhashO, Prabha
docetaxel focetaxel f
ogression ogression o
d phase 3 trd phase 3
JHH. MainteMaint
idea.idea. J ClJ Cl
ammachandraachandr
ential contrntial contr
N, ShepheN, Shephe
se III Trialse III Trial
PreviouslyPreviously Ty
Herr I, Herr I, 
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 96 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Juan O, Albert A, Ordono F, Casany R, Carana na V, Campos JM, et  al. Low-dose weekly 
paclitaxel as second-line treatment for advanced non-small cell l ung cancer: a phase II study. Jpn 
J Clin Oncol 2002;32:449â€“54.
Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, et al. Combination 
epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. 
Cancer Discov 2011 Dec;1(7):598-607.
Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R. FDA Drug Approval Summary: 
Azacitidine (5- azacytidine, Vidazaâ„¢) for Injectable Suspension. The Oncologist 2005 
Mar;10(3):176-82.
KeytrudaÂ®[package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2015. Available at:  
https://www.merck.com/product/usa/pi_ circulars/k/keytrud a/keytruda_pi.pdf.
Khan S, Lopez-Dee Z, Kumar R, Ling J. Acti vation of NFkB is a novel mechanism of pro-
survival activity of glucocorticoids in breast cancer cells. Cancer Lett. 2013;337(1),90-5.
Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel 
chemoimmunomodulating propert y of docetaxel: suppression of myeloid-derived suppressor 
cells in tumor bearers. Clin Cancer Res. 2010;16(18):4583-94.
Li Y, Hu W, Shen DY, Kavanagh JJ, Fu S. Azacit idine enhances sensitivit y of platinum-resistant 
ovarian cancer cells to carboplatin through induction of apoptosis. Am J Obstet Gynecol 2009 
Feb; 2009(2):177.e1-9.
Li Y, Chen N, Palmisano M, Zhou S. Pharmaco logic sensitivity of paclitaxel to its delivery 
vehicles drives distinct clinical outcomes of paclitaxel formulations. Mol Pharm 2015 Apr 
6;12(4):1308-17.
Liu SV, Powderly JD, Camidge DR, Ready N, S uk Heist R, Hodi FS, et al. Safety and efficacy 
of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in 
patients with advanced non-small cell lung cancer (NSCLC). In ASCO Annual Meeting Proceedings 2015 May 20 (Vol. 33, No. 15_suppl, p. 8030).
Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 
2011;480(7378):480 -9.
Narwal R, Roskos LK, Robbie GJ. Population pharmacokinetics of sifalimumab, an 
investigational anti-interferon- Î± monoclonal antibody, in sys temic lupus erythematosus. Clin
Pharmacokinet. 2013 Nov 1;52(11):1017-27. 
National Institute for Health & Clinical Excellence: The Diagnosis and Treatment of Lung 
Cancer: Methods, Evidence & Guidance, 2011.
Ng CM, Lum BL, Gimenez V, Kelsey S, Allison D. Rationale for fixed dosing of pertuzumab in 
cancer patients based on population pharmacokinetic analysis. Pharm Res. 2006 Jun 
1;23(6):1275-84.
Nishino M, Giobbie-Hurder A, Gargano M, Suda  M, Ramaiya NH, Hodi FS. Developing a 
common language for tumor response to immunotherapy: immune-related response criteria using 
unidimensional measurements. Clin Cancer Res. 2013 Jul 15;19(14):3936-43.&(/*(1(35235,(7$5<,1)250$7,21ble at:  le at:  
nism of proism of p
337(1),90337(1),90
ovel vel 
looidid--derivederive
es sensites sens iv
optosis. Amptosis. Am
c sensitc sens ivitiv
taxel formutaxel form
yyN, N, yy Suk HSuk H
atatioion win withtiiih
ll lung cancl lung ca
3, No. 15_3, No. 15
ff G. Canceff G. Canc
, Robbie GRobbie G
intnterferferoneronfff
2013 Nov 12013 Nov 
ttititutute for He for H
Methods, Evthods, E
M, LumM, Lum BLBmm
ncer patienncer patien
1;23(6):12;23(6):12
shinshin
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 97 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and 
response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5(6):649-
55.
OpdivoÂ®[package insert]. Princeton, NJ:  Bristol-Myers Squibb Company; 2016. Available at:  
http://packageinserts.bms.com/pi/pi_opdivo.pdf. 
Pang D, Kocherginsky M, Krausz T, Kim SY,  Conzen SD. Dexamethasone decreases xenograft 
response to Paclitaxel through inhibition of tumor cell apoptosis. Cancer Biol Ther. 2006;5(8),933-40.
Reck M, Kaiser R, Mellemgaard A, Douillard JY, Or lov S, Krzakowski M, et al. Docetaxel plus 
nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung 
cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 
2014a Feb;15(2):143-55.
Reck M, Popat S, Reinmuth N, De Ruyssche r D, Kerr KM, Peters S; ESMO Guidelines Working 
Group. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for 
diagnosis, treatment and follow-up. Ann O ncol. 2014 Sep;25 Suppl 3:iii27-39 doi: 
10.1093/annonc/m du199. Epub 2014 Aug 11.
Rizvi NA, Riely GJ, Azzoli CG, Miller VA, Ng KK, Fiore J, et al. Phase I/II trial of weekly 
intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with Stage IV 
non-small-cell lung cancer. J Clin Oncol 2008;26(4):639-43.
Rizvi N, Gray J, Ballas M, Jayawardene D,  Stockman P, Powderly JD. A Phase 2, non-
comparative, open-label, multicenter, international study of MEDI4736 in patients with locally 
advanced or metastatic PD-L1 positive NSCLC (Stage 3B-4) who have received â‰¥2 prior 
systemic treatment regimens (ATLANTIC). Anna ls of Oncology (2014) 25 (suppl_4): iv426-
iv470. 10.1093/annonc/mdu349
Saxena A, Christos PJ, Cagney JM, et al. Nanoparticle albumin-bound paclitaxel (NabP) as a 
single agent for the treatment of recurrent stage 4 non-small cell l ung cancer (NSCLC) [abstract]. 
Proceedings of the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology 
2012;.September 6-8; Chicago, IL; USA: Abstract #O-1075.
Schiller JH, Gandara DR, Goss GD, Vokes EE.  Non-small-cell lung cancer: then and now. 
J Clin Oncol 2013;31(8):981-3.
Sculier JP, Berghmans T, Lafitte JJ, Richez M, Recloux P, Van Cutsem O, et al. A phase II study 
testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell 
lung cancer failing after a first-line chemotherapy. Lung Cancer 2002;37:73â€“7.
Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, Oâ€™Rourke M, et al. Prospective 
randomized trial of docetaxel versus best supportive care in patients with nonâ€“small-cell lung 
cancer previously treated with platinum-b ased chemotherapy. J Clin Oncol. 2000;18(10), 2095-
103.
Socinski MA, Manikhas GM, Stroyakovsky DL, Makhson AN, Cheporov SV, Orlov SV, et al. A 
dose finding study of weekly and every-3-week nab-paclitaxel followed by carboplatin as 
first-line therapy in patients with advanced non-small cell l ung cancer. J Thorac Oncol 
2010;5(6):852-61.&(/*(1(35235,(7$5<,1)250$7,21elel plus  plus ll
cell lcell l ung ung lll
t t OncolOncol . 
GuidelinesGuidelin
PractPract ice Guice Gu
ii27i27-39-39doido
al. al. Phase I/Phase I
motherapymotherapy iyy
43.4
n P, Powdern P, Powder
sstudytudy ofofMMf
(Stage (Stage 3B3B
Annals of OAnnals of O
t al. Nanopt al. Nan
current stagrrent sta
o Multo Mult ididiscisc
go, IL; USAgo, IL; USA
, Goss GD, Goss G
(8):981(8):981 -3.
mans T, Lamans T, La
xel as seconel as seco
failing aftefailing afte
rd FA, Danrd FA, Dan
oomized triamized tri
ancer previoancer previo
103.0
cini
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 98 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Socinski MA, Schell MJ, Bakri K, Peterman A, Lee JH, Unger P, et al. Second-line, low-dose, 
weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line 
chemotherapy with carboplatin plus paclitaxel. Cancer 2002;95:1265â€“73. 
Socinski MA, Steagall A, Gillenwater H. Second -line chemotherapy with 96-hour infusional 
paclitaxel in refractory non-small cell lung cancer: report of a phase II trial. Cancer Invest 
1999;17:181â€“8. 
Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, et al. 
Weekly nab-paclitaxel in combination with ca rboplatin versus solvent-based paclitaxel plus 
carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final 
results of a phase III trial. J Clin Oncol 2012 Jun 10;30(17):2055-62.
Sui M, Chen F, Chen Z, Fan W. Glucocorticoids interfere with therapeutic efficacy of paclitaxel 
against human breast and ovarian xenogra ft tumors. Int J Cancer. 2006;119(3), 712-7.
Tanaka H, Matshushima H, Mizumoto N, Takashima A. Classification of chemotherapeutic 
agents based on their differential in vitro effects on dendritic cells. Cancer Res. 
2009;69(17):6978 -86.
Vansteenkiste J, Fehrenbacher L, Spira AI, Mazieres J, Park K, Smith D, et al. Atezolizumab 
monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, 
safety and predictive biomarkers from a randomized phase II study (POPLAR). European
Journal of Cancer 2015 Sep 1 (Vol. 51, pp. S716-S717). 
Wang DD, Zhang S, Zhao H, Men AY, Parivar K. Fixed dosing versus body size-based dosing 
of monoclonal antibodi es in adult clinical trials. J Clin Pharmacol. 2009 Sep 1;49(9):1012- 24. 
Wang E, Kang D, Bae KS, Marshall MA, Pavlov D, Parivar K. Population pharmacokinetic and 
pharmacodynamic analysis of tremelimumab in p atients with metas tatic melanoma. J Clin
Pharmacol. 2014 Oct 1;54(10):1108-16.
Yasuda K, Igishi T, Kawasaki Y, Kato K, Matsumoto S, Katayama S, et al. Phase II study of 
weekly paclitaxel in patients with non-small cell lung cancer who have failed previous 
treatments. Oncology 2004;66:347â€“52.
Yuan DM, Lv YL, Yao YW, Miao XH, Wang Q, Xiao XW, et al. Efficacy and safety of 
Abraxane in treatment of progressive and recurrent non-small cell lung cancer patients: a 
retrospective clinical study. Thoracic Cancer 2012;3(4):341-7.
Zhang L, Dermawan K, Jin M, Liu R, Zheng H, Xu L, et al. Differential impairment of 
regulatory T cells rather than effector T cells by paclitaxel-based chemot herapy. Clin Immunol. 
2008;129(2):219-29.
Zhang S, Shi R, Li C, Parivar K, Wang DD. Fixed dosing versus body size-based dosing of 
therapeutic peptides and proteins in adults. J Clin Pharmacol. 2012 Jan 1;52(1):18-28. 
Zavodovskaya M, Brachmann C, DiMartino J, Pierce D. Dexamethasone interrupts paclitaxel-
induced apoptosis in solid tumor cells [abstract].   Proceedings: AACR 106thAnnual Meeting 
2015; April 18- 22, 2015 Philadelph ia, PA: USA; abstract 5469. 
Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and 
targeted anticancer therapies: reins tating immunosurveillance. Immunity 2013;39(1),74-88.&(/*(1(35235,(7$5<,1)250$7,21oof f paclipacli taxtaxii
1212-7.7.
emotherapeemothera
Res. Res. 
mith D, ith D, et aet 
PrimaryPrim any
I studyI stud (POPOy
xed dosing xed dosing 
ClinClin PharmPharm
ov vD, ParivD, Pari
ab in patib in pati enen
ato K, Matsto K, Ma
non-non-smallsma
34747â€“52.â€“52.
W, Miao XMiao X
of progressof progres
l studystudy . Tho. Th
awan K, Jinwan K, Jin
ells rather lls rather
2):219):219 --29.29.
S, Shi R, LS, Shi R, L
rapeutiapeuti c pec pe
ZavodovskZavodovsk
nducednduce
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 99 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 201619. APPENDICES
Appendix A: ECOG Performance Status Score
Grade ECOG
0 Fully active, able to carry on all pre-disease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light 
or sedentary nature, eg, light house work, office work
2 Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and 
about more than 50% of waking hours
3 Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair
5D e a d
Oken, 1982 .
&(/*(1(35235,(7$5<,1)250$7,21,,7,7,of a light f a light $777
vities. Up anvities. Up a50
n 50% of wa50% o)2
onfined to bonfined to1)
<
$5<
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 100 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Appendix B: Recommendations for Management of Treatment-Induced 
Diarrhea
The following published guidelines ( Benson, 2004 ) were modified in order to be consistent with 
the clinical study protocol.
&(/*(1(35235,(7$5<,1)250$7,21

EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 101 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Appendix C: Treatment Modification and Toxicity Management for nab-
Paclitaxel /Durvalumab arm
(based on updated guidelines for Durvalumab/MEDI4736 - 09 Aug 2016 version)
General guidelines regarding treatment modification for MEDI4736 and/or nab-paclitaxel are 
provided b elow for immune-related AEs ( Table C1 ), infusion-related reactions ( Table C2 ), and 
non-immune-mediated reactions ( Table C3 ). 
These guidelines apply to AEs considered causally related to the durvalumab containing regimen 
by the reporting Investigator. Treatment modifications referring to â€œstudy regimenâ€ would apply 
to both nab-paclitaxel and durvalumab unless AEs are not considered causally related to nab-
paclitaxel by the reporting Investigator. In that case nab-paclitaxel treatment may be continued 
alone if deemed beneficial to the subject per Investigatorâ€™s assessment. 
&(/*(1(35235,(7$5<,1)250$7,21men en 
apply pply 
nabab-
contontinued inued 
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 102 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Table C1: Treatment Modification and Toxicity Management Guidelines for Immune-related Adverse Events
Event Dose Modifications Toxicity Management
Immune-related 
AEs (overall 
management for toxicities not 
noted below)Drug administration modifications of IP/study 
regimen will be made to manage potential 
immune-related AEs based on severity of treatment-emergent tox icities graded per NCI 
CTCAE v4.03.
In addition to the criteria for permanent 
discontinuation of IP/regimen based on CTC 
Grade/severity (table below), permanently discontinue IP/study regimen for the following 
conditions:
â€¢ Inability to reduce corticosteroid to a dose of 
â‰¤10 mg of prednisone per day (or equivalent) 
within 12 weeks after last dose of IP/regimen
â€¢ Recurrence of a previously experienced Grade 3 
treatment-related AE following resumption of dosingIt is recommended that management of irAEs follow the guidelines 
presented in this table
- Subjects should be thoroughly evaluated to rule out any alternative 
etiology (e.g. disease progression, concomitant medications, 
infections, etc.)
- In the absence of a clear alternative etiology, all events should be 
considered potentially immune related
- Symptomatic and topical therapy should be considered for low-
grade (Grade 1 or 2, unless otherwise specified) events
- For persistent (greater than 3 to 5 days) low-grade (Grade 2) or 
severe (Grade â‰¥3) events promptly start prednisone 1-2mg/kg/day PO 
or IV equivalent
- If symptoms recur or worsen during corticosteroid tapering 28 days 
of taper), increase the corticosteroid dose (prednisone dose [e.g. up to 
2-4mg/kg/day PO or IV equivalent]) until stabilization or improvement of symptoms, then resume corticosteroid tapering at a 
slower rate (> 28 days of taper)
- More potent immunosuppressives such as TNF inhibitors (eg, 
infliximab) â€“ (also refer to the individual sections of the immune 
related adverse event for specific type of immunosuppressive) should be considered for events not responding to systemic steroids 
- Discontinuation of IP is not mandated for Grade 3 / 4 inflammatory 
reactions attributed to local tumor response (e.g. inflammatory 
reaction at sites of metastatic disease, lymph nodes etc.). 
Continuation of IP in this situation should be based upon a benefit/risk analysis for that subjectGrade 1 No dose modification
Grade 2 Hold IP/study regimen dose 
until Grade 2 resolution to â‰¤ 
Grade 1
â€¢ If toxicity worsens then treat 
as Grade 3 or Grade 4
â€¢ IP/study treatment can be 
resumed once event stabilizes 
to Grade â‰¤1 after completion 
of steroid taper
Subjects with endocrinopathies 
who may require prolonged or 
continued steroid replacement 
can be retreated with IP/study 
priprietet(/*(1(35235,(7$5<,1)250$7,21e Corporae Corpora
21entsents
7,2AEs followAEs follow
aluaaluated to ruted to ru
on, concomitn, concomi
r alternative alternative 
immune relimmune r
topical theropical ther
or 2, unless 2, unless 
ent (greater ent (grea
rade ade â‰¥3) eveâ‰¥3) ev
quivalentquivalen
symptoms rsymptoms 
of taper), incof taper), in
2-24mg/kg4mg/kg
improvimpro
slowslo$7
5,(5,5,(5,( n dose dose 
ution to ution to â‰¤ â‰¤
worsens theworsens the
3 or Grade 3 or Grad
tudy treatmetudy treat
umed once umed once 
to Grade Grade â‰¤1â‰¤1
of steroidof steroid
SubjeSubj
whwh355
(/*(5
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 103 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Event Dose Modifications Toxicity Management
regimen on the following 
conditions: 
1) the event stabilizes and is
controlled, 
2) the subject is clinically 
stable as per Investigator or 
treating physicianâ€™s clinical judgment, and 
3) doses of prednisone are at 
less than or equal to 10mg/day 
or equivalent.
Grade 3 Depending on the individual 
toxicity, may permanently 
discontinue IP/study regimen. 
Please refer to guidelines 
below
Grade 4 Permanently discontinue 
IP/study regimen
Note: For Grade 3 and above asymptomatic amylase or lipase levels hold IP/regimen and if 
complete work up shows no evidence of 
pancreatitis, may continue or resume IP/regimen
Grade of the 
Event (NCI 
CTCAE version 
4.03) Dose Mo difications Toxicity Management
Pneumonitis/ILD Grade of 
Pneumonitis 
(CTCAE version 
4.03)General guidance - Monitor subjects for signs and symptoms of pneumonitis or ILD 
(new onset or worsening shortness of breath or cough). Subjects 
should be evaluated with imaging and pulmonary function tests 
including other diagnostic procedures as described below
&(/priprietet(/*(1(35235,(7$5<,1)250$7,21e Corporae Corpora
2127,2
5,(tic ic 
en and if en and if
e of o
ume IP/regimume IP/regi55
55
DoDo35
(1tis is 
AE version version 
3))GeG(1(1(1
(/(1
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 104 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Grade of the 
Event (NCI 
CTCAE version 
4.03) Dose Modifications Toxicity Management
- Initial wor k-up may include clinical evaluation, monitoring of 
oxygenation via pulse oximetry (resting and exertion), laboratory 
work-up and high-resolution CT scan.
Grade 1 (asymptomatic,
clinical or
diagnostic
observations only,intervention not 
indicated)No dose modification 
required. However, consider 
holding IP/study regimen 
dosing as clinically 
appropriate and during diagnostic work-up for other 
etiologiesFor Grade 1 (radiographic changes only)
- Monitor and closely follow up in 2-4 days for clinical symptoms, 
pulse oximetry (resting and exertion) and laboratory work-up and then as clinically indicated
- Consider pulmonary and infectious disease consult
Grade 2
(symptomatic,
medical
intervention
indicated, limitinginstrumental 
ADL)â€¢ Hold IP/study regimen 
dose until Grade 2 
resolution to â‰¤ Grade 1
â€¢ If toxicity worsens then 
treat as Grade 3 or Grade 4
â€¢ If toxicity improves to â‰¤ 
Grade 1 then the decision to 
reinitiate IP/regimen will be based upon treating physicianâ€™s clinical 
judgment and after 
completion of steroid taper.For Grade 2 (mild to moderate new symptoms)
- Monitor symptoms daily and consider hospitalization
- Promptly start systemic steroids (eg, prednisone 1-2 mg/kg/day PO 
or IV equivalent)
- Reimaging as clinically indicated
- If no improvement within 3-5 da ys, additional workup should be 
considered and prompt treatment with IV methylprednisolone 2-4 
mg/kg/day started
- If still no improvement within 3-5 days despite IV
methylprednisone at 2-4 mg/kg/day, promptly startimmunosuppressive therapy such as TNF inhibitors (eg, infliximab at 
5 mg/kg every 2 weeks). Caution: Important to rule out sepsis and 
refer to infliximab label for general guidance before using infliximab
- Once improving, gradually taper steroids over â‰¥28 days and 
consider prophylactic antibiotics, antifungal or anti PCP treatment (refer to current NCCN guidelines for treatment of cancer-related 
infections (Category 2B recommendation)
2
2ASCO Educational Book 2015 â€œManaging Immune Checkpoint Blocking Antibody Side Effectsâ€ by Michael Postow MD.
&(priprietet(/*(1(35235,44
to â‰¤ â‰¤ 
cision to cision to 
men will bemen will
eating tin
s clinical s clinical 
ntntand after and after 
pletion of steetion of st5,(7$5<ade 2 (mildade 2 (m
Monitor sympMonitor sym
-Promptly Promptly
or IV eqor IV e
--ReiRei5<,1)250$7,21e Corporae Corpora
21
mentment2
evavaluation,luation,
stingsting and exand ex
scan.scan.0$
hanges onlyhanges on
llow up in 2low up in 2
g and exertig and exer
ndicatedicated
monary and nary and25
5<
/*(15,
(/*015 â€œManagin15 â€œManagin
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 105 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Grade of the 
Event (NCI 
CTCAE version 
4.03) Dose Modifications Toxicity Management
- Consider pulmonary and infectious disease consult
- Consider as necessary discussing with study physician
Grade 3 or 4
(Grade 3: severe
symptoms; limiting self-care 
ADL; oxygen 
indicated;
Grade 4: life
threateningrespiratory
compromise, 
urgentintervention
indicated [e.g. 
tracheostomy or intubation])Permanently discontinue 
IP/study regimenFor Grade 3 or 4 (severe or new symptoms, new/worsening hypoxia, 
life threatening
- Promptly initiate empiric IV methylprednisolone 1 to 4 mg/kg/day 
or equivalent
- Obtain pulmonary and infectious disease consult- Hospitalize the subject- Supportive Care (oxygen, etc.)- If no improvement within 3-5 da ys, additional workup should be 
considered and prompt treatment with additional immunosuppressive therapy such as TNF inhibitors (eg, infliximab at 5mg/kg every 2 weeks dose) started. Caution: rule out sepsis and refer to infliximab
label for general guidance before using infliximab
- Once improving, gradually taper steroids over â‰¥28 days and 
consider prophylactic antibiotics, antifungals and in particular, anti PCP treatment (please refer to current NCCN guidelines for treatment of cancer-related infections (Category 2B recommendation)
2
Diarrhea/
enterocolitisGrade of Diarrhea 
(CTCAE version 
4.03)General Guidance - Monitor for symptoms that may be related to diarrhea/ enterocolitis 
(abdominal pain, cramping, or changes in bowel habits such as 
increased frequency over baseline or blood in stool) or related to 
bowel perforation (such as sepsis, peritoneal signs and ileus)
- Subjects should be thoroughly ev aluated to rule out any alternative 
etiology (eg, disease progression, other medications, infections 
including testing for clostridium difficile toxin, etc.)
- Steroids should be considered in the absence of clear alternative 
etiology, even for low grade events, in order to prevent potential progression to higher grade event
&(/priprietet(/*(1(/(1(352uidanceuidance5235,(7$5<,1)25w symptomw symptom
ric IV methic IV m
ary and infecry and inf
the subjecthe sub
ve Care (oxyve Care (ox
mprovemenmproveme
sidered and sidered and 
herapy suchherapy suc
weeks dosweeks do
label folabel fo
-OO250$7,21e Corporae Corpora
21
mentment2
disease consusease cons
with study with study 0$
25
5,
52
(1
EDMS Doc. Number:nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 106 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Grade of the 
Event (NCI 
CTCAE version 
4.03) Dose Modifications Toxicity Management
- Use analgesics carefully; they can mask symptoms of perforation 
and peritonitis
Grade 1 diarrhea
(stool frequency 
of <4 over baseline per day)No dose modification For Grade 1 diarrhea:
- Close monitoring for worsening symptoms
- Consider symptomatic treatment including hydration, electrolyte 
replacement, dietary changes (eg, American Dietetic Association 
colitis diet), and loperamide. Use of probiotics as per treating 
physicianâ€™s clinical judgment.
Grade 2 diarrhea
(stool frequency 
of 4-6 over baseline per day)â€¢ Hold IP/study regimen 
until resolution to â‰¤ Grade 1
â€¢ If toxicity worsens then 
treat as Grade 3 or Grade 4
â€¢ If toxicity improves to â‰¤ 
Grade 1 then IP/study 
regimen can be resumed after completion of steroid 
taperFor Grade 2 diarrhea:
- Consider symptomatic treatment including hydration, electrolyte 
replacement, dietary changes (e.g., American Dietetic Association 
colitis diet), and loperamide and/or budesonide
- Promptly start prednisone 1 to 2 mg/kg/day PO or IV equivalent
- If event is not responsive within 3-5 days or worsens despite 
prednisone at 1-2 mg/kg/day PO or IV  equivalent, GI consult should 
be obtained for consideration of further workup such as imaging 
and/or colonoscopy to confirm colitis and rule out perforation, and prompt tr eatment with IV methylprednisolone 2 to 4mg/kg/day 
started.
- If still no improvement within 3-5 days despite 2 to 4 mg/kg IV 
methylprednisolone, promptly start immunosuppressives such as 
(infliximab at 5mg/kg once every 2 weeks). Caution : important to 
rule out bowel perforation and refer to infliximab label for general
guidance before using infliximab
- Consult study physician if no resolution to â‰¤ Grade 1 in 3-4 days
- Once improving, gradually taper steroids over â‰¥28 days and 
consider prophylactic antibiotics, antifungals and anti PCP treatment 
(please refer to current NCCN guidelines for treatment of cancer-related infections
&(/*(1priprietet(/(1(35235,teroid teroid 5,(7$5<,1)250$7,21e Corporae Corpora
21
mentment2
ask symptomsk sympto0$
sening sympsening sym
treatment itreatme
changes (changes ( egeg
operamide. Uoperamide
nical judgmeal judgm5
2 diarrhea:2 diarrhea:
der symptomder symptom
acement, dieacement, die
litis dlitis iet), aet)
--PromptlPrompt
-If evIf ev
prepr
b<
(15,
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 107 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Grade of the 
Event (NCI 
CTCAE version 
4.03) Dose Modifications Toxicity Management
[Category 2B recommendation])2
Grade 3 or 4
Diarrhea
(Grade 3: stool
frequency of â‰¥7
over baseline perday;
Grade 4: life
threatening
consequences)Permanently discontinue 
IP/study regimenFor Grade 3 or 4 diarrhea:
- Promptly initiate empiric IV methylprednisolone 2 to 4 mg/kg/day 
or equivalent
- Monitor stool frequency and volume and maintain hydration- Urgent GI consult and imaging and/or colonoscopy as appropriate- If still no improvement within 3-5 days of IV methylprednisolone 2 
to 4mg/kg/day or equivalen t, promptly s tart further 
immunosuppressives (eg, infliximab at 5mg/kg once every 2 weeks).
- Caution: ensure GI consult to rule out bowel perforation and refer to 
infliximab label for general guidance before using infliximab.
- Once improving, gradually taper steroids over â‰¥28 days and 
consider prophylactic antibiotics, antifungals and anti PCP treatment 
(please refer to current NCCN guidelines for treatment of cancer-
related infections
[Category 2B recommendation])
2
Hepatitis (elevated 
LFTs)
Infliximab
should not be
used for
management ofimmune related
hepatitisGrade of liver
function test
elevation (CTCAE
version 4.03)
Any gradeGrade 1 (AST or 
ALT > to 3 times ULN and/or TB > to 1.5 times ULN)No dose modification
If it worsens, treat as Grade 
2 event- Monitor and evaluate liver function test: AST, ALT, ALP and total 
bilirubin
- Evaluate for alternative etiologies (eg, viral hepatitis, disease 
progression, concomitant medications)
For Grade 1 AST or ALT and/or TB elevation
- Continue LFT monitoring per protocol
Grade 2 (AST or 
ALT > 3 to 5 
times ULN and/or Hold IP/study regimen dose 
until Grade 2 resolution to â‰¤ 
Grade 1For Grade 2 AST or ALT and or TB elevation:
- Regular and frequent checking of LFTs (e.g. every 1-2 days) until 
elevations of these are improving or resolved.
&(priprietet(/*(1(3523> > 
ULN)LN)ationation
, treat as Gr, treat as G35,(7$5<,1)250$7,21e Corporae Corpora
21
mentment2
0$
methylpredmethylpre
cy and volumy and v
and imagingand imaging
ovement witvement wi
y or equivaleor equival
ppressives (ppressives 
n: ensure Gn: ensure G
ximab label ximab label
Once Once improimp
consider pconsider 
(please(please
rerelatlat
[50
5,35
(1 (AST or AST or 
> 3 to 5 o 5 
es ULN andes ULN an*(((
(/(
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 108 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Grade of the 
Event (NCI 
CTCAE version 
4.03) Dose Modifications Toxicity Management
TB >1.5-3.0 times 
ULN)â€¢ If toxicity worsens then 
treat as Grade 3 or Grade 4
â€¢ If toxicity improves to â‰¤ 
Grade 1 then resume 
IP/study regimen after
completion of steroid taper- If no resolution to â‰¤ Grade 1 in 1-2 days, discuss with study 
physician.
- If event is persistent (> 3-5 days) or worsens, promptly start 
prednisone 1-2mg/kg/day PO or IV equivalent.
- If still no improvement within 3-5 days despite 1- 2mg/kg/day of 
prednisone PO or IV equivalent, consider additional workup and 
prompt treatment with IV methyl prednisolone 2-4mg/kg/day.
- If still no improvement within 3-5 days despite 2-4mg/kg/day of IV 
methylprednisolone, promptly start immunosuppressives (mycophenolate mofetil). Discuss with study physician if mycophenolate mofetil is not available. Infliximab should NOT be 
used .
- Once improving, gradually taper steroids over â‰¥28 days and 
consider prophylactic antibiotics, antifungals and anti PCP treatment (please refer to current NCCN guidelines for treatment of cancer-related infections [Category 2B recommendation])
2
Grade 3
(AST or ALT >5-
20 times ULN 
and/or TB > 3.0-10 times ULNFor elevations in 
transaminases â‰¤ 8 Ã— ULN, 
or elevations in bilirubin â‰¤ 5 
Ã— ULN:
â€¢ Hold IP/study regimen 
dose until resolution to â‰¤ 
Grade 1 or baseline
â€¢ Resume IP/study regimen 
if elevations downgrade â‰¤ 
Grade 1 or baseline within 
14 days, and after 
completion of steroid taper
â€¢ Permanently discontinue 
IP/study regimen if the For Grade 3 or 4 AST or ALT and/or TB elevation:
- Promptly initiate empiric IV methylprednisolone at 1 to 4mg/kg/day 
or equivalent
- If still no improvement within 3-5 days despite 1 to 4 mg/kg/day 
methylprednisolone IV or equivalent, promptly start treatment with immunosuppressive therapy (mycophenolate mofetil). Discuss with study physician if mycophenolate is not available. Infliximab should 
NOT be used.
- Hepatology consult, abdominal workup, and imaging as
appropriate.
- Once improving, gradually taper steroids over â‰¥28 days and 
consider prophylactic antibiotics, antifungals and anti PCP treatment 
&(priprietet(/*(1(35235,(7$5<,1)250$7,21e Corporae Corpora
21
mentment2
days, discussys, discus
ys) or worseys) or worse
or IV equivor IV equi
within 3within 3 -5 d5d
quivalent, cquivalent
ith IVth IV metmethh
ovement wivement wi
solone, promolone,
nolate mofenolate mofe
henolate mohenolate mo
Once Once improimp
consider pconsider 
(please(please
rerelatla0$
5,8 Ã— ULN, 8 Ã— ULN
n bilirubin bilirubin 
PP/study reg/study reg
until resoluntil resolu
rade 1 or barade 1 or b
â€¢ Resumeâ€¢ Resume
if if elevaeleva
GraG
113555
(/(15
EDMS Doc. Number:nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 109 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Grade of the 
Event (NCI 
CTCAE version 
4.03) Dose Modifications Toxicity Management
elevations do not downgrade
to â‰¤Grade 1 or baseline 
within 14 days
â€¢ For elevations in 
transaminases > 8 Ã— ULN or 
elevations in bilirubin > 5 Ã— ULN, discontinue IP/study 
regimen
â€¢ Permanently discontinue 
IP/study regimen for any 
case meeting Hyâ€™s law criteria (AST and/or ALT > 
3x ULN + bilirubin > 2x
ULN without initial findings of cholestasis (ie, elevated alkaline P04) and in the 
absence of any alternative 
cause
3(please refer to current NCCN guidelines for treatment of cancer-related infections
[Category 2B recommendation])
2
Grade 4
(AST or ALT > 20 
times ULN and/or 
TB > 10 times 
ULN)Permanently discontinue 
IP/study regimen
Nephritis or renal
dysfunction
(elevated serum
creatinine)Grade of elevated
serum creatinine
(CTCAE version
4.03)
Any gradeGeneral guidance - Consult with nephrologist
- Monitor for signs and symptoms that may be related to changes in 
renal function (e.g. routine urinalysis, elevated serum BUN and 
creatinine, decreased creatinine clearance, electrolyte imbalance, 
decrease in urine output, proteinuria, etc.)
3FDA Liver Guidance Document 2009 Guidance for Industry: Drug Induced Liver Injury â€“ Premarketing Clinical Evaluation.
&(priprietet(/*(1(3523scontinue continue 
imenimen235,(7$5<,1)250$7,21e Corporae Corpora
21
mentment2
tive ive nes for treates for treat
))0$
5,
23
onon
deGeneral guGeneral g(
/*(1
(/*ment 2009 Gument 2009 Gu
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 110 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Grade of the 
Event (NCI 
CTCAE version 
4.03) Dose Modifications Toxicity Management
- Subjects should be thoroughly ev aluated to rule out any alternative 
etiology (e.g. disease progression, infections, etc.)
- Steroids should be considered in the absence of clear alternative 
etiology even for low grade events (Grade 2), in order to prevent 
potential progression to a higher grade event
Grade 1 [serumcreatinine > 1-1.5X baseline; > 
ULN to 1.5X  ULN]No dose modification For Grade 1 elevated creatinine:
- Monitor serum creatinine weekly and any accompanying symptom
!If creatinine returns to baseline, resume its regular 
monitoring per study protocol.
!If it worsens, depending on the severity, treat as Grade 2 or 
Grade 3 or 4
- Consider symptomatic treatment including hydration, electrolyte 
replacement, diuretics, etc.
Grade 2 [serum
creatinine>1.5-
3.0X baseline; >1.5X- 3.0XULN]Hold IP/study regimen until 
resolution to â‰¤ Grade 1 or 
baseline
â€¢ If toxicity worsens then 
treat as Grade 3 or Grade 4
â€¢ If toxicity improves to â‰¤ 
Grade 1 or baseline then resume IP/study regimen 
after completion of steroid 
taperFor Grade 2 elevated creatinine:
- Consider symptomatic treatment including hydration,
electrolyte replacement, diuretics, etc.- Carefully monitor serum creatinine every 2-3 days and as clinically 
warranted
- Consult nephrologist and consider renal biopsy if clinically 
indicated
- If event is persistent (> 3-5 days) or worsens, promptly start 
prednisone 1 to 2 mg/kg/day PO or IV equivalent
- If event is not responsive within 3-5 days or worsens despite 
prednisone at 1-2 mg/kg/day PO or IV equivalent, additional workup 
should be considered and prompt treatment with IV 
methylprednisolone at 2-4mg/kg/day started.
- Once improving gradually taper steroids over â‰¥28 days and 
consider prophylactic antibiotics, antifungals and anti PCP treatment 
priprietet(/*(1(35235,(7$5<,1)250$7,21e Corporae Corpora
21
mentment2
ated to rule ted to rule 
nfections, enfections, e
in the absenin the absen
events (Gradevents (Grad
higher gradehigher grad0$
creatinine:creatinine:
reatinine weatinine 
atinine returntinine retur
nitoring pernitoring p
If it worsenIf it worsen
Grade 3Grade 3
Consider syConsider 
rereplacemeplaceme1)
,ntil ntil 
or or 
sens then sens then
e 3 or Grade3 or Gra
ty improvesy improve
11or obaselinbase
ume IP/studyume IP/s
after complefter comple
tapertaperFor GFor G
--C,,,(
(/(15,
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 111 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Grade of the 
Event (NCI 
CTCAE version 
4.03) Dose Modifications Toxicity Management
(please refer to current NCCN guidelines for treatment of cancer-
related infections [Category 2B recommendation])2.
- When event returns to baseline, resume IP/study regimen and 
routine serum creatinine monitoring per study protocol.
Grade 3 or 4
(Grade 3: serum
creatinine > 3.0 X
baseline; >3.0-6.0
X ULN
Grade 4: Serum 
Creatinine > 6.0 X ULN)Permanently discontinue 
IP/study regimen- Carefully monitor serum creatinine on daily basis
- Consult Nephrologist and consider renal biopsy if clinically 
indicated
- Promptly start prednisone 1 to  2 mg/kg/day PO or IV equivalent
- If event is not responsive within 3-5 days or worsens despite 
prednisone at 1-2 mg/kg/day PO or IV equivalent, additional workup 
should be considered and prompt treatment with IV methylprednisolone 2-4mg/kg/day started.
- Once improving, gradually taper steroids over â‰¥28 days and 
consider prophylactic antibiotics, antifungals and anti PCP treatment 
(please refer to current NCCN guidelines for treatment of cancer-
related infections [Category 2B recommendation]
2
Rash (excludingbullous skin
formations)Grade of Skin 
Rash (Please refer 
to NCICTCAE 
version 4.03 for definition of 
severity/grade 
depending on type of skin rash)General guidance â€¢ Monitor for signs and symptoms of dermatitis (rash and pruritus)
â€¢ **IF THERE IS ANY BULL OUS FORMATION,  THE STUDY 
PHYSICIAN SHOULD BE CONTACTED AND IP
DISCONTINUED **
Grade 1 No dose modification For Grade 1:
- Consider symptomatic treatment including oral antipruritics (e.g.
diphenhydramine or hydroxyzine) and topical therapy (e.g. urea 
cream)
priprietet(/*(1(35235,(7$5<,1)250$7,21e Corporae Corpora
21
mentment2
nes for treates for treat
ommendatioommendati
e, resume e, resum IPIP
nitoring pernitoring per0$
m creatininem creatinin
ist and consist and cons
rt prednisonrt prednison
s not respons not respo
one at 1-e at 1- 2 m2m
d be considd be consi
ethylprednisethylpred
--Once Once impim
consideconsid
(plea(plea
rer)2
5,355
1No dNo d111
(/(1
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 112 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Grade of the 
Event (NCI 
CTCAE version 
4.03) Dose Modifications Toxicity Management
Grade 2 For persistent (> 1- 2 weeks) 
Grade 2 events, hold 
scheduled IP/study regimen until resolution to â‰¤ Grade 1 
or baseline
â€¢ If toxicity worsens then 
treat as Grade 3
â€¢ If toxicity improves to 
Gradeâ‰¤ 1 or baseline, then 
resume
IP/study regimen after 
completion of steroid taperFor Grade 2:
- Obtain dermatology consult
- Consider symptomatic treatment including oral antipruritics (e.g.
diphenhydramine or hydroxyzine) and topical therapy (e.g. urea 
cream)
- Consider moderate-strength topical steroid
- If no improvement of rash/skin lesions occurs within 3-5 days or is 
worsening despite symptomatic treatment and/or use of moderate 
strength topical steroid, discuss with study physician and promptly start systemic steroids prednisone 1-2 mg/kg/day PO or IV equivalent
- Consider skin biopsy if persistent for >1-2 weeks or recurs
Grade 3 â€¢ Hold IP/study regimen 
until resolution to â‰¤ Grade 1 
or baseline
â€¢ If temporarily holding the 
study drug/study regimen does not provide 
improvement of the Grade 3 
skin rash to â‰¤ Grade 1 or 
baseline within 30 days, 
then permanently 
discontinue IP/study regimenFor Grade 3 or 4:
- Consult dermatology
- Promptly initiate empiric IV methylprednisolone 1 to 4 mg/kg/day 
or equivalent
- Consider hospitalization- Monitor extent of rash [Rule of Nines]- Consider skin biopsy (preferably more than 1) as clinically feasible.- Once improving, gradually taper steroids over â‰¥28 days and 
consider prophylactic antibiotics, antifungals and anti PCP treatment (please refer to current NCCN guidelines for treatment of cancer-related infections [Category 2B recommendation])
2
- Discuss with study physician Grade 4 Permanently discontinue 
IP/study regimen
Endocrinopathy(eg,hyperthyroidism,Any grade
(Depending on the type of General guidance - Consult Endocrinologist
- Monitor subjects for signs and symptoms of endocrinopathies. Non-
specific symptoms include headache, fatigue, behavior changes, 
&(/priprietet(/*(1(35235,ng the ng the 
egimen gimen
t of the Gradof the Gr
o o â‰¤ Grade 1â‰¤ Grade 1
e within 30 e within 30 
permanentlermanentl
scontinue scontinue IP
regimenregimen5,(7$For Grade 3For Grade 
--7$5<,1)250$7,21e Corporae Corpora
21
mentment2
ment includinent includ
xyzine) andxyzine) and
stretrength topngth to
ent of rash/sent of rash
pite symptompite sympto
ical steroid,ical steroi
emic steroidmic stero
nsider skin bsider skin 0$
ConsuCons
--ProPr
oo7$
15,
PerPermm
IPIP/111((1 de
nding nding on thon th
e of e of *(((
(/(
EDMS Doc. Number:nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 113 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Grade of the 
Event (NCI 
CTCAE version 
4.03) Dose Modifications Toxicity Management
hypothyroidism,
hypopituitarism,
adrenal
insufficiency, etc.)endocrinopathy, 
refer to NCI 
CTCAE version 
4.03 for defining the CTC grade/severity)changed mental status, vertigo, abdominal pain, unusual bowel 
habits, hypotension and weakness.
- Subjects should be thoroughly evaluated to rule out any alternative 
etiology (e.g. disease progression including brain metastases,
infections, etc.)
- Monitor and evaluate thyroid function tests: TSH, free T3 and free 
T4 and other relevant endocrine labs depending on suspected 
endocrinopathy.
- If a subject experiences an AE that is thought to be possibly of 
autoimmune nature (e.g. thyroiditis, pancreatitis, hypophysitis, diabetes insipidus), the investigator should send a blood sample for 
appropriate autoimmune antibody testing
Grade 1(depending on thetype of
endocrinopathy,refer to NCICTCAE version
4.03 for defining
the CTC Grade 1)No dose modification For Grade 1: (including those with asymptomatic TSH elevation)
- Monitor subject with appropriate endocrine function tests- If TSH < 0.5X LLN, or TSH >2X ULN or consistently out of range 
in 2 subsequent measurements, include FT4 at subsequent cycles as clinically indicated and consider endocrinology consult.
Grade 2
(depending on the
type ofendocrinopathy,refer to NCI
CTCAE version
4.03 for definingthe CTC 
Grade/severity 2)For Grade 2 endocrinopathy 
other than hypothyroidism, 
hold IP/study regimen dose until subject is clinically stable
â€¢ If toxicity worsens then 
treat as Grade 3 or Grade 4
â€¢ IP/study regimen can be 
resumed once event For Grade 2 (including those with symptomatic endocrinopathy):
- Isolated hypothyroidism may be treated with replacement therapy 
without treatment interruption and without corticosteroids
- Initiate hormone replacement as needed for management- Evaluate endocrine function, and as clinically indicated, consider 
pituitary scan
- For subjects with abnormal endocrine work up, except for those 
with isolated hypothyroidism, consider short-term, corticosteroids 
(eg, 1-2 mg/kg/day methylprednisolone or IV equivalent) and prompt
&(/priprietet(/*(1nn
finingfining
e/severity 2)/severity 2)
(/(1(352ade 2 endocrade 2 endoc
r than hypothan hypo
old old IPP/studyud
until subjeuntil subj
stablestable
â€¢ If â€¢ I
trt5235,(7$5<,1)250$7,21e Corporae Corpora
21
mentment2
minal pain, unnal pain, u
evaluated tevaluated t
ssion includision includ
e thyroid fune thyroid f
nt endocrinet endocrin
experiencesxperie
ne nature (ne nature ( ee
s insipidus),s insipidus)
opriateopriate autoauto0$
For Grade 1For Grade 
--MonitoMoni
--If TIf T
inin7$
5,
52
(1
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 114 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Grade of the 
Event (NCI 
CTCAE version 
4.03) Dose Modifications Toxicity Management
stabilizes and after 
completion of steroid taper
Subjects with 
endocrinopathies who may 
require prolonged or 
continued steroid replacement can be retreated 
with IP/study regimen on 
the following conditions: 
1) the event stabilizes and is
controlled,
2) the subject is clinically 
stable as per Investigator or 
treating physicianâ€™s clinicaljudgement, and 
3) doses of prednisone are at
less than or equal to 
10mg/day or equivalent.initiation of treatment with relevant hormone replacement (eg,
levothyroxine, hydrocortisone, or sex hormones). 
- Once improving, gradually taper steroids over â‰¥28 days and 
consider prophylactic antibiotics, antifungals and anti PCP treatment 
(please refer to current NCCN guidelines for treatment of cancer-
related infections
[Category 2B recommendation])
2
- For subjects with normal endocrine work up (lab or MRI scans), 
repeat labs/MRI as clinically indicated.
Grade 3 or 4
(depending on the
type of
endocrinopathy,
refer to NCICTCAE version
4.03 for defining
the CTC Grade/severity 3 or 4)â€¢ For Grade 3 or 4 
endocrinopathy other than 
hypothyroidism, hold 
IP/study regimen dose until 
endocrinopathy symptom(s) are controlled
â€¢ IP/study regimen can be 
resumed once event 
stabilizes and after 
completion of steroid taperFor Grade 3 or 4:
- Consult endocrinologist
- Isolated hypothyroidism may be treated with replacement therapy 
without treatment interruption and without corticosteroids
- Promptly initiate empiric IV methylprednisolone 1 to 2 mg/kg/day 
or equivalent
- Administer hormone replacement therapy as necessary
- For adrenal crisis, severe dehydration, hypotension, or shock: 
immediately initiate intravenous corticosteroids with 
mineralocorticoid activity
&(/priprietet(/*(1//
r4)4)(1(35235,(7$5<,1)250$7,21e Corporae Corpora
21
mentment2
are atare at
valent.valent.rmonemone rereplaplee
exexhorhormmoneone
per steroids oper steroids 
tics, antifuntics, antifun
CCNCNguideliguideli
mmendation]mendation
ith normal eh normal e
MRI as clinicRI as c0$
5,
or 4 4
pathy other pathy other 
yroidism, hoyroidism, ho
udy regimendy regime
ndocrinopathndocrinopa
areare control contree
â€¢ â€¢ IPIP/stu/stu
reresu
ss23
(/(1
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 115 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Grade of the 
Event (NCI 
CTCAE version 
4.03) Dose Modifications Toxicity Management
- Once improving, gradually taper immunosuppressive steroids over 
â‰¥28 days and consider prophylactic antibiotics, antifungals and anti 
PCP treatment (please refer to current NCCN guidelines for treatment 
of cancer related infections [Category 2B recommendation])2
- Discuss with study physician
Immune mediated
neurotoxicity (toinclude but not
limited to limbicencephalitis.autonomic
neuropathy,
excludingmyasthenia gravis
and Guillain-
Barre)Grade of 
Neurotoxicity
Depending on the 
type of 
neurotoxicity refer 
to NCI CTCAE version 4.03 for defining the CTC 
grade/severityGeneral guidance - Subjects should be evaluated to rule out any alternative etiology 
(eg, disease progression, infections, metabolic syndromes and medications, etc.)
- Monitor subject for general symptoms (headache, nausea, vertigo, 
behavior change, or weakness)
- Consider appropriate diagnostic testing (e.g. electromyogram and 
nerve conduction investigations)
- Symptomatic treatment with neurological consult as appropriate
Grade 1 No dose modifications See â€œAny Gradeâ€ recommendations above.
Grade 2 â€¢ For acute motor 
neuropathies or
neurotoxicity, hold IP/studyregimen dose until resolution to â‰¤ Grade 1
â€¢ For sensory neuropathy/ 
neuropathic pain, consider 
holding IP/study regimen 
dose until resolution to â‰¤ 
Grade 1
- If toxicity worsens then 
treat as Grade 3 or Grade 4
â€¢ IP/study regimen can be 
resumed once event For Grade 2:
- Discuss with the study physician
- Obtain Neurology Consult- Sensory neuropathy/ neuropathic pain may be managed by 
appropriate medications (e.g. gabapentin, duloxetine, etc.)
- Promptly start systemic steroids prednisone 1-2mg/kg/day PO or IV 
equivalent
- If no improvement within 3-5 days despite 1-2mg/kg/day
prednisone PO or IV equivalent consider additional workup and promptly treat with additional immunosuppressive therapy (e.g.
IVIG)
priprietet(/*(1(35235,(7$5<,1)250$7,21e Corporae Corpora
21
mentment2
mununosuppreosuppre
cantibioticsantibiotics
urrent NCCNurrent NCC
Category 2Btegory 2B
iciancian0$
evaluated to valuated t
ssion,ion,infectinfec
.)
bject for gebject for 
change, or whange, or w
sider appropder appr
ve conductive conducti
-S-Symptomymptom1)
,See â€œSee â€œ,,,(5,
hold old IPIP/stud/stu
e until e until 
to to â‰¤ Gradeâ‰¤ Grad
sensory neuensory ne
uropathic pauropathic 
holding holding IP/s
dose untidose unt
GradeGrad
-IIFF5,5,5,
(/(15,
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 116 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Grade of the 
Event (NCI 
CTCAE version 
4.03) Dose Modifications Toxicity Management
improves to Grade â‰¤1 and 
after completion of steroid 
taper
Grade 3 â€¢ Hold IP/study regimen 
dose until resolution to â‰¤ 
Grade 1
â€¢ Permanently discontinue 
IP/study regimen if Grade 3 
irAE does not resolve to â‰¤ 
Grade 1 within 30 days.For Grade 3 or 4:
- Discuss with study physician
- Obtain Neurology Consult
- Consider hospitalization- Promptly initiate empiric IV methylprednisolone 1 to 2 mg/kg/day 
or equivalent
- If no improvement within 3-5 days despite IV corticosteroids, 
consider additional workup and promptly treat with additional 
immunosuppressants (e.g. IVIG)
- Once stable, gradually taper steroids over â‰¥28 daysGrade 4 Permanently discontinue 
IP/study regimen
Immune mediatedperipheral
neuromotor
syndromes, such
as Guillain-Barreand myastheniagravisGeneral guidance - The prompt diagnosis of immune-mediated peripheral neuromotor 
syndromes is important, since certain subjects may unpredictably 
experience acute decompensations which can result in substantial 
morbidity or in the worst case, death. Special care should be taken for 
certain sentinel symptoms which may predict a more severe outcome, such as prominent dysphagia, rapidly progressive weakness, and signs of respiratory insufficiency or autonomic instability
- Subjects should be evaluated to rule out any alternative etiology 
(e.g. disease progression, infections, metabolic syndromes and 
medications, etc.). It should be noted that the diagnosis of immune-mediated peripheral neuromotor syndromes can be particularly challenging in subjects with underlying cancer, due to the multiple 
potential confounding effects of cancer (and its treatments) 
throughout the neuraxis. Given the importance of prompt and accurate diagnosis, it is essential to have a low threshold to obtain a 
neurological consult
priprietet(/*(1(/(1(35235,(7$5<,1)25siciansician
ConsultConsult
alizationalization
tiate empiritiate empiri
ntnt
mprovemenmprovemen
ider additionider additio250$7,21e Corporae Corpora
21
mentment2
0$
mmunosupprmmunosup
--Once staOnce st25
,--TheThe
synsy,,,(
(15,
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 117 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Grade of the 
Event (NCI 
CTCAE version 
4.03) Dose Modifications Toxicity Management
- Neurophysiologic diagnostic testing (e.g. electromyogram and 
nerve conduction investigations, and â€œrepetitive stimulationâ€ if 
myasthenia is suspected) are routinely indicated upon suspicion of 
such conditions and may be best facilitated by means of a neurology consultation
Important to consider that the use of steroids as the primary treatment 
of Guillain-Barre is not typically considered effective. Subjects 
requiring treatment should be started with IVIG and followed by 
plasmapheresis if not responsive to IVIG
Grade 1 No dose modification For Grade 1:
- Discuss with the study physician
- Care should be taken to monitor subjects for sentinel symptoms of a 
potential decompensation as described above
- Obtain a neurology consult unless the symptoms are very minor and 
stable
Grade 2 â€¢ Hold IP/study regimen 
dose until resolution to â‰¤ 
Grade 1
â€¢ Permanently discontinue 
IP/study regimen if it does not resolve to â‰¤ Grade 1 
within 30 days or if there 
are signs of respiratory insufficiency or autonomic instabilityFor Grade 2:
- Discuss with the study physician
- Care should be taken to monitor subjects for sentinel symptoms of a 
potential decompensation as described above
- Obtain a Neurology Consult- Sensory neuropathy/ neuropathic pain may be managed by 
appropriate medications (eg, gabapentin, duloxetine, etc.)
MYASTHENIA GRAVIS
o Steroids may be successfully used to treat Myasthenia Gravis. 
Important to consider that steroid therapy (especially with high 
doses) may result in transient worsening of myasthenia and should 
&(/*priprietet/*(1(35235,(7$5<,1)250$7,21e Corporae Corpora
21
mentment2
(e.g.e.g.electroelectro
d â€œrepetitived â€œrepetitiv
tinely indicatinely indic
est facilitatest facilitat
hat the use ot the u
not typicallynot typically
nt should bent should b
s ifnot respnot resp0$
1:1:
uss with the ss with t
are should bare should b
potential depotential de
--ObtainObtai
stablestable5<
5,men men 
on to n toâ‰¤ â‰¤ 
tly discontintly disconti
regimen if iregimen if
solve to olve tâ‰¤ Gâ‰¤ 
thin 30 dayshin 30 da
arere signs of signs ofee
insufficieinsufficie
instabinstabFF5,5,5,
/*(15,
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 118 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Grade of the 
Event (NCI 
CTCAE version 
4.03) Dose Modifications Toxicity Management
typically be administered in a monitore dsetting under supervision of 
a consulting neurologist.
o Subjects unable to tolerate steroids may be candidates for treatment 
with plasmapheresis or IVIG. Such decisions are best made in 
consultation with a neurologist, taking into account the unique needs 
of each subject.
o If Myasthenia Gravis-like neurotoxicity present, consider starting 
AChE inhibitor therapy in addition to steroids. Such therapy, if successful, can also serve to reinforce the diagnosis.
GUILLAIN-BARRE:
o Important to consider here that the use of steroids as the primary 
treatment of Guillain-Barre is not typically considered effective.
Subjects requiring treatment should be started with IVIG and 
followed by plasmapheresis if not responsive to IVIG.
Grade 3 â€¢ Hold IP/study regimen 
dose until resolution to â‰¤ 
Grade 1
â€¢ Permanently discontinue 
IP/study regimen if Grade 3 irAE does not resolve to â‰¤ 
Grade 1 within 30 days or if 
there are signs of respiratory insufficiency or autonomic 
instabilityFor severe or life threatening (Grade 3 or 4) events:
- Discuss with study physician
- Recommend hospitalization- Monitor symptoms and obtain neurological consult
MYASTHENIA GRAVIS
o Steroids may be successfully used to treat Myasthenia Gravis. It 
should typically be administered in a monitored setting under 
supervision of a consulting neurologist.
o Subjects unable to tolerate steroids may be candidates for treatment 
with plasmapheresis or IVIG.
Grade 4 Permanently discontinue 
IP/study regimen
&(/*priprietet/*(1(35235,(7$5<,1)250$7,21e Corporae Corpora
21
mentment2
eddsesetting untting u
roids may broids may b
Such decisSuch decis
ogist, takingogist, taking
avisvis--like neulike ne
herapy in adherapy in a
n also serven also
AINAIN-NBARREBA
mportant to mportant to 
reatment ofreatment o
SubjectsSubjec
followfollow0$
5,men men 
on to n toâ‰¤ â‰¤ 
tly discontintly disconti
regimen if Gregimen if
does not resoes not re
ade 1 withinade 1 wit
herhere aree a sig
insufficieinsufficie
instabinstabFF5,5,5,
(15,
PeP(1(1(1
/*(1
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 119 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Grade of the 
Event (NCI 
CTCAE version 
4.03) Dose Modifications Toxicity Management
o If Myasthenia Gravis-like neurotoxicity present, consider starting 
AChE inhibitor therapy in addition to steroids. Such therapy, if 
successful, can also serve to reinforce the diagnosis.
GUILLAIN-BARRE :
â—¦Important to consider here that the use of steroids as the primary 
treatment of Guillain-Barre is not typically considered effective. 
Subjects requiring treatment should be started with IVIG and
followed by plasmapheresis if not responsive to IVIG
AChE = acetylcholine esterase; ADL = activities of daily living; AE = adverse event; ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = 
aspartate aminotransferase; BUN = blood urea nitrogen; CT = computed tomography; CTC = Common Terminology Criteria; FT4 = free thyroxine; GI = 
gastrointestinal; ILD = interstitial lung disease; irAE = immune-related adverse event; IV = intravenous; IVIG = intravenous im munoglobulin; LFT = liver 
function test; LLN = lower limit of normal; MRI = magnetic resonance imaging; NCCN = National Comprehensive Cancer Network; NCI  CTCAE = National 
Cancer Institute Common Terminology Criteria for Adverse Events; PCP = pneumocystis pneumonia; PO = oral; TB = total bilirubin;  TNF = tumor necrosis 
factor; TSH = thyroid-stimulating hormone; ULN = upper limit of normal.
priprietet(7$5<,1)250$city present,ty present
to steroids. to steroids.
force the diforce the di
er here that tr here that
inn--Barre is nBarre is 
ng treatmeng treatmen0$7,21e Corporae Corpora
21
mentment2
plasmaphereasmap0$
5<lkaline phospkaline phos
C = CommoC = Commo
IV = intravenIV = intrave
CCN = NatioCCN = Na
mocystis pnemocystis pne
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 120 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Table C2: Treatment Modification and Toxicity Manageme nt Guidelines for Infusion-related Adverse Events
Severity Grade of the 
Event (NCI CTCAE 
version 4.03) Dose Modifications Toxicity Management
Any grade General guidance - Management per institutional standard at the discretion of 
investigator
- Monitor subjects for signs and symptoms of infusion-related 
reactions (e.g. fever and/or shaking chills, flushing and/or itching, 
alterations in heart rate and blood pressure, dyspnea or chest 
discomfort, skin rashes etc.) and anaphylaxis (eg, generalized urticaria, angioedema, wheezing, hypotension, tachycardia, etc.)
Grade 1 The infusion rate of IP/study regimen may 
be decreased by 50% or temporarily 
interrupted until resolution of the eventFor Grade 1 or Grade 2:
- Acetaminophen a nd/or antihistamines may be administered per 
institutional standard at the discretion of the investigator
- Consider premedication per institutional standard prior to 
subsequent doses
- Steroids should not be used for routine premedication of â‰¤Grade 2 
infusion reactionsGrade 2 The infusion rate of IP/study regimen may 
be decreased 50% or temporarily interrupted 
until resolution of the event
Subsequent infusions may be given at 50% 
of the initial infusion rate
Grade 3 or 4 Permanently discontinue IP/study regimen For Grade 3 or 4:
Manage severe infusion-related reactions per institutional standards
(e.g. IM epinephrine, followed by IV diphenhydramine and ranitidine, and IV glucocorticoid) 
IM = intramuscular; IV = intravenous.
&(/*(1(35235,(7$5<,1)250$7,21e Corporae Corpora
21
priprietetentsnts
ementment7,2
dard at the ddard at the 
nd symptomd symptom
r shaking chr shaking ch
and blood pnd blo
hes etc.) andhes etc.) and
ema, wheezema, whe0
r Grade 2:r Gra
nophen andnophen and
ional standaional standa
onsider premonsider pre
subsequent dsubsequent
-SteroidSteroid
infusiinfusi<,
% % 
5,( regimengimen3555
355
EDMS Doc. Number: nab-paclitaxel
Protocol ABI-007-NSCL-006 Celgene Corporation
Confidential and Propri etary 121 ABI-007-NSCL-006 Amendment 5.0 Final: 09 Dec 2016Table C3: Treatment Modification and Toxicity Management Guidelines for Non-immune-mediated Reactions
Severity Grade of the 
Event (NCI CTCAE 
version 4.03) Dose Modifications Toxicity Management
Any grade Note: dose modifications are not required for adverse events not 
deemed to be related to study treatment (i.e. events due to 
underlying disease) or for laboratory abnormalities not deemed 
to be clinically significant.Treat accordingly as per institutional standard
Grade 1 No dose adjustment Treat accordingly as per institutional standard
Grade 2 Hold IP/study regimen until resolution to â‰¤ Grade 1 or baseline Treat accordingly as per institutional standard
Grade 3 Hold IP/study regimen until resolution to â‰¤ Grade 1 or baseline
For AEs that downgrade to â‰¤ Grade 2 within 7 days or resolve to 
â‰¤ Grade 1 or baseline within 14 days, resume IP/study regimen 
administration. Otherwise, discontinue IP/study regimenTreat accordingly as per institutional standard
Grade 4 Discontinue IP/study regimen (Note for Grade 4 labs, decision to 
discontinue would be based on accompanying clinical 
signs/symptoms and as per Investigatorâ€™s clinical judgment and
in consultation with the sponsor)Treat accordingly as per institutional standard
AE = adverse event; CTC = Common Terminology Criteria.
&(/*(1(35235priprietet35,(7$labs, decisilabs, decis
g clinical clinical 7$5<,1)250$7,21e Corporae Corpora
21tionstions
ty ManagemManag7,2
ly as per insly as per in0
eat accordint accord)2
Treat accoTreat acco1
<ee
lve to lve t
egimen egimen 
menmenTreat t<<<,1<
clinical judglinical judg7$
35
EDMS Doc. Number: 
Celgene Signing Page
This is a representation of an electronic record that was signed electronically in Livelink.
This page is the manifestation of the electronic signature(s) used in compliance with
the organizations electronic signature policies and procedures.
8VHU1DPH
7LWOH'DWH7XHVGD\'HFHPEHU30(DVWHUQ'D\OLJKW7L PH
0HDQLQJ$SSURYHGQRFKDQJHVQHFHVVDU\                                                
&(/*(1(35235,(7$5<,1)250$7,21